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General introduction
Inflammatory bowel diseases (IBD) include Crohn’s disease (CD) 
and ulcerative colitis (UC). These diseases are characterized by 
chronic recurrent intestinal inflammation that is limited to the 
colon in UC but may affect any segment of the gastrointestinal 
tract in the case of CD. In the Netherlands there are currently 
more than 90,000 IBD patients. IBD has typically a young onset 
and follows an unpredictable course with periods of remission 
and relapses. Symptoms vary according to the disease location 
and may consist of abdominal pain, diarrhoea, bloody stools, 
weight loss and fatigue.
  The medical treatment of IBD aims to induce and maintain 
prolonged remission and to prevent complications. In order to 
reach these treatment goals several therapies are available, such 
as 5-aminosalicylates (5-ASA), thiopurines, methotrexate, TNF 
alpha inhibitors (anti-TNF agents) and the recently introduced 
integrin and interleukin IL12/IL23 inhibitors. The expansion of 
the arsenal of IBD drugs has not resulted in a cure for IBD (yet). 
As a result, patients are chronically treated with a variety of im-
munosuppressive medications, during long periods of time in or-
der to prevent long-term complications. Unfortunately, current 
treatment strategies are not fully sufficient to prevent complica-
tions and surgery in IBD patients.
 
Malignancies in IBD
One of the most serious complications of IBD is cancer deve- 
lopment. For example, continuous chronic inflammation increa- 
ses the risk of colorectal cancer (CRC). This will be discussed 
further below. In addition, the use of long-term immuno- 
suppressive medication increases the risk of extra-intestinal 
malignancies.
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treated with thiopurine and anti-TNF combination therapy. 
 Two factors are important in IBD related lymphoprolifera-
tions. Firstly, the importance of local IBD–related inflammation 
is illustrated by the excess of intestinal lymphoproliferations12. 
Secondly, the decreased immunosurveillance of EBV as evidenced 
by a high rate of EBV-replication found in IBD lymphomas. These 
factors show an interesting interplay as EBV is identified in the 
majority of the intestinal lymphoproliferations13 suggesting that 
local inflammation promotes EBV replication.
 
EBV in lymphoproliferation
An acute EBV infection causes a polyclonal expansion of B lym-
phocytes containing EBV. In immunocompetent individuals, 
antigens expressed by the infected B lymphocytes provoke a T 
lymphocyte immune reaction that eliminates almost all infected 
B lymphocytes. However, some infected B lymphocytes escape 
surveillance due to downregulation of antigen expression and 
this causes a lifelong latent EBV infection of B lymphocytes. Any 
mucosal biopsy will contain B lymphocytes and therefore may 
harbour amplifiable EBV DNA.
 In thiopurine-induced EBV reactivation, the infected B cell 
restarts replication to create more infected B cells and ultimately 
will produce thousands of virions. In case of malignant transforma-
tion, neoplastic daughter cells possess the identical viral episomal 
structure, making the EBV genome a marker for clonality analyses. 
 
Post-transplant like lymphoproliferations
The post-transplant like lymphomas account for most thiopu-
rine-related lymphomas in IBD and are histologically comparable 
to post-transplant lymphoproliferative disorders (PTLD). PTLD 
are uncommon B-cell lymphoproliferations, with high mortality 
when left untreated14, 15.  
 The World Health Organization (WHO) histological classifi-
cation of PTLDs describes the spectrum of lymphoproliferative 
Drug induced carcinogenesis
Thiopurines and anti-TNF agents have distinct mechanisms 
of action that may explain their dissimilar role as risk factors 
for cancer. Anti-TNF agents (infliximab, adalimumab, and goli- 
mumab) may increase the risk of cancer through two mechanisms: 
impaired immunosurveillance and the inhibition of tumor cell 
necrosis1. Nevertheless, anti-TNF use in IBD is only linked to an 
increased risk of melanoma development, and no overall increased 
risk of cancer has been established1. However, it is difficult to 
separate the effect of anti TNF therapy from thiopurines, since 
most IBD patients will be exposed to both drugs.
 Thiopurines (azathioprine, 6-mercaptopurine and 6-thiogua-
nine) increase the overall risk of developing cancer in IBD 
patients (rate ratio 1.41; 95% confidence interval: 1.15 - 1.74)2. 
Thiopurines can induce carcinogenesis through 3 different 
pathways. Firstly, they can induce carcinogenic DNA mutations3. 
Secondly, they impair immunosurveillance of (pre)cancerous 
cells4 and thirdly, they reduce the activity of T lymphocytes that 
prevent chronically virally infected cells (Epstein-Barr virus 
(EBV) or human papillomavirus (HPV)) to proliferate4, 5. The 
latter is especially relevant for the development of lymphoid 
malignancies, as well as virus-associated solid tumors, such as 
squamous cell carcinomas of the cervix and the head and neck area.
 
Lymphoproliferative disorders
Population-based studies show no or only a minimal increase 
in the risk of lymphoma development in the general IBD 
population6-8, however, there is an increased risk associated with 
thiopurine therapy (SIR 5.7, 95 % CI, 3.2 – 10.1)9.
  Three types of thiopurine-related non-Hodgkin lympho-
mas are reported. Two are EBV- related: post-transplant like 
lymphomas and post-mononucleosis lymphomas10, 11. The third 
type is rare. Hepatosplenic T-cell lymphoma has mainly been 
reported in male IBD patients younger than 35 years-of-age 
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colitis-associated cancer by perpetuating chronic inflammation 
and / or producing carcinogenic factors10.
 CRC patients with IBD are younger at cancer diagnosis, more 
likely to have multiple neoplastic lesions and have an impaired 
survival compared to sporadic CRC patients19, 20.
 
Surveillance
The increased risk and impaired outcomes of colitis-associated 
CRC warrant endoscopic colonic surveillance to detect and treat 
(pre)cancerous lesions. Subsequent subtotal colectomy is an im-
portant treatment option in case complete endoscopic treatment 
is not possible. Although subtotal colectomy reduces the CRC 
risk, neoplasia of the residual colonic mucosa may still arise. Un-
fortunately, specific surveillance guidelines for these post-surgi-
cal IBD patients are lacking at this time. Further data regarding 
risk factors, incidence and prevalence of CRC following subtotal 
colectomy are needed to further develop these guidelines. 
 
Gastric cancer
The incidence of gastric cancer (GC) is declining in the Western 
world21. This may be partially due to the treatment of the carcino-
genic Helicobacter pylori (H. pylori). Other risk factors for GC in-
clude EBV infection, pernicious anemia, gastric surgery and fa-
milial predisposition. No IBD specific risk factors are known, but 
an increased risk for GC development has been reported for CD 
patients22 with a pooled SIR of 2.05 (95 % CI 1.06 – 3.97).
  GC is classified by Lauren in diffuse and intestinal GC. Two 
entities with different etiologies, pathogenesis and behavior23, 
but both related to H. pylori. The morphologic differences are 
attributable to intercellular adhesion molecules, which are 
preserved in intestinal-type tumors and defective in diffuse types23. 
 The pathogenesis of intestinal GC is poorly understood. How-
ever, it follows a multistep progression that is usually initiated 
by H. pylori infection and follows a well-characterized sequence: 
disorders under immunosuppressive therapy in three categories. 
This is based on the morphology of the inflammatory infiltrate16. 
Due to preventive strategies like monitoring the EBV load and 
pre-emptive use of anti-B-cell monoclonal antibody treatment, the 
prognosis of PTLD has improved over time, although there is still 
considerable mortality. At present no histological classification 
or preventive strategies are available for IBD-related lympho- 
proliferations.
Solid malignancies
 
Colorectal malignancies
The most frequent malignancy in IBD is directly related to chronic 
inflammation: CRC10. The risk of developing CRC in IBD is 
increased 1.5 to 2 times compared to that of the general popula-
tion, with a linear increase over time. Recently, a decrease in coli-
tis associated CRC was observed17, 18, supposedly due to better dis-
ease control by improved  IBD management and more adequate 
endoscopic surveillance.
 There are specific IBD related risk factors for the develop-
ment of CRC. These factors include chronicity and severity of 
inflammation, extensive disease, presence of pseudopolyps and 
strictures, history of colonic dysplasia and co-existing primary 
sclerosing cholangitis10. 
 
Pathogenesis and outcomes
The pathogenesis of colitis-associated CRC resembles the patho-
genesis of sporadic CRC, although the timing and frequency of 
molecular changes are different. Chronic  inflammation may 
cause oxidative stress–induced DNA damage10. This results in 
the activation of oncogenes and the silencing of tumor-suppres-
sor pathways, leading to an accelerated dysplasia-carcinoma se-
quence. Furthermore, an altered microbiome may contribute to 
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needed to guide clinical decision making. 
Oral cavity and pharyngeal cancer
In immunosuppressed transplant patients, non-cutaneous head 
and neck cancer (HNC) incidence is higher compared to the 
general population32, 33. In IBD, data are limited and conflicting. 
Danish historical cohorts report no increased risk for lip, oral 
cavity and pharyngeal cancer2, 34, while more recent US data show 
a standardized incidence ratio (SIR) for oral cancer of 9.77 (95% 
confidence interval (CI), 5.14–16.98)35.
 The main risk factors for HNC are tobacco use, alcohol 
consumption and HPV infection. HPV associated HNC primarily 
occur in the (oro)pharynx: the tonsils and tongue base36. These 
cancers generally affect younger patients without a history of 
excessive alcohol and tobacco use37 and account for more than 
half of the oropharyngeal cancers38. HPV positive cancers tend to 
present with regional lymph node metastases and smaller prima-
ry tumors and are associated with a better prognosis than HPV 
negative tumors. In HPV negative squamous cell carcinomas, p53 
mutations are very frequent, along with decreased p16 levels. By 
contrast, HPV positive carcinomas are associated with wild-type 
p53 and upregulation of p16. 
 HNC survival is impaired in immunosuppressed transplant 
patients compared to the general population32, 39. In IBD, currently 
no studies on HPV-involvement, the role of immunosuppression 
and disease course of HNC are available. 
 
 
Management of IBD patients with a present or 
past malignancy
 
The increasing life expectancy and rising IBD prevalence provide 
new challenges. Due to the aging IBD population, a growing num-
ber of IBD patients will develop and may be cured of cancer, re-
chronic active gastritis; multifocal atrophic gastritis; intestinal 
metaplasia; dysplasia; and invasive carcinoma. There is a second 
infectious agent contributing to intestinal GC development: EBV. 
It is detected in approximately 9 % of the gastric adenocarcino-
mas. EBV positive GC’s display extreme DNA hypermethylation, 
specific mutations (such as PIK3CA) and amplications24. 
 
Gastric cancer and IBD
Approximately 5% of CD patients have gastric inflammatory in-
volvement25. As such, IBD related chronic inflammation may 
influence GC development. Furthermore, decreased immuno-
surveillance of both H. pylori and EBV may contribute to GC de-
velopment in immunosuppressed IBD patients. At present it is 
unclear whether chronic IBD related (gastric) inflammation and/
or impaired immunosurveillance may play a role in the develop-
ment of GC in IBD patients. 
Melanoma
The incidence of melanoma is increasing in western countries. 
Although under debate, IBD patients may have a higher risk of 
developing melanoma26. Nevertheless, most studies conclude 
that IBD itself does not increase the risk of melanoma22, 27. Risk 
factors include blistering sunburns in early years, sun sensitivity, 
family history, previous melanoma or non-melanoma skin can-
cer and multiple benign naevi. In IBD, anti-TNF alpha therapy 
increases the risk of cutaneous melanoma development by 1.5 to 
2 times1, 28, 29.
 Although the prognosis of melanoma has improved over the 
last decades, mortality is still considerable. Indeed, impaired sur-
vival in immunosuppressed melanoma patients is reported in 
transplant medicine30, 31. In IBD melanoma survival rates are un-
known, as well as the influence of anti-TNF therapy on patient 
outcome. Further data regarding the clinical course and influence 
of immunosuppressive therapy, including anti-TNF agents, are 
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 Chapter 2 of this thesis will focus on lymphoproliferations, 
whereas chapter 3 focuses on solid malignancies. Chapter 4 con-
tains the general discussion and future perspectives. 
 
Aims
Lymphoproliferative disorders (chapter 2)
-  To assess the utility of histological features in predicting EBV 
presence in colonic mucosa (chapter 2.1).
-  To correlate histopathological assessment (including EBV 
load and immunoglobulin clonality) with clinical outcomes 
in IBD patients (chapter 2.1 and 2.2). 
Solid malignancies (chapter 3)
-  To identify IBD-specific risk factors regarding melanoma, 
gastric, pharyngeal and oral cavity cancer and colorectal neo-
plasia following subtotal colectomy (chapter 3.1 to 3.4).
-  To compare clinical characteristics, immunosuppression and 
survival after melanoma, gastric, pharyngeal and oral cavity 
cancer in IBD patients to unselected ‘non-IBD’ patients with 
those cancers (chapter 3.1 to 3.3).
Study design
 
To address these aims we used the following study designs. 
Lymphoproliferative disorders (chapter 2)
 
I: retrospective single-centre cohort study
To assess histologic features and correlate these with EBV load 
and clinical outcomes, we searched our local pathology database 
and included all IBD patients who underwent EBV testing in in-
sulting in new clinical challenges and questions. Renal transplant 
patients with a pre-transplant malignancy are at increased risk of 
recurrence and of the development of a second malignancy40, 41. 
The risk of recurrence is highest in the first two years after treat-
ment and varies with cancer type. Therefore it is of crucial impor-
tance to establish the impact of IBD and immunosuppression on 
the development and clinical course of malignancies.
  In IBD, data on this topic are very limited. The only pro-
spective data available are from the French CESAME cohort42. In 
this IBD cohort (n = 17,047), 405 IBD patients had a history of 
cancer. The risk of recurrence or the development of a second 
malignancy is increased in this population, independent of im-
munosuppression use. A recent meta-analysis observed similar 
rates of cancer recurrence among IBD patients with a history of 
malignancy regardless of immunosuppression43. However, these 
results are under debate, because cancer patients with high risk of 
recurrence may not be treated with immunosuppression by their 
treating physician. 
 
 
This thesis
 
This thesis is limited to rare malignancies in IBD, which may be 
related to IBD due to the presence of IBD related inflammation 
and / or to impaired immunosurveillance due to immunosuppres-
sion use. 
 Although rare, malignant complications show a rising inci-
dence and may occur in all IBD patients. Due to the growing and 
aging IBD population this will become increasingly important in 
clinical practice. Balancing the effects and risks of IBD treatment 
with optimal cancer treatment is very important to achieve the 
best IBD and cancer outcomes. Therefore, additional information 
is needed regarding IBD specific risk factors, incidence, clinical 
course and influence of IBD medical therapy on different malig-
nancies.  
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non-academic hospitals in the Netherlands. We used each cohort 
of specific cancer types and IBD cases for two case control studies: 
 1: to assess risk factors for cancer development in IBD we 
compared IBD cases with a specific malignancy to IBD con-
trols without, derived from the IBD South Limburg46 cohort. 
2: to compare clinical characteristics and survival we compared 
the IBD cases to non-IBD controls with the same specific malig-
nancy. The non-IBD controls were derived from the Eindhoven 
Cancer Registry (http://www.eindhovencancerregistry.nl), which 
is part of the Dutch Cancer Registry (IKNL). 
 
IV: Systematic review 
To determine risk factors and assess incidence and prevalence of 
neoplasia in IBD patients following subtotal colectomy, we per-
formed a systematic review and meta-analysis. We reviewed ob-
servational studies to collect the available data. Subsequently we 
determined a pooled incidence and prevalence of CRC in three 
subgroups: A: patients with a rectal stump, B: patients with an 
ileorectal anastomosis (IRA) and C: patients with an ileal pouch 
– anal anastomosis. Finally we determined the risk factors for de-
veloping post-colectomy neoplasia in a pooled model. These data 
are a solid basis to provide recommendations for endoscopic sur-
veillance in IBD patients after subtotal colectomy.
testinal biopsies. All biopsies were classified according to the 
WHO PTLD classification and the EBV load was scored. For EBV 
detection we used the golden standard: EBV-encoded RNA in situ 
hybridization. EBV positive cases were divided into a low and high 
EBV concentration group. Histological classification was correlated 
with the EBV concentration and clinical data. Clinical data were 
collected from patient charts. Reported clinical outcomes included 
colectomy, need for chemotherapy and mortality.
 
II: Retrospective multi-centre cohort study 
To study the clinical implications of IG-clonality testing, we per-
formed a retrospective analysis in a large multicentre cohort 
using the EuroClonality database. Both PTLD and IBD related 
PTLD-like patients were included. IG-gene clonality testing and 
molecular characterization were performed by the assessment of 
the IGHV(D)J, -DJ as well as IGK rearrangements. Interpretation 
of the clonality findings was performed according to the EuroClo-
nality guidelines44. Patients were classified EBV-LPD according 
to the WHO criteria16. Clinical data were collected from patient 
charts and the EuroClonality database. Multivariable analysis was 
performed to indentify clinical and histological risk factors for 
poor disease outcome. 
Solid malignancies (chapter 3)
 
III: retrospective case control studies
To identify IBD-specific risk factors and to compare clinical 
characteristics, we created three nationwide cohorts of IBD pa-
tients with a specific malignancy by using PALGA. PALGA is 
the Dutch nationwide network and registry of histo- and cytopa-
thology45. This registry contains pathology reports generated in the 
Netherlands since 1971 and has complete national coverage since 
1991 encompassing all pathology laboratories from all academic and 
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Abstract
Background 
Inflammatory bowel disease (IBD) patients on thiopurine therapy 
are at increased risk of Epstein-Barr virus (EBV) associated lym- 
phomas. This virus is frequently detected in the intestinal mucosa 
of IBD patients and may cause a wide spectrum of lymphoprolifera-
tions similar to post-transplantation lymphoproliferative disorders 
(PTLDs).  We aimed to assess whether histological aberrations aid 
in predicting EBV presence and to correlate histological assess-
ment and EBV load with disease outcome in IBD.
Methods
We included all IBD patients from our centre who underwent EBV 
testing of intestinal biopsies between January 2004 and October 
2013. All biopsies were classified according to the WHO PTLD 
classification and the EBV load was scored per high-power field 
(HPF). Clinical data were collected from patient charts. Reported 
clinical outcomes included colectomy, need for chemotherapy and 
mortality. 
Results 
Our cohort included 58 patients: 28 EBV-positive and 30 EBV- 
negative. An atypical infiltrate was seen more frequently in EBV- 
positive than in EBV-negative patients (57.1 versus 3.3%; p < 0.001). 
A high EBV load occurred more frequently in EBV-positive patients 
undergoing colectomy than in EBV-positive patients without colec-
tomy (50.0 versus 10.0%; p = 0.048). 
Monomorphic lymphoproliferative disorders, including two overt 
lymphomas, were present in 10 patients. Reduction of immunosup-
pression resulted in histological normalization and loss of EBV 
expression in seven of eight non-lymphoma patients. 
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Conclusion
The presence of atypical infiltrate in the intestinal mucosa of IBD 
patients warrants EBV testing. Reduction of immunosuppression is 
an effective strategy to achieve morphological normalization and 
loss of EBV. Lymphoproliferation related to IBD appears to have 
less aggressive clinical behaviour than PTLDs. 
Key words: 
Inflammatory bowel diseases, Epstein-Barr virus, lymphoma
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1. Introduction
 
The use of immunosuppressive therapy is associated with an in-
creased risk of lymphoproliferation in patients with inflammatory 
bowel disease (IBD)1, 2 as well as in post-transplantation patients2. 
Post-transplantation lymphoproliferative disorders (PTLDs) are 
uncommon B-cell lymphoproliferations that are frequently associ-
ated with Epstein-Barr virus (EBV).2, 3 High mortality rates, (up to 
80%),  have been reported when PTLDs are left untreated.2, 3
 The World Health Organization (WHO) histological classifica-
tion on PTLD describes the continuum of lymphoproliferative dis-
orders under immunosuppressive therapy in three categories.4 This 
is based on the extent, architectural characteristics and B-lympho-
cyte cytology of the inflammatory infiltrate.4
 Similarly, IBD lymphoproliferative disorders are also pre-
dominantly EBV-associated5, 6 and histologically comparable to 
PTLDs.1, 5 They are associated with thiopurine therapy, which im-
pairs T-cell activity, leading to decreased immunosurveillance of 
latent EBV infection.2, 7 This decreased immunosurveillance can 
facilitate the reactivation of this oncogenic virus.7 Indeed, IBD pa-
tients on thiopurine therapy have a 3- to 5-fold increased lympho-
ma risk.1, 8 This is mainly attributed to the development of primary 
intestinal lymphomas, which are rare in the general population.9 
EBV-positive cells can be found in the colonic mucosa in up to 60% 
of IBD patients, predominantly in the inflamed areas.10, 11, 12
This high percentage is caused by both the increased num-
ber of infiltrating B-lymphocytes due to inflammation and the in-
creased EBV replication rate as a result of immunosuppression.11, 
13 The clinical relevance of EBV-positive colon cells in IBD patients 
remains unclear. No serological or histological predictors of intesti-
nal lymphoma development in IBD patients are currently available. 
 In transplantation medicine, strategies like regular measure-
ment of EBV load have been developed to detect a “prelymphoma 
state”.14 Preventive treatment in this state can reduce the morbid-
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ity and mortality of EBV-related lymphoproliferative disorders in 
PTLD.14 
 Unfortunately, the clinical impact of intestinal EBV and which 
IBD patients should be tested for intestinal EBV presence remain 
unclear. Therefore, we aimed to assess the utility of histological 
aberrations in predicting EBV presence. Furthermore, we aimed to 
correlate histological assessment and mucosal EBV load with clini-
cal outcomes in IBD patients.
 
2. Materials and methods
2.1. Patient selection
For this retrospective single-centre cohort study, we initially included 
all IBD patients at the Radboud University Medical Center (Rad-
boudUMC; Nijmegen, The Netherlands) who underwent EBV testing 
of ileocolonic mucosal biopsies between January 2004 and October 
2013. The RadboudUMC functions as a tertiary referral centre for 
IBD patients. The local pathology database was used for the patient 
selection. Search terms used in this query included “Inflammatory 
Bowel Disease”, “Crohn’s Disease”, “Ulcerative Colitis”, “colitis” or 
“indeterminate colitis” combined with “Epstein-Barr virus”, “EBV” 
or “EBV encoded RNA (EBER)”. Inclusion criteria were a confirmed 
IBD diagnosis, IBD treatment at the RadboudUMC and EBER 
testing on ileocolonic mucosa at our institution. 
 Clinical data were retrieved from medical records, including 
age, gender, EBV serology if available (also before 2004) and IBD 
characteristics (year of diagnosis, Montreal classification, type 
and duration of IBD medication and intestinal surgery). Prescribed 
anti-inflammatory immunosuppressive IBD drugs were record-
ed, defined as thiopurines, corticosteroids, anti-TNF agents and 
methotrexate. The number of immunosuppressive drugs at the 
time of biopsy was also recorded. Clinical endpoints included IBD- 
related intestinal surgery, lymphoma development and mortality. 
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Figure 1: Histology and immunohistochemistry.
(A, B) Haematocylin-eosin-staining for inflammatory infiltrate: (A) normal; (B) atypical  (increased, disorga-
nized lymphoplasmacytic infiltrate in lamina propria [white arrow]).  
(C-D) CD20 staining for B-lymphocytes: (C) normal; (D) atypical. ( presence of large, atypical  CD20-positive 
B-lymphocytes [black arrow]. 
(E) EBER-ISH staining for EBV-positive cells (blue arrow).
2.2. Histopathology
Previously EBV tested ileocolonic biopsies from all enrolled patients 
were reviewed  by one expert gastro-intestinal pathologist (JHJM 
vK), who was blinded to prior results. Every biopsy was assessed 
for three histological features: the architecture of the lymphocy-
toplasmatic infiltrate in the lamina propria; the presence of aty- 
pical, large B-lymphocytes; and third the presence and number of 
EBER-positive cells. This was performed at the histologically most 
inflamed site with the most dense atypical lymphocytoplasmic 
infiltrate. 
 
2.3. Immunohistochemistry
We used immunohistochemistry for the assessment of lymphop-
lasmacytic infiltrate and B-lymphocytes. The lymphoplasmacytic 
infiltrate was scored as normal or atypical in a haematoxylin and eo-
sin (HE) staining (figure 1A-B). Atypical was defined as increased, 
disorganized lymphoplasmacytic infiltrate in the lamina propria. 
 We visualized B-lymphocytes by immunohistochemistry 
using an antibody against CD20 (B-lymphocyte antigen Clone: L26; 
Thermo scientific, USA) and evaluated them as normal or atypical 
(figure 1C-D). Atypical was defined as the presence of large, 
atypical  CD20-positive B-lymphocytes.
2.4. EBV testing
The gold standard for identifying EBV in biopsies is in situ hybridiza-
tion for EBV-encoded RNA (EBER-ISH).15 Standardized EBER-ISH 
testing (DAKO, Belgium, and Roche, Switzerland) was used for all 
included mucosal biopsies. Formalin-fixed, paraffin-embedded tis-
sue sections (4 μm) were floated on Superfrost slides. Deparaffin-
ized slides were treated with Proteinase K (DAKO PNA ISH Detec-
tion Kit [K5201]). After hybridization with DAKO EBV (EBER) PNA 
Probe (Y5200) and detection with rabbit anti-FITC/AP (DAKO PNA 
ISH Detection Kit [K5201]), the EBER PNA probes were visualized 
with NBT/BCIP (4-Nitro blue tetrazolium chloride/5-Bromo-
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Figure 2: Patient selection and categorization.
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4-chloro-3-indoyl-phosphate; Roche) followed by counterstaining 
with Nuclear Fast Red.
 EBER-positive cases (Figure 1) were scored quantitatively in 
the area of the highest EBV concentration per high-power field 
(HPF, 0.2 mm2) (x400 magnification) and divided into two catego-
ries: low EBV concentration (<10 EBER positive cells per HPF) and 
high EBV concentration (≥ 10 EBER positive cells per hpf). 
 
2.5. Classification
Following WHO guidelines on PTLDs,4 we used three categories to 
classify the EBV-positive infiltrate in IBD patients: morphologically 
benign (normal lymphoplasmacytic infiltrate in the lamina propria 
irrespective of B-lymphocyte morphology); polymorphic lesions 
(atypical lymphoplasmacytic infiltrate and at most only rare aty- 
pical B-lymphocytes); and monomorphic lesions (atypical lympho- 
plasmacytic infiltrate with numerous large B-lymphocytes). 
Subsequently, these three categories were correlated with the EBV 
concentration and clinical data. 
 
2.6. Monomorphic lesions
In the case of monomorphic lesions, we collected all ileocolonic bi-
opsies available at the RadboudUMC from the same patient with-
out prior EBER testing before and after the included first (mono-
morphic) biopsy. These additional biopsies were also scored for the 
described histological features in order to study the longitudinal 
course of lymphoproliferation. Cases with sheets of large B-cells 
were classified as diffuse large B-cell lymphomas.
 
2.7. Statistical analysis
Baseline characteristics were expressed as percentages in the case 
of proportions and as medians with (minimum – maximum) range 
in the case of continuous data. Categorical variables were analyzed 
using the χ2 test or Fisher’s exact test as appropriate. A p-value of 
<0.05 was considered statistically significant. Test characteristics, 
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including sensitivity, specificity, negative predictive value (NPV) 
and positive predictive value (PPV), were calculated, using only the 
first EBV-tested biopsy. We used IBM SPSS version 20.0 for win-
dows (SPSS Inc., Chicago, IL, USA) for statistical analysis. 
3. Results
3.1. Patients and biopsies
Initially, we identified 120 patients who underwent EBV testing on 
intestinal mucosa (Figure 2). Sixty-two patients were excluded due 
to lack of IBD diagnosis (49 patients) or treatment at other medi-
cal centres (13 patients). The remaining 58 patients comprised 16 
(27.6%) diagnosed with Crohn’s disease, 41 (70.7%) with ulcerative 
colitis and one with indeterminate colitis (1.7%). We evaluated the 
first EBV-tested mucosal biopsy in all 58 included IBD patients; 28 
patients were EBV-positive and 30 were EBV-negative (figure 2). 
All included biopsies involved mucosa with active inflammation on 
endoscopy and histology. The majority of the biopsies were colonic 
(n = 53; 91.4%); five biopsies (8.6%) were obtained from the ter-
minal ileum. 
 
3.2. Histopathology and immunohistochemistry
The lymphoid infiltrate was scored in all 58 samples; in 70.7% (n = 
41) it was not considered atypical. The B-lymphocytes were normal 
in 69.0% (n = 40). Normal lymphoid infiltrate and B-lymphocytes 
were more frequent in the EBV-negative than in the EBV-positive 
group (83.3% [n = 25/30] versus 32.1% [n = 9/28], p < 0.001). An 
atypical infiltrate and atypical B-lymphocytes were significantly 
more frequent in the EBV-positive than in the EBV-negative group 
(35.8% [n = 10/28] versus 3.3% [n = 1/30]; p < 0.005).
   Only nine out of 28 cases with mucosal EBV positivity had a nor-
mal lymphoid infiltrate and B-lymphocytes, all with ≤10 EBER-posi-
tive cells per HPF. 
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 To evaluate whether the presence of an atypical infiltrate or 
atypical B-lymphocytes was predictive of mucosal EBV presence, 
we calculated the sensitivity, specificity, PPV and NPV. For an 
atypical infiltrate, specificity was 96.7%, sensitivity 57.1%, PPV 
94.1% and the NPV 70.7%. These numbers were lower when using 
atypical B-lymphocytes: 83.3%, 46.4%, 72.2% and 62.5%, respec-
tively. 
3.3. Classification
All EBV-positive biopsies were classified into three histological cate- 
gories according to the WHO classification, as outlined in section 
2.5 (Figure 2). Twelve patients had morphologically benign lesions, 
including three patients with normal lymphoid infiltrate but a few 
atypical B-lymphocytes. Six patients had polymorphic lesions and 
10 had monomorphic lesions. High EBV concentrations were sig-
nificantly more frequent in the monomorphic group (70.0% (n = 
7/10) compared with the benign and polymorphic groups (16.7% 
[n = 2/12] and 16.7% [n= 1/6]), respectively (p = 0.019). We did 
not find significant differences in EBV concentrations between the 
morphologically benign and polymorphic group. 
 For our analysis we included the three patients with atypical 
B-lymphocytes and normal infiltrate in the polymorphic group. 
Comparing the benign, polymorphic and monomorphic lesions again, 
we now observed a gradual increase in the frequency of high EBV 
concentrations over the three categories (benign, 0.0% [n = 0/9]; 
polymorphic, 33.3% [n = 3/9]; monomorphic 70.0% [n = 7/10]; p = 
0.009). Patients with morphologically benign lesions had low EBV 
concentrations (<10 EBV-positive cells per HPF) significantly more 
frequently than patients with monomorphic lesions. 
3.4. Clinical data
3.4.1. Intestinal EBV-positive patients
The median age for having a EBV-positive biopsy was 45 years 
(range 21-76, SD 14.9). Only one patient had a known serological 
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Table 1: Comparison between EBV-positive and -negative patients. 
Variable    EBV-positive EBV-negative p-value 
     (N = 28)  (N = 30) 
Histology 
Atypical inflammatory infiltrate, n (%)  16 (57.1) 1 (3.3)  < 0.001 * 
Atypical B lymphocytes, n (%)  13 (46.5) 5 (16.6)     0.014 * 
   
Clinical  
Age at IBD diagnosis (years),       
     median ± SD     30.5 ± 15.6 24.5 ± 15.2  
Male sex, n (%)    15 (53.6) 15 (50.0)  
IBD type          
     Ulcerative colitis, n (%)   23 (82.1) 17 (56.7)    0.052 
 E2*    7 (25.0)  3 (10.0) 
 E3*    16 (57.1) 14 (46.7) 
     Crohn’s disease, n (%)   5 (17.9)  12 (40.0) 
     Indeterminate colitis, n (%)  0 (0.0)  1 (3.3) 
 
Total number immunosuppressiveϯ therapies at time of biopsy 
     0     5 (17.9)  8 (26.7)    0.025 * 
     1     9 (32.1)  17 (56.7) 
     ≥ 2     14 (50.0) 5 (16.7) 
       
*Montreal classification. 
ϯ Defined as thiopurines, corticosteroids, anti-TNF agents and methotrexate 
 
 
  
Table 1: Comparison between EBV-positive and -negative patients.
EBV status at the start of immunosuppressive therapy. Eighteen out 
of 28 (64.3%) intestinal-EBV-positive patients underwent intesti-
nal surgery (all colectomy) during follow-up. Patients undergoing 
surgery had high EBV concentrations significantly more often than 
patients without surgery (50.0% [n = 9/18] versus 10.0% [n = 1/10], 
p = 0.048). No mortality was observed in our cohort, with a median 
follow-up of 58 months (range 8 – 108 months), even though none of 
our patients with polymorphic lesions and only two with monomorphic 
lesions received chemotherapy or immunotherapy (Rituximab). 
3.4.2. EBV-positive versus EBV-negative patients
The median age at IBD diagnosis was 30.5 years (range 12-75) 
in the EBV-positive group and 24.5 years (range 13-80) in the 
negative group (Table 1). Ulcerative colitis was more frequent in 
the EBV-positive group (82.1% [n = 23]) than in the EBV-negative 
group (56.7% [n = 17/30], p = 0.052). We found no difference in 
endoscopic Mayo score between the EBV-positive and -negative 
ulcerative colitis patients. Seven patients did not receive any treat-
ment (three EBV-positive patients) and an additional six patients 
did not receive immunosuppressants (two EBV-positive patients). 
EBV positive patients used corticosteroids and anti-TNF therapy 
significantly more frequently than EBV-negative patients (cortico-
steroids, 57.1% [n = 16/29] versus 30.0% [n = 9/30], p = 0.037; 
anti-TNF therapy 35.7% [n = 10/28] versus 13.3% [n = 4/30], p = 
0.047).
  We found no significant differences between EBV-positive 
and –negative patients in the use of 5-aminosalicytes (46.4% [n = 
13/28] versus 26.7% [n = 8/30], p = 0.12) and thiopurines (46.4% [n 
= 13/28] versus 43.3% [n = 13/30], p = 0.81) between EBV positive 
and negative patients. However, EBV-positive patients used com-
binations of immunosuppressive drugs more frequently compared 
with EBV-negative patients (50.0% [n = 14/28] versus 16.7% [n = 
5/30], p = 0.025). For detailed information on each enrolled patient, 
we refer to supplementary file 1.
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Table 2: Comparison between benign, polymorphic an monomorphic lesions.
Table 2: Comparison between benign, polymorphic an monomorphic lesions. 
Variable    Benign  Polymorphic Monomorphic       p-value 
                  (N = 12)  (N = 6)  (N = 10) 
 
Age at IBD diagnosis (years),     
median ± SD         45 ± 16.4  38.5 ± 15.6                   27 ± 15.4                 0.63 
Male sex, n (%)        5 (41.7)  4 (66.7)  6 (60.0)               0.53 
IBD type           
     Ulcerative colitis, n (%)       3 (25.0)  6 (100.0)  8 (80.0)               0.42 
     Crohn’s disease, n (%)       9 (75.0)  0 (0.0)  2 (20.0) 
Age at EBV diagnosis (years),     
     median ± SD         45 ± 15.3  59 ± 12.2  39.5 ± 12.4             0.64 
EBV load  
     Low, n (%)   10 (83.3)  5 (83.3)  3 (30.0) 
 0.019 * 
     High, n (%)   2 (16.7)  1 (16.7)  7 (70.0) 
Surgery    6 (50.0)  3 (50.0)  9 (90.0) 
 0.048 * 
IS reduction    4 (41.6)  3 (50.0)  9 (90.0) 
 0.041 * 
     
Low: < 10 EBER-positive cells per HPF; high, ≥ 10 EBER-positive cells per HPF. 
IS, immunosuppressive therapy, defined as thiopurines, corticosteroids, anti-TNF agents 
and methotrexate. 
Table 2: Comparison between benign, polymorphic an monomorphic lesions. 
Variable    Benign  Polymorphic Monomorphic       p-value 
                  (N = 12)  (N = 6)  (N = 10) 
 
Age at IBD diagnosis (years),     
median ± SD         45 ± 16.4  38.5 ± 15.6                   27 ± 15.4                 0.63 
Male s x, n (%)        5 (41.7)  4 (66.7)  6 (60.0)               53
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     Ulcerative colitis, n (%)       3 (25.0)  6 (100.0)  8 (80.0)               0.42 
     Crohn’s disease, n (%)       9 (75.0)  0 (0.0)  2 (20.0) 
Age at EBV diagnosis (years),     
     median ± SD         45 ± 15.3  59 ± 12.2  39.5 ± 12.4             0.64 
EBV load  
    Low, n (%)   10 (83.3)  5 (83.3)  3 (30.0) 
 0.019 * 
     High, n (%)   2 (16.7)  1 (16.7)  7 (70.0) 
Surgery    6 (50.0)  3 (50.0)  9 (90.0) 
 0.048 * 
IS reduction    4 (41.6)  3 (50.0)  9 (90.0) 
 0.041 * 
    
Low: < 10 EBER-positive cells per HPF; high, ≥ 10 EBER-positive cells per HPF. 
IS, immunosuppressive therapy, defined as thiopurines, corticosteroids, anti-TNF agents 
and methotrexate. 
 The EBV PCR load in the blood was available for only 27 of our 
patients (14 with EBV-positive biopsies and with 13 EBV-negative 
biopsies). In this small group there was no correlation between se-
rum EBV PCR load and the mucosal presence of EBV in biopsies.
3.4.3. WHO classification
No differences were found in type of IBD, age at IBD diagnosis or 
age at EBV diagnosis, between the three histological WHO catego-
ries (Table 2). Intestinal surgery was significantly more frequent in 
patients with monomorphic lesions: 90.0% (n = 9/10) versus 50.0% 
in patients with benign (n = 6/12) or polymorphic [n = 3/6) lesions. 
A high EBV load was more frequent in patients with monomorphic 
lesions than in other groups (monomorphic, 70 % [n = 7/10]); be-
nign, 16.7 % [n = 1/6]; polymorphic [n = 2/12]; p = 0.019). After an 
EBV-positive biopsy, immunosuppression was reduced in most pa-
tients with monomorphic lesions (90.0%, [n = 9/10] versus 50.0%, 
[n = 3/6] in patients with polymorphic lesions and 41.6%, [n = 5/12] 
in those with benign lesions; p = 0.041). 
3.5. Monomorphic lesions
Ten EBV-positive patients in our cohort were classified as mono-
morphic (characterized by both atypical infiltrate and atypical 
B-lymphocytes), based on their first EBV-tested biopsy (index bi-
opsy). In these 10 patients, we identified 39 additional series of bi-
opsies (figure 2), obtained before and after the index biopsy during 
separate endoscopic procedures, but without prior EBV testing. 
These 39 series of biopsies were also assessed for histological fea-
tures. A timeline of EBV status and histological features in patients 
with a monomorphic infiltrate is presented in supplementary file 2. 
 In the eight patients with monomorphic histology (exclud-
ing the lymphoma patients because they were treated with both 
chemotherapy and stopping of immunosuppressive therapy), im-
munosuppression was reduced by the treating physician. Seven 
patients became EBV-negative following reduction in immunosup-
40 2.1
pression (median 4 months; range 1-10; SD 3.2) and the remaining 
patient showed a clear reduction in the quantity of EBV-positive 
cells. Normalization of the histological features occurred in all pa-
tients after 6.5 months (median; range 1-48, SD 17.0), although the 
endoscopic surveillance frequency was reduced after the patients 
became EBV-negative. In four patients surgery was planned after 
the EBV-positive diagnosis, without awaiting the effect of reduced 
immunosuppression. Three patients in the cohort with monomor-
phic lesions latee underwent a subtotal colectomy due to disease 
activity. Overt lymphoma was not found in anyone of the resection 
specimens.
 Two patients in this cohort developed overt colonic EBV-as-
sociated diffuse large B-cell lymphomas (one due to EBV reacti-
vation during the use of thiopurines, the other after a primary EBV 
infection). Both patients presented with a colonic perforation and 
underwent surgery, were treated with chemotherapy (combination 
of Cyclophosphamide, Hydroxydaunorubicin, vincristine [Oncovin], 
Prednisone and Rituximab) and reached complete remission (fol-
low-up at 9 and 7 years). In both patients all immunosuppressive 
medication was stopped and never reintroduced during follow-up.
 
 
4. Discussion
 
In the current study, we showed that histological assessment of the 
inflammatory infiltrate and B-lymphocytes in intestinal biopsies can 
be used to guide EBV diagnostics in IBD patients. The presence of 
an atypical inflammatory infiltrate and  atypical B-lymphocytes was 
associated with a high mucosal EBV load (≥ 10 EBER-positive cells 
per HPF). A high mucosal EBV load was also correlated with subse-
quent surgery. Despite two lymphoma cases, we observed no mor-
tality in this IBD cohort. Our findings suggest that EBV-associated 
lymphoproliferative disorders in IBD have a much better outcome 
compared with EBV-associated PTLDs with similar morphology. 
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 This is the first study that describes the lymphoproliferative 
spectrum in IBD. Currently, no specific guideline is available for the 
classification of EBV-associated lymphoproliferations in IBD. We 
used the WHO PTLD classification4  to predict EBV presence and 
to classify the lymphoproliferative disorders in IBD, since PTLDs 
and lymphoproliferations in IBD show similarities in aetiology and 
morphology .1, 5 
 Previous studies demonstrated EBV-positive cells in the co-
lonic mucosa in up to 60% of IBD patients.10, 11, 12 However; in daily 
practice EBER-ISH is performed infrequently. This suggests that 
intestinal EBV presence may be underestimated in daily practice. 
The histology of intestinal biopsies may  guide the decision about 
when to perform EBER –ISH, leading to increased EBV detection. 
 Monomorphic lesions, characterized by an atypical infiltrate 
and atypical B-lymphocytes, are accompanied by high EBV loads 
and high surgery rates. Approximately 68% of the EBV-positive 
patients can be identified when EBER is performed in cases with 
atypical infiltrate or atypical B-lymphocytes. In contrast, very few 
EBV-positive cells are found in benign and polymorphic lesions. 
Approximately 32% of patients with EBV-positive cells have normal 
histology. However, these patients may be at low risk of lympho- 
proliferation due to the lower number of EBV-positive cells. Classi-
fication of biopsies with few atypical B-lymphocytes but a normal 
 inflammatory infiltrate as polymorphic lesions instead of benign 
lesions may result in better differentiation between the three WHO 
categories in IBD patients.
 In line with previous studies,16, 17 we showed that  reduction of 
immunosuppressants led to regression of both atypical lymphopro-
liferative disorders and intestinal EBV load. Our data suggest that 
there is limited need to treat EBV-associated lymphoproliferative 
disorders with chemotherapy. Reduction of immunosuppressive 
therapy might be sufficient in most cases. Four out of eight pa-
tients with monomorphic lesions  in whom immunosuppression was 
reduced, underwent colectomy before the effect of reduction was 
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evaluated. Interestingly, three of these patients were EBV-negative 
at histological assessment of the resection specimen.
  Two patients with overt EBV-associated diffuse large B-cell 
lymphoma showed a very good prognosis. These findings are in 
sharp contrast with the high reported mortality in untreated PTLD 
patients.2 No histological predictor of lymphoma development was 
found in prior intestinal biopsies. However, both lymphoma patients 
possibly had an additional risk factor for lymphoma development. 
The first (male) patient had EBV reactivation within 1 year after 
starting thiopurine therapy. From transplant medicine we know that 
most PTLD’s occur within the first year after transplantation.2,18 
This might also apply to IBD, although future research is needed to 
prove this. The second patient developed a lymphoma during aza-
thioprine therapy just after a primary EBV infection. A primary EBV 
infection may result in a higher lymphoma risk compared with pa-
tients who are EBV-positive before the start of immunosuppressive 
therapy.1 
 The European Crohn’s and Colitis Organisation recently em-
phasized the need to determine the prelymphoma state and to de-
velop preventive strategies similar to those for PTLDs.19 Currently, 
when there is clinical suspicion of lymphoproliferation in IBD pa-
tients, the EBV viral load is measured. However, an IBD flare may 
result in a temporarily increased  EBV viral load  unrelated to lymph-
oproliferation.20  Despite the small available numbers of EBV PCRs 
in this study, no correlation was observed between the presence of 
EBV in the blood and in the biopsies. Large prospective studies are 
needed to test alternative strategies to screen and treat potential 
lymphoproliferative disorders in IBD patients, such as the prophy-
lactic antiviral therapy used in transplant medicine.21 
 The results of this study have implications for clinical practice. 
First, EBER-ISH testing of intestinal biopsies is currently clinically 
based, but should also be guided by the presence of atypical in-
flammatory infiltrate and / or atypical B-lymphocytes. Second, re-
duction of immunosuppression should be considered in IBD patients 
43Lymphoproliferations in inflammatory bowel diseases
who are diagnosed with EBV-associated lymphoproliferative disor-
ders of all morphologies, except those with overt lymphoma mor-
phology; these patients require additional treatment, which often 
includes chemotherapy.
  Our study has several limitations. First, only patients who 
underwent EBV testing on clinical or histological grounds were 
included. Ideally, all IBD patients (who underwent endoscopy with 
biopsies in the study period) should have been enrolled, but this 
was not feasible due to the high number and the costs related to 
testing. Of note, there are currently no guidelines available that 
indicate when to perform EBV testing on intestinal biopsies. There-
fore, most of the included patients had significant disease activity, 
resulting in a selection bias. Furthermore, due to the retrospec-
tive design, disease activity was not uniformly described and no 
standardized biopsy protocol was used Future studies with a 
prospective design, larger patient numbers and systematic collec-
tion of data and tissue may provide further insight into the timing 
and significance of intestinal EBV testing.
 In conclusion, we showed that histological assessment of in-
testinal biopsies is of value in predicting EBV presence in mucosal 
biopsies from IBD patients. EBER-ISH testing should be considered 
in IBD patients with atypical inflammatory infiltrate and/or B-lym-
phocytes. Furthermore, reduction of immunosuppression is an 
effective strategy to achieve resolution of intestinal EBV. Finally, 
our data suggest that EBV-driven lymphoproliferative disorders in 
IBD have a better outcome compared with PTLDs. 
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Supplementary file 1: Detailed information on first biopsy of included EBV   
positive (upper panel) and EBV-negative (lower panel) patients.
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Supplementary file 2: Timeline of histological and clinical features and EBV status in patients with 
monomorphic lesions.
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Letter to the editor
Immunodeficiency-associated Epstein-Barr (EBV)-related lym- 
phoproliferative disorders (EBV-LPD), including the post-transplant 
lymphoproliferative disorders (PTLD), are aggressive hematologic 
malignancies which, despite improvements in therapy, including the 
use of anti-CD20 monoclonal antibody, result in considerable morbi-
dity and mortality.1–3 Retrospective analyses have revealed several 
clinical risk factors, including therapeutic interventions, that pre-
dict outcome in patients with EBV-LPD. However, pre-treatment 
risk stratification that can be used to guide therapeutic decisions 
remains difficult and algorithms are lacking.1 Although morpho-
logy is regarded to be a cornerstone in therapy decision making, 
immunoglobulin (IG) clonality might help prognostication. Despite 
efforts to standardize the pathological classification of EBV-LPD,4 
neither histology nor IG clonality has been shown to consistent-
ly predict outcome.5–7 Nevertheless, comprehensive IG clonality 
testing, with a high detection rate of clonality, allows an objective 
pathological parameter to be re-evaluated in risk stratification of 
EBV-LPD.8
 We performed a retrospective analysis in a large multi-center 
cohort of 86 patients with EBV-LPD: 62 patients with an EBV-posi-
tive PTLD and 24 with another iatrogenic immunodeficiency related 
EBV-LPD. Patients from 2000–2012 were included in the analysis; 
patients’ characteristics are presented in Online Supplementary 
Table S1. IG-gene clonality testing was performed by assessment 
of the IGH-V(D)J, -DJ as well as IGK (VJ and KDE) rearrangements 
using the BIOMED2 approach. This IG clonality assay has an unpre-
cedented high detection rate8,9 due to the complementarity of the 
PCR- targets with a sensitivity of each individual PCR of 5%–10% 
and the specificity of the IG-clonality assay of 94%.10 In this study 
cohort, 20% of the clonal cases had clonal IGK and/or incomplete 
IGH-DJ rearrangements without having clonal IGH V(D)J-FR1, 2 or 
3 rearrangements. These cases were found in both the EBV-posi-
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tive PTLD and the iatrogenic immunodeficiency-related EBV-LPD 
group, and would have gone unnoticed when clonality testing was 
based only on assessment of the complete IGH rearrangement. In-
terpretation of the clonality findings was performed according to the 
EuroClonality guidelines.11 Patients were classified as having either 
monoclonal or oligo/polyclonal EBV-LPD. Histology was examined 
by 2 experienced hematopathologists and designated either mono-
morphous or reactive/polymorphous (no Burkitt-or Hodgkin-type 
lesion was included) according to the WHO criteria.4 In the majority 
of the cases, IG clonality was detected in multiple PCRs. There was 
no clear difference in clonality pattern in monomorphic subtype PT-
LDs versus the reactive/polymorphic PTLDs, albeit the last group 
tended to have more cases showing monoclonality with a polyclonal 
background, although this is not exclusively seen in this group. A sta-
tistical analysis was performed to identify pre-treatment risk factors 
for poor outcome defined as EBV-LPD-related mortality, with an 
emphasis on pathological features, but also clinical stage according 
to Ann Arbor, extra-nodal disease, age and underlying diagnosis.  
 Univariable analysis using the Fisher exact test revealed multi-
ple risk factors for EBV-LPD-related mortality; P<0.05 was con-
sidered significant (Table 1). This included PTLD as underlying 
diagnosis, disease stage II-IV and IG monoclonality, but not age 
50 years or over, EBV load at diagnosis, and monomorphic histo-
logy. Next we performed a multivariable logistic regression analy-
sis with the four variables having at least a P value of 0.10 in the 
univariable analysis. In the first model, incorporating all four risk 
factors, underlying diagnosis was not associated with EBV-LPD- 
related mortality (P=0.6), but the other three, including age 50 years 
or over, showed an association with P≤0.1. Analyzing these three 
risk factors simultaneously in a second model revealed that age 
and disease stage were significantly related to EBV-LPD-related 
mortality (Table 1), and that IG-clonality showed a trend (P=0.09). 
Nevertheless, the high odds ratios at least suggest that the risk 
factors might all have had an impact and that significance was 
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not established in all three of them due to the small cohort size.  
 Because diseases with a high mortality rate require prognostic 
factors that preferably identify all those at risk for mortality, we 
next investigated which of the pathological factors had the highest 
sensitivity and negative-predictive value for EBV-LPD-related mor-
tality. Sensitivity, specificity, negative predictive and positive pre-
dictive value for EBV-LPD-related mortality in the total cohort were 
68%, 53%, 83%, 33% for monomorphic morphology and 95%, 
30%, 95%, 32% for monoclonal IG-gene status, respectively. When 
looking at PTLD cases separately, similar results were seen with 
the sensitivity and negative predictive value of monoclonal IG-gene 
status exceeding that of monomorphic morphology (95% and 89% 
vs. 70% and 74%, respectively).
 The higher negative predictive value at least suggests that 
IG-clonality testing performs better than histological examination 
when used to identify patients that are not at high risk of death. So, 
patients can be identified that might not require prompt treatment, 
that is, those with oligo/polyclonal disease. Clonality testing, howe-
ver, has a similar, but equally low, positive predictive value as histo-
logy. Therefore, establishing either monoclonality or monomorphic 
disease does not necessarily mean that a patient is at high risk for 
death from EBV-LPD, and therapeutic decision making based on 
clonality status alone might result in overtreatment.
 Realizing the limitations of the multivariable analysis, and the 
very different clinical context of patient groups defined as eit-
her PTLD or another iatrogenic immunodeficiency EBV-LPD, the 
decision was made to analyze the two groups separately (Online 
Supplementary Table S1); this precluded comprehensive statistical 
analysis and, therefore, only descriptive statistics were used.
 The subgroup of patients with PTLD consisted of 41 hemato-
poietic stem cell and 21 solid organ transplant recipients. The distri-
bution of morphological subtypes was similar in the SOT and SCT 
subgroups with approximately 60%–65% monomorphic disease. In 
those patients presenting with monomorphic PTLD, 90% (35 of 39) 
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The therapy that had been applied mostly is shown in the dark blue boxes. The number of patients who actually 
did receive rituximab alone or in combination with chemotherapy (R/R-chemo) are shown in the green boxes. 
Outcome is expressed as mortality rate and indicated in the red boxes. IS: immunosuppressant; MC: monoclonal; 
O/PC: oligo/polyclonal.
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Figure 1: Flowcharts of the clinico-pathological features and patient outcome of patients 
with EBV-related lymphoproliferative disorders and separated by diagnose subgroups. 
Table 1: Univariable and multivariable analysis of risk factors for EBV-LPD related mortality.  
 
Risk factor   EBV-LPD  OR (95 % CI)  P   OR (95 % CI)  P 
    Mortality  univariable  univariable  multivariable  multivariable 
 
Age    
     ≥ 50 years    13 / 36 (36 %)  2.6 (1.0 – 6.9)  0.08   3.6 (1.2 – 11)2  0.03 
     < 50 years   9 / 50 (18 %) 
 
Sex 
     Male    17 / 55 (31 %)  2.3 (0.8 – 7.1)  0.2   -    -  
     Female   5 / 31 (16 %) 
 
Diagnosis 
    PTLD    20 / 62 (32 %)  5.2 (1.1 – 24.5)  0.03   1.5 (0.3 – 8.7)1  0.6   
    Iatrogenic EBV-LPD   2 / 24 (8 %) 
 
Stage 
     II – IV    21 / 59 (36 %)  14.4 (1.8 – 113.5) 0.001   13.8 (1.6 – 117.2)2 0.02 
     I    1 / 27 (4 %) 
 
Extranodal disease 
     Yes    12 / 46 (26 %)  1.1 (0.4 – 2.8)  1.0   -    -  
     No    10 / 40 (25 %)   
 
Morphology 
     Monomorphic   15 / 45 (33 %)  2.5 (0.9 – 6.8)  0.14   -    -  
     Reactive / polymorphic  7 / 41 (17 %)   
 
IG- clonality2 
     Monoclonal       21 / 66 (32 %)  8.9 (1.1 – 70.7)  0.02   6.6 (0.8 – 59.1)2  0.09 
    Oligo / polyclonal  1 / 20 (5 %) 
 
EBV load at diagnosis3 
     ≥ log 3   17 / 45 (38 %)  1.5 (0.5 – 4.3)  0.5 
     < log 3   3 / 12 (25 %) 
 
P < 0.05 was considered statistically significant. OR: odds ratio. 1Model with four covariates. 2Model with three covariates. 3Data on EBV load only present in 57 patients.  
EBV: Epstein-Barr virus; LPD: lymphoproliferative disorder; PTLD: post-transplant lymphoproliferative disorder; IG: immunoglobulin.  
  
Table 1: Univariable and multivariable analysis of risk factors for EBV-LPD related mortality.
P < 0.05 was considered statistically significant. OR: odds ratio. 1Model with four covariates. 2Model 
with three covariates. 3Data on EBV load only present in 57 patients. 
EBV: Epstein-Barr virus; LPD: lymphoproliferative disorder; PTLD: post-transplant lymphoproliferative 
disorder; IG: immunoglobulin
had been classified as monoclonal EBV-LPD. The 4 monomorphic 
PTLD cases without monoclonal IG status all had oligoclonal EBV-
LPD and displayed similar clinical features to the monoclonal cases. 
Mortality was high at 36% (14 of 39) despite the use of R/R-chemo 
(Figure 1A) More specifically, of the 14 patients who died, 13 had 
monoclonal and one oligoclonal EBV-LPD. In patients with reac-
tive/polymorphic PTLD, the IG-clonality status seemed to be of 
importance. Monoclonality resulted in an unfavorable outcome with 
a mortality rate of 33%, which is similar to that seen in the patients 
with monomorphic PTLD. However, a considerable number of deaths 
were caused by insufficient treatment. Five patients who died had 
not received R/R-chemo, probably as a result of inadequate risk 
assessment based on morphology, age and stage. In contrast, po-
lyclonal reactive/polymorphic PTLD patients had a good outcome 
with modification of immunosuppression only (Figure 1A).
 There were 24 patients with another iatrogenic immunodefici-
ency EBV-LPD, which involved 22 patients treated for inflammatory 
bowel disease, e.g. Crohn disease and ulcerative colitis. Extranodal 
disease involving the diseased colon itself was very common, 72% 
(16 of 22). Overall, EBV-LPD mortality was 8% (2 of 24). Ann Arbor 
staging seemed most predictive for outcome (Figure 1B). Stage I 
disease (n=16) was effectively cured by only modifying immunosup-
pressive therapy, sometimes complemented by surgical resection; 
the IG clonality status (44% monoclonal) was not relevant. More 
advanced stages, II-IV (n=8), which proved monoclonal in 75% of 
the cases, required treatment with rituximab (R) alone or combined 
with chemotherapy (R-chemo), but there was still a mortality rate 
of 25% (2 of 8) (Figure 1B). The 2 patients who had died both had 
monoclonal disease and succumbed despite use of R/R-chemo.
Our analysis shows that IG-clonality status might be useful in the 
risk stratification and therapeutic decision making in patients with 
EBV-LPD in the setting of PTLD. Monoclonal, monomorphic EBV-
LPD in PTLD requires early aggressive intervention; polyclonal re-
active EBV-LPD may be managed conservatively. In IBD patients 
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with EBV-LPD, low disease stage is more predictive of survival, 
regardless of whether or not the disease is monoclonal. The fast 
and full recovery of immunity with reduction of immunosuppres-
sants expected in these patients, who have no additional immuno-
logical deficits, seems sufficient to achieve a remission. This con-
trasts with the situation of PTLD after transplantation where more 
profound and prolonged immune deficits arise from pre-treatment 
and conditioning therapy, which precludes control of EBV-LPD 
by a functional immune system on cessation of immunosuppres-
sants.12,13 Reactive/polymorphic and polyclonal PTLD probably 
reflects an earlier phase of the disease where there might be more 
time for immune recovery to occur, and so, even in the setting of 
transplantation, additional therapy can be reserved for those failing 
modification of immunosuppressive therapy.
 Our analysis has several limitations that are related to the re-
trospective nature of the study and the limited sample size. Ne-
vertheless, our findings appeal for future multicenter prospective 
studies that incorporate IG-gene clonality testing in a risk stratified 
approach to PTLD.
 
Footnotes
•  Information on authorship, contributions, and financial & other disclosures was 
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Abstract
Hepatosplenic T-cell lymphoma (HSTCL) is a rare non-Hodgkin 
lymphoma with a high mortality rate. Higher incidence is reported 
in patients with inflammatory bowel disease, specifically in male 
patients that are younger than 35 years, and have been treated with 
thiopurine and tumor necrosis factor (TNF)-α inhibitor combination 
therapy for over 2 years. In this case report we describe a 47-year-
old patient with Crohn’s disease (CD) who developed HSTCL after 
having been treated with thiopurine monotherapy for 14 years. To 
our best knowledge, only eleven cases exist of patients with CD who 
developed HSTCL while on thiopurine monotherapy. We report the 
first patient with CD, older than 35 years, who developed HSTCL 
while on thiopurine monotherapy. This emphasizes that HSTCL risk 
is not limited to young men receiving both thiopurines and TNF- α 
inhibitors.
 
Key words:  
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Core tip
In this manuscript we provide an overview of all known cases in lite- 
rature with Crohn’s disease (CD) who developed hepatosplenic T-cell 
lymphoma (HSTCL) while on thiopurine monotherapy. In addition, 
we present our case of a patient with CD on thiopurine monotherapy 
who developed HSTCL at a relatively old age. This emphasizes that 
HSTCL may develop at all ages, even when the patient is solely on 
thiopurine monotherapy.
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Introduction
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype (1%) 
of peripheral T-cell non-Hodgkin lymphomas[1]. It is an extranodal 
and systemic neoplasm deriving from cytotoxic T-cells, usually 
with a gamma-delta (γδ )-T-cell receptor type[2]. These atypical 
lymphocytes display global infiltration in the splenic red pulp 
and in the intrasinusoidal space in the liver and bone marrow[3]. 
As a consequence, patients present with hepatomegaly (77%), 
splenomegaly (96%), constitutional symptoms (70%), anemia 
(85%), thrombocytopenia (89%), leukopenia (72%) and liver 
enzyme abnormalities (46%), in the absence of lymphadenopathy[3]. 
HSTCL mainly affects male[4] adults with a median age of 20 to 
35 years[1,3]. HSTCL has a rapidly progressive course with a mean 
overall survival less than 16 mo, regardless of the available treatment 
modalities (chemotherapy, splenectomy, bone marrow or stem cell 
transplantation)[3]. 
 The incidence of the highly lethal HSTCL is very low in the 
general population[1]. However, at least 10% of HSTCL arises 
in inflammatory bowel disease (IBD) patients treated with 
immunomodulatory therapy (thiopurines and/or tumor necrosis 
factor (TNF)- α inhibitors)[3]. This results in an increased HSTCL 
risk in IBD patients compared to the general population, although 
the absolute risk remains low[1,5]. Especially men younger than 35 
years with Crohn’s disease (CD) who are treated with thiopurines 
and TNF-a inhibitor combination therapy for at least two years are 
at increased risk[4]. The estimated absolute risk to develop HSTCL 
in  IBD patients treated with combination therapy is 1:22000 in 
general and 1:3534 for men younger than 35 years old. By contrast, 
IBD patients on thiopurine monotherapy had an estimated absolute 
risk of 1:45000 and 1:7404 in general IBD patients and men younger 
than 35 years old, respectively[4-6]. IBD patients with HSTCL have a 
poor prognosis with a median survival of seven to eight months[7,8].
In this case report, we present a 47-year-old male CD patient on 
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Figure 1: Positron emission tomography showing hepatosplenomegaly with increased metabolic 
activity in liver, spleen and bone marrow.
Figure 2: Liver biopsy showing hepatosplenic T-cell lymphoma.
thiopurine monotherapy. To our best knowledge, this is the first 
case report describing an IBD patient on thiopurine monotherapy 
who developed HSTCL at an age older than 35 years.
 
Case report
A 47-year-old Caucasian man with CD presented at our hospital with 
painless icterus, weight loss and malaise, without fever. He had a 
33-year history of penetrating CD in the colon (Montreal Classifi-
cation L2, B3 + P) and was treated with thiopurine monotherapy at 
presentation. Initial CD treatment had consisted of budesonide and 
mesalamine which was followed by azathioprine 150-200 mg per 
day for 14 years. Subsequently, he received infliximab at the age of 
33 (three doses, remission induction therapy) and 36 (maintenance 
therapy for one-and-a-half years, discontinued due to neurologic 
side-effects). During his course of CD, he underwent both right and 
left hemicolectomy (at the age of 18 and 30 years, respectively) and 
received a permanent ileostomy at the age of 41 due to active peri-
anal fistulating disease in the three years before. CD had been in re-
mission in the five years preceding presentation at our hospital.  
 Physical examination of our patient revealed hepatosplenomegaly 
in the absence of lymphadenopathy, which was confirmed by computed 
tomography and positron emission tomography (Figure 1). Laboratory 
testing indicated anemia, thrombocytopenia and liver test abnor-
malities (Table 1A). Imaging did neither reveal dilated bile ducts 
nor other (obstructive) abnormalities. Furthermore, viral causes of 
hepatitis, including Epstein-Barr virus, were excluded by serology. 
Based on these results, we suspected an hematological malignancy 
and performed a liver and bone marrow biopsy. Liver biopsy showed 
sinusoidal and portal infiltration of atypical lymphocytes (Figure 2). 
Immunophenotyping of both biopsies confirmed a T-cell population 
with the surface proteins listed in Table 1B. Based on these biop-
sies, γδ-HSTCL was diagnosed[1].
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Left: Hematoxylin and eosin staining (magnification × 100) showing intrasinusoidal and portal infiltration of 
atypical lymphocytes; 
Right: CD3 staining (magnification × 100) showing neoplastic cells (appearing in brown colour).
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 Following the diagnosis of HSTCL, high dose corticosteroids 
(125 mg per day) were administered, followed by chemotherapy 
(CHOP regimen; cyclophosphamide, hydroxydoxorubicin, vincris-
tine and prednisone). Despite this treatment, both clinical and bio-
chemical parameters rapidly deteriorated and the patient died 21 d 
post-diagnosis due to massive esophageal bleeding, secondary to 
therapy-induced mucositis.
Discussion
In this case report, we presented a male CD patient who 
developed HSTCL at the age of 47 years and after having been 
on thiopurine monotherapy during 14 years. Remarkably, this rare 
malignancy developed at an age older than 35, which is in contrast 
with previous cases in patients on thiopurine monotherapy. As 
HSTCL is very rare, and controlled cohort studies are lacking, 
this case report may contribute to the assessment of HSTCL 
risk and its relation with immunosuppressive therapies[7].   
 IBD patients, especially CD patients, are twice more likely 
to develop any lymphoma, regardless of immunosuppressive 
treatment[9,10]. The risk to develop HSTCL is also increased in auto-
immune disorders like rheumatoid arthritis[11,12], specifically in those 
patients, treated with TNF- α inhibitors, and in immunocompromised 
patients with, among others, renal or heart transplant[3].
 In IBD patients, thiopurine treatment is associated with a 
significantly increased overall risk (rate ratio of 1.41) of developing 
cancer[13], specifically non-melanoma skin cancer, urinary tract 
cancers and lymphoproliferative disorders (multivariate adjusted 
hazard ratio of 5.28)[10,14].
More specifically, thiopurines promote development of lymphomas: 
a recent meta-analysis found an overall standard incidence ratio 
for lymphoma of 5.7 in IBD patients receiving thiopurines, but 
not in patients formerly treated with thiopurines or patients who 
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Table 1: Results of our patient 
 
A: laboratory findings 
 
B: immunophenotyping of liver and bone marrow biopsy 
Analysis (Unit) 
 
Results 
 
    Reference value 
 
Immunophenotype 
 
Results 
 
Typical HSTCL[1,3] 
 
White blood cell count (× 109/L) 
 
 4.6 
 
  4.0-10.0 
 
CD 2 and 3 
 
+ 
 
+ 
 
Platelet count (× 109/L) 
 
  42 
 
150-400 
 
CD 4 and 5 
 
- 
 
- 
 
Hemoglobin (mmol/L) 
 
 7.7 
 
  8.5-11.0 
 
CD 7 
 
+ 
 
+/- 
 
Bilirubin (�mol/L) 
 
175 
 
  0-17 
 
CD 8 
 
+/- 
 
- 
 
ALP (IU/L) 
 
265 
 
    0-125 
 
CD 16 
 
- 
 
+/- 
 
GGT (IU/L) 
 
154 
 
  0-45 
 
CD 56 
 
+ 
 
+ 
 
ASAT (IU/L) 
 
250 
 
  0-34 
 
T-cell receptor 
 
+ 
 
+ 
 
ALAT (IU/L) 
 
437 
 
  0-44 
 
TIA 
 
- 
 
+ 
 
LDH (IU/L) 
 
701 
 
    0-247 
 
   
ALP: Alkaline phosphatase; ASAT: Aspartate transaminase; ALAT: Alanine transaminase; GGT: gamma-glutamyl- 
transferase; LDH: Lactate dehydrogenase; TIA: T-cell restricted intracellular antigen.  
  
Table 1: Results of our patient
ALP: Alkaline phosphatase; ASAT: Aspartate transaminase; ALAT: Alanine transaminase; GGT: gamma-
glutamyl- transferase; LDH: Lactate dehydrogenase; TIA: T-cell restricted intracellular antigen. 
 
had never used these drugs[4]. The excess risk can be reversed by 
thiopurine withdrawal. Thiopurine cytotoxicity is mediated by the 
incorporation of 6-thioguanine during DNA replication in targeted 
cells, instead of guanine, which ultimately leads to apoptosis[10].
   Previous studies showed a higher absolute risk of developing 
HSTCL in patients receiving both thiopurines and TNF-α inhibitors, 
compared to patients on thiopurine monotherapy[4-6]. Furthermore, a 
review including 25 IBD patients with HSTCL reported an increased 
HSTCL risk in those on thiopurine monotherapy compared to 
patients using TNF-α inhibitor monotherapy[11].   
 Duration of immunosuppressive therapy may also influence the 
risk of developing HSTCL. For example, more than 80% of HSTCL 
cases occur in the first two years after initiation of combination 
therapy[12]. Median time from initiation of thiopurines to HSTCL 
development did not significantly differ between patients on 
thiopurine monotherapy and combination therapy (5.5 years vs 6 
years, P = 0.39)[4]. 
 A review of the literature revealed 38 cases of  γδ -HSTCL in 
patients with CD, including 27 patients on combination therapy and 
11 on thiopurine monotherapy (Tables 2 and 3)[7,15]. In contrast to 
these previous cases, our patient developed HSTCL after a longer 
period of thiopurine treatment (14 years vs a mean time of 5 years 
in the previously reported cases) and at an older age (47 years). 
HSTCL in general mainly affects men with a median age of 20 to 
35 years[1,3,4]. Only 7 CD cases are known to develop HSTCL at an 
age older than 35, all of them were receiving combination therapy 
(Table 2)[7,15]. Time to HSTCL development following initiation of 
thiopurine treatment was reported in three cases, including 5.5, 
7.3 and 13.5 years. In addition, all ulcerative colitis patients on 
thiopurine monotherapy (7 cases) developed γδ HSTCL below the 
age of 35[4,5]. Finally, our patient had a very short survival (21 d) in 
contrast to previous cases (Table 3) with a median survival of 7-8 mo. 
 The proven benefit of thiopurines in combination with TNF α 
inhibitors to maintain corticosteroid free clinical remission and 
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mucosal healing should outweigh the risk of serious infections 
and secondary malignancies, such as untreatable lymphoma[16]. 
Therefore, the recent published European Crohn’s and Colitis 
Organisation guideline recommends to limit the duration of 
combination therapy to 2 years, if possible[10]. In addition, de-
escalation of monotherapy (drug cessation or dose reduction) has 
to be considered to reduce risk of secondary malignancies. Several 
factors impact this decision, such as disease phenotype and extent, 
duration of remission, prior surgery, and a history of cancer. Given 
the prolonged clinical remission in our case, thiopurine withdrawal 
could have been considered to reduce HSTCL risk, although the 
extensive, relapsing disease course including surgery called for 
prolonged therapy[17]. 
 This case report presents the first IBD patient on thiopurine 
monotherapy for an extended period of time, who developed a γδ 
-HSTCL at an age older than 35 years. This highlights the clinical 
relevance of knowledge and awareness of HSTCL risk in patients 
with CD on immunomodulatory therapies.
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Table 2:  Number of Crohn’s disease cases with hepatosplenic T-cell lymphoma[7,15] 
 
 
Age 
 
Combination therapy 
 
Monotherapy Total 
 
> 35 year 
 
  7 
 
  0 
 
  7 
 
< 35 year 
 
20 
 
11 
 
31 
 
Total 
 
27 
 
11 
 
38 
 
 
  
Table 3  Cases of gamma/delta-hepatosplenic T-cell lymphoma in patients with Crohn’s disease on thiopurine 
monotherapy 
 
 
Index 
 
Age, 
sex 
 
Years of 
thiopurine 
Presentation Treatment 
 
Survival 
(mo) 
 treatment 
(type) 
Index case  47, M 
 
14 (AZT) 
 
HSM, icterus, anemia, thrombocytopenia 
 
Ch. (CHOP) 
 
< 1 
 
Selvaraj et al[7] 2013 (AERS 
6751796)  
 
 18, M 
 
< 1 (AZT, 6MP) 
 
NS 
 
NS 
 
7 
 
Selvaraj et al[7] 2013 (AERS 
7554658)  
 
 13, M 
 
NS (6MP) 
 
NS 
 
NS 
 
NS 
 
Fowler et al[18] 2010  
 
 19, M 
 
6 (AZT) 
 
SM, leucocytopenia 
 
Ch. (NS) + splenectomy 
 
4 
 
Fowler et al[18] 2010  
 
 22, M 
 
8 (6MP) 
 
SM, night sweats, fever, abdominal 
tenderness 
 
Ch. (NS) 
 
Survival 
 
Ochenrider et al[8] 2010  
 
 18, M 
 
5 (6MP) 
 
Fever, night sweats, SM, anemia, 
thrombocytopenia 
 
Ch. (Pentostatin, ICE) + 
auto-SCT 
 
7 
 
Humphreys et al[19] 2008  
 
27, F 
 
5 (AZT) 
 
Fever, nights sweats, pancytopenia, HSM 
 
Interferon-� 
 
> 31 
 
Zeidan et al[20] 2007  
 
 31, M 
 
 6 (6MP)1 
 
Chills, SM, fever, pancytopenia 
 
Ch. (CHOP, cytarabine, 
ESHAP) 
 
7 
 
Falchook et al[15] 2006  
 
NS 
 
NS (6MP) 
 
SM 
 
Ch. (NS) 
 
NS 
 
Mittal et al[21] 2006  
 
 18, M 
 
6 (AZT) 
 
Fever, pancytopenia, HSM 
 
Ch. (IVE, ESHAP, 
alemtuzumab 
 
NS 
 
fludarabine) + allo-SCT 
 
Navarro et al[22] 2003  
 
 35, M 
 
5.6 (AZT) 
 
Fever, night sweats, HSM, anemia, 
thrombocytopenia 
 
Ch. (NS) + splenectomy 
 
NS 
 
Lémann et al[23] 1998  
 
NS 
 
4 (AZT) 
 
NS 
 
NS 
 
NS 
 
 
 
1Received one single gift infliximab 51 mo before presentation, therefore considered as TNF-� inhibitor naive. 
AERS: Adverse Event Reporting System; AZT: Azathioprine; Ch.: Chemotherapy; CHOP: Cyclophosphamide, 
hydroxydoxorubicin, vincristine and prednisone; EHSAP: Etoposide, methylprednisolone, cytarabin, cisplatin; 
ICE: Ifosphamide, carboplatin, etoposide; IVE: Ifosphamide, carboplatin and etoposide; NS: Not specified; 
(H)SM: (hepato)splenomegaly; SCT: Stem cell transplantation; 6MP: 6-mercaptopurine. 
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Abstract
Background and aims
Both chronic inflammation and reduced immunosurveillance con-
tribute to malignancy development in inflammatory bowel disease 
(IBD). Previous literature suggests that especially Crohn’s disease 
patients are at increased risk for developing gastric cancer (GC).
 This study aimed to identify risk factors for GC development 
in IBD and to compare the clinical characteristics of GC to those in 
IBD to the general population.
  
Methods
We retrospectively searched the Dutch Pathology Database to 
identify all Dutch IBD patients with GC between January 2004 and 
December 2008. Two case-control studies were performed. I: to 
identify risk factors for GC in IBD, with controls from the IBD South 
Limburg (IBDSL) population-based cohort; II: to compare GC disease 
course in IBD patients with the general population. General popula-
tion data were obtained from the Eindhoven Cancer Registry (ECR).
  
Results
We included 59 patients with IBD and GC (cases). Cases were sig-
nificantly older at IBD diagnosis than IBDSL controls (median age 
61 year versus 40; p<0.01) and ulcerative colitis (UC) was more fre-
quent in the case group (69.5% versus 51.4%; p<0.01). We found 
no difference in age at diagnosis, gender, tumor location and tumor 
differentiation between IBD GC patients and ECR controls. When 
corrected for confounders and TNM-stage, IBD patients showed 
impaired survival (p=0.035; HR 1.385). 
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Conclusions
Survival is significantly reduced in IBD patients compared to the 
general population in the multivariable analysis of our study, but 
age at GC diagnosis and TNM-stage were comparable between IBD 
cases and controls. Elderly onset IBD emerged as a risk factor for 
GC development in IBD patients, particularly in UC.
Key words: 
Inflammatory bowel diseases; gastric cancer; immunosuppressive therapy.
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Introduction
Inflammatory bowel disease (IBD), consisting of Crohn’s disease 
(CD) and ulcerative colitis (UC), is characterized by chronic intes-
tinal inflammation resulting in for example abdominal pain, (bloody) 
diarrhea, weight loss and / or peri-anal fistula. IBD patients are 
at increased risk for developing colorectal cancer (CRC) due to 
chronic intestinal inflammation1,2. In addition, several other malig-
nancies, such as Epstein-Barr virus (EBV) positive lymphomas and 
non melanoma skin cancer3, also show an increased incidence in IBD 
patients. Similarly, a recent meta-analysis described an increased 
risk of gastric cancer (GC) in CD patients4.
 The cause of GC development in IBD patients is unclear. The 
majority of sporadic GC’s develop via an intestinal metaplasia – 
dysplasia pathway under influence of Helicobacter pylori (H. pylori) 
infection5. However, in IBD, prevalence of H. pylori is lower com-
pared to the general population6,7. In addition, impaired immunosur-
veillance8 of oncogenic viruses and bacteria has been suggested 
as a causative factor for cancer development in IBD patients. Ten 
percent of sporadic gastric intestinal-type adenocarcinoma is as-
sociated with gastric EBV infection9,10. It is unknown whether this 
infection contributes to GC in IBD patients. Furthermore, approxi-
mately 5% of CD patients have gastric inflammatory involvement11 
and local chronic inflammation may influence GC development.
 At present it is unclear whether chronic inflammation and/or 
impaired immunosurveillance play a role in the development of GC 
in IBD patients. Furthermore, it is unknown whether risk factors, 
histologic features and clinical course of GC in IBD patients differ 
from the general population. All of these features are clinically rele-
vant regarding the course of management of immunosuppressive 
therapies in IBD patients with cancer. In order to elucidate a profile 
that will allow dissection of the elements that affect the risk for GC 
in IBD patients we established a nation-wide cohort.
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The purpose of this study was to explore potential risk factors for 
GC development in IBD patients, and to compare the histological 
features and clinical course of GC in IBD patients with the general 
population. 
 
Methods
Design and data sources
We studied the clinical course, outcomes and histology of GC in 
IBD patients. To this end we established a nationwide cohort of IBD 
patients who developed GC (cases) using PALGA (Dutch nationwide 
network and registry of histo- and cytopathology)12. Subsequently, 
cases were included in the following two case control studies:
 
I   Case control study I was performed to identify risk factors 
for developing GC in IBD patients. Cases were compared with 
IBD controls, which were randomly selected from the popula-
tion-based IBD South Limburg Cohort (IBDSL Cohort) in The 
Netherlands13,14. 
II  Case control study II was performed to compare clinical 
characteristics and outcomes of GC in IBD cases to GC in the 
general population. We used the Eindhoven Cancer Registry 
(ECR) to extract controls. 
This study was approved by the PALGA Privacy Committee and 
Scientific Council and by the medical ethical committee of the 
Radboudumc (number 2013/059), The Netherlands. 
Selection of cases
In order to identify all IBD patients who were diagnosed with GC 
between January 2004 and December 2008 in The Netherlands, 
we performed a PALGA-database search. PALGA has complete 
national coverage for academic and non-academic hospitals since 
199112. The following search terms were used: “Crohn’s Disease”, 
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“Ulcerative Colitis”, “Inflammatory Bowel Disease”, “Indeter-
minate colitis”, “chronic colitis”, “acute colitis”, “lymphocytic 
colitis”, “necrotizing colitis” or “colitis” combined with “gastric 
carcinoma”, “gastric dysplasia” or “gastric adenoma”. Our selec-
tion strategy ran through 3 stages: 1) selection and exclusion of 
patients was based on evaluation of the individual pathology reports; 
2) intestinal and gastric histologic specimens were reviewed by 
an expert gastro-intestinal pathologist (I.N.) to confirm both IBD 
as well as the GC diagnosis; 3) patient charts were evaluated to 
confirm both diagnoses and to collect additional demographic and 
clinical data. Patients were excluded when either the IBD or GC 
diagnosis could not be confirmed, when the IBD diagnosis was 
established more than 6 months after GC diagnosis or when the 
GC diagnosis was made before 2004 or after 2008. Only gastric 
carcinomas were included.
 
Data collection cases
Two authors (L.N. and E.A.) reviewed anonymized medical 
charts and extracted both IBD and GC data. The collected data 
of the cases included the following patient characteristics: date 
of birth, gender, medical history, alcohol and smoking history. 
 For IBD, the following variables were collected: type of IBD 
based on histopathologic evaluation of the histologic specimen, 
date of IBD diagnosis, IBD phenotype according to the Montreal 
Classification15, diagnosis of primary sclerosing cholangitis, use of 
IBD medication (5-aminosalicylates, corticosteroids, thiopurines, 
methotrexate and biological therapy) and duration of therapy. 
For GC the following variables were collected: prior upper endos-
copy and histology (with or without gastritis, metaplasia or dyspla-
sia), EBV status, H. pylori (both histological and serological data), 
family history of GC, use of protonpumpinhibitors, date of GC diag-
nosis, location, histological classification according to Laurén16 and 
the World Health Organization (WHO)17, tumor stage according to 
the TNM classification (6th edition), treatment and overall survival. 
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Case control study I. Selection of controls from the 
IBDSL Cohort
IBD controls for the identification of risk factors were randomly se-
lected (using a 1:3 ratio) from the IBDSL Cohort13. The IBDSL co-
hort is a prospectively followed, population-based cohort, including 
all new adult IBD cases since 1991. Patients with indeterminate coli-
tis are not included, unless they are classified as UC or CD during 
a later stage of their disease course. South Limburg is an enclosed 
geographic area in the southeast of The Netherlands with 605,000 
inhabitants and three hospitals (1 university hospital and 2 general 
district hospitals). As cross-border health care use is limited and 
migration rates are low, South Limburg provides a good setting 
for population-based research. The total number of IBD patients 
in this registry is 2807 IBD patients (40.9% CD, 59.0% UC). This 
represents 93% of the regional IBD population14.
 
Case control study II. Selection of controls from the ECR
To compare clinical characteristics and outcome of GC in IBD pa-
tients to the general population, we identified controls in the ECR 
(managed by The Netherlands Comprehensive Cancer Organisa-
tion (NCCO)) from January 2004 until December 2008. Since 1989, 
the ECR prospectively registers all newly diagnosed cancers in the 
regions “Noord-Brabant” and “Noord-Limburg”, two provinces in 
the south of The Netherlands, covering an area with 2.3 million in-
habitants, encompassing over 95% of all cancers in this region. We 
used the search term “C16 (stomach)” according to the ICD-0 third 
edition18. Only carcinomas were included.
 The following variables for GC in the general population were 
collected: gender, age and year of diagnosis, tumor location (cardia 
or non-cardia), tumor stage according to the TNM  classification 
(6th edition), histologic classification according to the ICD-0 classi-
fication18, treatment and follow-up. Obtained histological data were 
evaluated according to the Lauren16 and WHO classification17. 
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Additional histopathological analyses of cases
To gain insight into the pathogenesis of GC in IBD, we performed 
additional histopathological stainings in a subset of patients. 
 We performed EBV-encoded RNA – in situ hybridization 
(EBER-ISH), the gold standard test for EBV detection19, using for-
malin-fixed, paraffin-embedded (FFPE) tissues of GC specimens 
(biopsy or resection)20. Deparaffinized slides were treated with 
Proteinase K (DAKO PNA ISH Detection Kit(K5201)). After hybri- 
dization with DAKO EBV (EBER) PNA Probe (Y5200), and detection 
with rabbit-anti-FITC/AP (DAKO PNA ISH Detection Kit [K5201]), 
the EBER PNA probes were visualized with NBT/BCIP (4-Nitro 
blue tetrazolium chloride/5-Bromo-4-chloro-3-indoxyl-phosphate, 
Roche) followed by counterstaining with Nuclear Fast Red. Tumors 
were scored EBV positive or negative. Positive was defined as the 
presence of EBV in all or in the vast majority of tumor cells.
 Immunohistochemical staining of mismatch repair (MMR) pro-
teins was performed on 4-um-thick FFPE GC tissue sections. Slides 
were stained with antibodies against MLH1 (Pharmingen code: 51-
1327gr; dilution 1 : 50), PMS2 (Pharmingen code: 556415; dilution 1 
: 80), MSH2 (Oncogene Research Products code: NA26; dilution 1 : 
100) and MSH6 (Transduction Laboratories code: G70220; dilution 
1 : 250). Staining interpretation was done by the investigators (L.N. 
and R.v.d.P.) and expert pathologist (I.N.). Staining pattern was as-
sessed as follows: (1) positive – showing nuclear staining in at least 
some tumor cells; (2) negative – no nuclear staining at all in tumor 
cells with a positive internal control (staining of normal epithelial, 
stromal and inflammatory cells); or (3) not assessable – insufficient 
technical quality to provide an unambiguous result despite repeated 
assays21.
 
Statistics
First, we compared potential risk factor, clinical characteristics of 
case control study I and II with univariable analyses. For the univari-
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able analysis, we used a χ2-test or Fisher exact test (if expected cell 
counts were <5) for categorical data and independent Student t 
test or Mann-Whitney U test for continuous data. Variables with a p 
value of <0.1 in univariable analyses were included the multivariable 
analyses.
  For case control study I, a binary logistic regression analysis 
with backward elimination of non-significant confounders was per-
formed to determine risk factors for IBD patients to develop GC. 
The calculated odds ratios (OR) were presented with 95 % confi-
dence interval (95 % CI). This model was always adjusted for the 
duration of follow up (fixed variable). For cases, follow up was de-
fined as time since IBD diagnosis until GC diagnosis. For controls, 
follow up was defined as time since IBD diagnosis until death or 
end of follow up. As medication use in especially the distant past 
might not be reliable and may be different from current regimes, we 
did not include medical therapy in the first multivariable analysis. 
Therefore, we performed a multivariable logistic regression analysis 
(called sensitivity analysis) including patients with an IBD diagnosis 
since 1991 in both the case and control group. Patients from the 
IBDSL cohort with GC were included as cases. 
 For case control study II, which was performed to compare clinical 
characteristics and outcomes of GC in IBD cases to GC in the 
general population, survival plots were derived from Kaplan–Meier 
curves. Confounder correction was performed with a Cox regression 
model with forward sampling. A covariate was considered as a 
confounder when the beta coefficient of the variable of interest 
changed by 10% or more22. TNM stage was included as fixed 
variable. All missing values were considered to be at random and 
were therefore excluded from analyses. For our analysis we used 
IBM SPSS statistics version 20.0 for windows (SPSS In., Chicago, 
IL). A p-value of < 0.05 was considered statistically significant.
 
87Solid malignancies in inflammatory bowel diseases
Results
Selection of cases and controls
 
With the PALGA search we identified 478 possible cases of 
GC in IBD patients (Figure 1). After an initial selection based on 
pathology reports and subsequent biopsy revision, medical record 
research was performed in 92 patients. In total, 33 patients were 
excluded: 15 because they had no confirmed diagnosis of IBD, six 
had no primary gastric carcinoma, six had esophageal carcinoma, 
three because IBD was diagnosed more than six months after 
GC diagnosis and three patients were excluded for other reasons. 
Finally, 59 patients were included with both IBD and GC. 
 To identify risk factors in IBD patients (case control study 
I), we randomly selected a control group consisting of 177 
IBD patients from the IBDSL cohort (based on a 1:3 ratio). 
 For case control study II, we selected controls from the ECR. 
This search yielded 1534 non-IBD GC patients in the general popu-
lation. We excluded 195 patients (110 lymphomas, 50 gastrointes-
tinal stromal tumors, 30 neuro-endocrine tumors, two sarcomas 
and three for other reasons), resulting in 1339 GC patients select-
ed from the general population from January 2004 until December 
2008.
 
Case control study I. Risk factors: cases versus IBD controls
Table 1 displays the univariable comparison of potential risk fac-
tors for GC development between IBD cases with GC and IBDSL 
controls. Both age at IBD diagnosis (median age 61 year versus 
40; p<0.01) and the number of UC patients (69.5% versus 51.4%; 
p<0.01) significantly differed between cases and controls. There 
was a trend towards over-representation of male gender in the case 
group (p=0.06). We found no difference in disease localization and 
behavior, IBD related surgery and use of 5-aminosalicylates, metho- 
trexate and cyclosporin. However, use of steroids, thiopurines and 
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Figure 1: Flowchart patient selection
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Table 2: Final model of binary logistic regression analysis 
 
Model   Variable  Coefficient β Odds Ratio  P-  
(95 % CI)  value 
 
 
Ulcerative colitis    Age at IBD diagnosis 0.081  1.084(1.043 – 1.126) 0.000 
All cases (n=41)    
 
Ulcerative colitis (> 1991)  Age at IBD diagnosis 0.073  1.075 (1.034 – 1.119) 0.000 
Sensitivity analysis (n=29) 
 
Ulcerative colitis (>1991; + med) Age at IBD diagnosis 0.066  1.068 (1.022 – 1.117) 0.004 
Sensitivity analysis (n=29) 
 
      
 
Crohn’s disease   Age at IBD diagnosis 0.048  1.049 (1.012 – 1.088) 0.010 
All cases (n=18)    
 
Crohn’s disease (>1991)  Age at IBD diagnosis 0.069  1.072 (1.024 – 1.122) 0.003 
Sensitivity analysis (n=15) 
 
Crohn’s disease (>1991; + med) No risk factors identified 
Sensitivity analysis (n=15) 
 
Final multivariable regression model after adjustment for duration of follow up since IBD diagnosis and backward elimination of 
non-significant variables for the identification of independent risk factors to develop gastric cancer. Similar inclusion periods of 
IBD diagnosis (since 1991) for cases and controls were used in the sensitivity analysis. 
IBD, inflammatory bowel disease; + med: including medication in analysis. 
  
Table 2: Final model of binary logistic regression analysis
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Table 1a / b: Risk factors for the development of gastric cancer
Table 2: Final model of binary logistic regression analysis 
 
Model   Variable Coefficient β Odds Ratio  P-  
(95 % CI)  value 
 
 
Ulcerative colitis    Age at IBD diagnosis 0.081  1.084(1.043 – 1.126) 0.000 
All cases (n=41)    
 
Ulcerative colitis (> 1991)  Age at IBD diagnosis 0.073  1.075 (1.034 – 1.119) 0.000 
Sensitivity analysis (n=29) 
 
Ulcerative colitis (>1991; + med) Age at IBD diagnosis 0.066  1.068 (1.022 – 1.117) 0.004 
Sensitivity analysis (n=29) 
 
      
 
Crohn’s disease   Age at IBD diagnosis 0.048  1.049 (1.012 – 1.088) 0.010 
All cases (n=18)    
 
Crohn’s disease (>1991)  Age at IBD diagnosis 0.069  1.072 (1.024 – 1.122) 0.003 
Sensitivity analysis (n=15) 
 
Crohn’s disease (>1991; + med) No risk factors identified 
Sensitivity analysis (n=15) 
 
Final multivariable regression model after adjustment for duration of follow up since IBD diagnosis and 
backward elimination of non-significant variables for the identification of independent risk factors to develop 
gastric cancer. Similar inclusion periods of IBD diagnosis (since 1991) for cases and controls were used in the 
sensitivity analysis. 
IBD, inflammatory bowel disease; + med: including medication in analysis. 
  
Table 3: Univariable comparison of gastric cancer characteristics 
 
 
Variable    IBD patients  ECR patients                  Missing (n) P-value 
    N = 59   N = 1339                          IBD / ECR                      
Age at diagnosis (y),    
     median    73.0  71.0   0 / 0  0.67 
Female sex; n (%)   21 (35.6 %) 517 (38.6 %)  0 / 0  0.64 
Tumor location  
     Cardia (vs non-cardia); n (%)  12 (20.3 %) 313 (23.4 %)  0 / 0  0.59 
Histology 
     Lauren – intestinal   35 (59.3 %) 86 (20.3 %)  0 / 915  < 0.01 * 
     WHO          
                  Tubular; n (%)  28 (49.1)  84 (19.8)   2 / 915  < 0.01  * 
Papillair; n (%)  3 (5.3)  7 (1.7) 
Mucinous; n (%)  3 (5.3)  48 (11.3) 
Poorly cohesive;n (%) 23 (40.4)  338 (79.7)   
Differentiation 
     Good & moderate / poor; n (%) 19(32.2) / 40(67.8) 298 (30.5) / 679 (69.5) 0 / 362  0.78 
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anti-TNF agents was significantly higher in the control group com-
pared to cases: steroids 65.9% versus 38.3% (p<0.01); thiopurines 
42.2% versus 15.2% (p<0.01) and anti-TNF agents 21.7% versus 
2.1 (p<0.01), respectively. In Table 1b only cases with an IBD diag-
nosis after 1990 are included, but the same risk factors (age at IBD 
diagnosis and IBD type) still emerged. In addition, cases used less 
5-aminosalisylates (71.9% versus 88.1%; p=0.03).
 In the multivariable analysis (Table 2) age at IBD diagnosis and 
gender were included. Second, medication use (corticosteroids, 
thiopurines and anti-TNF agents) was added. In the sensitivity 
analysis, the same factors were included with addition of 5-amino-
salicylates, as it was a potential confounder (Table 1b). In both the 
analysis including all cases and in the sensitivity analysis, age at IBD 
diagnosis was identified as risk factor for GC development in IBD 
patients. This applied to both UC (OR 1.043 – 1.12; p<0.01 and OR 
1.034 – 1.119; p<0.001) and CD (OR 1.012 – 1.088; p=0.01 and OR 
1.024 – 1.122, p<0.01). 
Case control study II. Clinical characteristics and outcomes: 
cases versus general population
We found no difference in age at diagnosis, gender, tumor loca-
tion and tumor differentiation between the IBD patients and general 
population with GC (Table 3). Although IBD patients presented with 
a more advanced T-stage (pT3 48.8% versus 28.1%; p=0.01), they 
had comparable lymph node stages and distant metastases rates. 
IBD patients were more extensively treated with surgery (57.6% 
and 32.2%; p=0.01) and chemotherapy (40.8% and 20.6%; p=0.01) 
at initial treatment. 
 Most IBD patients with GC presented with an intestinal type 
GC (59.3%). Histological classification was lacking in 915 out of 
1339 GC patients in the general population. Of the remaining 424 
patients, 20.3% presented with an intestinal type GC.
 We found no survival difference in the univariable analy-
sis (Figure 2A; p=0.53), but when corrected for confounders, 
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Stage 3; n (%)    9 (16.4)  140 (13.8) 
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IBD cases showed a poorer survival (Figure 2B; hazard 
ratio 1.385 (95 % confidence interval 1.023 – 1.875).
 At least 19 patients received different (combinations of) IBD 
medication after GC diagnosis. We found no difference in survival 
comparing IBD patients with immunosuppressive therapy after GC 
diagnosis (n=10) versus ECR controls (n=1339; p=0.86). 
Histopathology: exploring the etiology of IBD related gastric 
cancer
Additional staining of the GC was performed in 48 of 59 IBD cases 
(Figure 3). We excluded 11 cases for analysis due to insufficient 
amounts of tissue. Two of 48 tumors (4.2%) were EBER positive, 
four (8.3%) tumors lacked protein expression of MLH1 and PMS2. 
There were no cases without protein expression of MSH2 and 
MSH6.
 The medical history before the GC diagnosis revealed a prior 
upper endoscopy in 18 IBD patients (30.5%). Histologic gastritis 
was present in ten, intestinal metaplasia in nine and dysplasia in 
one patient. Twenty-one (46.7%) out of 46 patients had a positive 
history for tobacco use, 21 (56.8%) out of 37 for alcohol use. Fif-
teen (25.4%) patients were H. pylori positive and six patients had a 
positive family history of GC.
Discussion
This nationwide cohort study described GC in IBD patients and 
showed that GC survival was significantly worse in IBD in the 
multivariable analysis compared to the general population after 
correction for confounders. Other clinical characteristics were 
comparable between IBD cases and GC in the general population. 
Elderly onset IBD emerged as a risk factor for GC development in 
IBD patients, particularly in UC patients.
 There is only limited information available on GC survival in IBD, 
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Figure 2: Overall survival curves of IBD cases and general population following gastric 
cancer diagnosis
A: Univariable analysis: Kaplan-Meier curve 
B: Multivariable analysis (correction for TNM correction): Cox model (hazard ratio 1.385) 
IBD = inflammatory bowel diseases; ECR = Eindhoven Cancer Registry
Figure 3: Gastric cancer histology of IBD patients, including additional staining.
Magnification images: 200 x.  
EBV = Epstein Bar virus, MSI = microsatellite instability, GS= genomic stable, CIN= chromosomal instable 
Literature33
partially explained by the low absolute risk to develop gastric cancer 
in IBD patients. Unlike our results, Shu et al23 found no difference in 
GC survival between IBD patients and the general population. This 
may be explained by the small number of GC patients with IBD and 
short follow-up duration (median follow up 5 months) in the latter 
study. 
 An impaired prognosis compared to the general population for 
IBD patients with cancer was previously described for CRC24-26, 
lymphomas, and bladder cancer23. As immunosuppressive thera-
py may promote tumor progression23,27-29, we studied the survival 
of patients with immunosuppression use after GC diagnosis, but 
found no difference in survival related to immunosuppression use 
(p=0.86; adjusted for confounders and TNM stage). However, this 
subanalysis included only 10 IBD patients and should be interpreted 
with caution.
 Unexpectedly, we found that older age at IBD diagnosis is a 
risk factor for developing GC. With both ageing populations and 
an increasing IBD prevalence30, this group of elderly IBD patients 
is rapidly expanding. In our univariable comparisons we found less 
use of medical therapy in the IBD GC cases (with older IBD onset). 
However, in multivariable analysis no differences in medication use 
between IBD GC cases and IBD controls were found and thera-
py-induced immunosuppression seems not linked to GC develop-
ment in IBD patients in our study. It could be speculated that the 
genotype and phenotype of elderly onset IBD are associated with a 
higher cancer risk and thus making these patients more susceptible 
to (gastric) cancer development.
 We analyzed the number of EBV-positive GC’s in IBD patients, 
but did not find an increase of EBV-positive tumors compared to 
sporadic GC. Only 2 out of 48 (4.2%)  of the GC’s were EBV posi-
tive, which is in line with the literature10, suggesting that decreased 
immunosurveillance of EBV is not a causative factor for GC in IBD. 
Similarly, we considered H. pylori as a causative factor for GC de-
velopment in IBD, since this infection is present in up to 80% of spo-
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radic GC patients31. In our IBD cohort only 25% of GC patients had 
a positive H. pylori status, which is in line with previous literature. 
This suggests that it is unlikely that impaired immune surveillance 
of H. pylori causes and increased risk for GC in IBD. Treatment with 
5-aminosalicylates may protect against H. pylori7. In the majority of 
our patients (79.2%) 5-aminosalicylates were part of the treatment 
strategy. The use of antibiotics in IBD treatment unintentionally re-
sulting in H. pylori eradication, could also explain the lower H. pylori 
prevalence.
 Although gastric inflammation in CD could be a causative factor 
for gastric carcinogenesis, we found more frequent GC develop-
ment in UC patients than in CD (69.5 % versus 51.4%; p<0.01). This 
is in contrast to a previous meta-analysis by Pedersen et al.4 sug-
gesting that CD patients are at increased risk for GC development. 
However, the different time frame of this study may explain this 
difference. While we presented data from a period (2004-2008) 
that reflects modern treatment strategies, the previous meta-anal-
ysis was based on periods between 1950 and 2004. Furthermore, 
the larger amount of UC patients may be caused by the fact that 
UC is more prevalent in elderly onset IBD32 and that elderly onset is 
the most important risk factor for GC development in IBD. 
 Recent TCGA (The Cancer Genome Atlas) data demonstrated 
a new GC classification33, based on molecular background of GC’s, 
dividing GC into EBV positive, microsatellite instable, genomic sta-
ble and chromosomal instable tumors. Genomic stable histology 
represents mainly diffuse tumors, as chromosomal instable tumors 
represent mainly intestinal histology. Compared to these series, we 
found an increased percentage of diffuse tumors (35.4% versus 
19.7%, Figure 3). Diffuse GC are associated with a CDH1 mutation, 
which is also important in the epithelial barrier function in UC34, 35, 
but not in CD. This characteristic might contribute to our finding of 
more UC than CD patients with GC.
 Several limitations can be recognized in the current study. We 
used two prospective databases to answer our research questions, 
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in contrast to our retrospectively collected data about the GC 
cases. This may cause an information bias. Furthermore, the 
limited number of IBD GC cases, although the largest series thus 
far, may result in type 2 errors. Therefore the conclusions must be 
interpreted with caution.
 We are also aware that IBD GC cases and IBD controls are ob-
tained from different databases and that the source populations 
of these databases are not completely identical (the Netherlands 
versus part of the Netherlands). This can give a selection bias, but 
IBD cases and controles are treated in the Netherlands according 
to the same IBD standards. Furthermore, The Netherlands is a small 
country with limited geographical differences. Unfortunately, the 
required data needed to address our research questions could not 
be extracted from one single database, which would have been 
preferable. 
 Furthermore, data collection was different for cases and con-
trols, as we studied medical records for GC cases and retrieved 
GC control data from the ECR database. The imbalance of missing 
data, for example for TNM stage, and different ways of data ascer-
tainment may impact our results.
 The IBDSL cohort only included patients diagnosed since 1991 
and excluded patients with a final diagnosis of indeterminate coli-
tis. This may have caused a selection bias and resulted in different 
treatment regimes due to differences in time frame, as we included 
IBD patients with GC diagnosed before as cases. Therefore, 
we performed a sensitivity analyses in which we only included the 
cases with an IBD diagnosis after 1990. These analyses showed 
similar results compared to the analyses of the case group as a 
whole. Furthermore, we included follow up as fixed factor in the 
analyses to correct for differences in follow up duration. 
 In conclusion, survival of GC patients in our study was signifi-
cantly worse in IBD patients compared to the general population in 
the multivariable analysis, when corrected for confounders. How-
ever, age at GC diagnosis and TNM-stage were comparable be-
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tween IBD cases and controls. Elderly onset IBD emerged as a risk 
factor for GC development, particularly in UC patients.
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Abstract
Background
Patients with inflammatory bowel disease (IBD) are at increased 
risk to develop malignant melanoma and this risk may increase with 
use of anti-tumor necrosis factor (TNF) therapy. Impaired survival 
of immunosuppressed melanoma patients is reported in transplant 
and rheumatology patients.
 This study aims to (1) identify risk factors for melanoma deve- 
lopment in patients with IBD, (2) compare clinical characteristics 
of melanoma in patients with IBD to the general population, and (3) 
assess the influence of immunosuppressive medication on survival.
 
Methods: 
We retrospectively searched the Dutch Pathology Database to 
identify all Dutch patients with IBD with cutaneous melanoma between 
January 1991 and December 2011. 
 We then performed two case-control studies. To identify risk 
factors for melanoma development in IBD, we compared patients 
with IBD with melanoma to the general IBD population. To compare 
outcome and survival after melanoma diagnosis, we compared cases 
with non-IBD melanoma patients.
Results:
We included 304 patients with IBD with melanoma, 1,800 IBD con-
trols, and 8,177 melanoma controls. IBD cases had more extensive 
IBD (ulcerative colitis: pancolitis: cases 44.5% versus IBD controls 
without melanoma 28.1%; p < 0.01; Crohn’s disease: ileocolonic 
disease: cases 57.9% versus controls 48.9%; p = 0.02).
 Despite a lower Nodes (N)-stage in patients with IBD (N1+ 
8.3% versus 18.2%; p<0.01) with comparable Tumor (T) and Metas-
tasis (M) stages, survival was similar in all three groups, regardless 
of immunosuppressive or anti-TNF therapy. 
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Conclusion
This study showed that IBD extent is a risk factor for melanoma 
development. Despite the lower N-stage in patients with IBD, we 
could not confirm impaired survival after melanoma in patients 
with IBD, regardless of anti-TNF with or without thiopurine use. 
 
Key words
inflammatory bowel diseases, melanoma, immunosuppressive therapy
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Introduction
Patients with inflammatory bowel disease (IBD) are at increased 
risk to develop nonmelanoma skin cancer (also called keratinocyte 
carcinoma)1-5, especially those patients on thiopurine therapy3, 6, 7. 
In addition, a recent meta-analysis showed that the risk for deve- 
loping cutaneous melanoma is slightly elevated in patients with 
IBD compared with the general population2, 8. Anti-tumor necrosis 
factor (TNF) therapy may further increase the risk of melanoma 
development in patients with IBD3, as is the case in rheumatic 
arthritis patients on anti-TNF therapy9. Thiopurine therapy does 
not seem to affect the risk of melanoma development in IBD3.
  Melanoma is considered an immunogenic malignancy: melano-
ma tumor antigens can trigger the immune response. Therefore, 
it is possible that immunosuppression can influence its clinical 
behavior. Indeed, immunosuppressed patients with cutane-
ous malignant melanoma were more likely to die of melanoma 
compared with immunocompetent controls 10-12. Overall and melanoma 
 cause-specific 3-year survival were significantly worse in immuno-
suppressed patients, especially with increasing Breslow thickness13. 
 In patients with IBD, additional risk factors for melanoma are 
unknown. Furthermore, the clinical course of melanoma in patients 
with IBD remains unclear, as well as the influence of immunosup-
pressive IBD therapy on the survival. Therefore, we designed a 
case-control study with 2 specific aims. First, we aimed at identi-
fying IBD-specific risk factors for melanoma by comparing patients 
with IBD with melanoma to patients with IBD without melanoma. 
Secondly, we researched clinical characteristics and survival after 
melanoma by comparing patients with IBD with melanoma to unse-
lected ‘non-IBD’ melanoma patients. 
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Materials and Methods
Study design
We conducted two retrospective case-control studies in The Neth-
erlands (Figure 1). 
 The first case-control study (I) was performed to identify risk 
factors for melanoma development in patients with IBD. The se-
cond case-control study (II) was performed to compare the clinical 
course after melanoma. This study was approved by the PALGA 
Privacy Commission and Scientific Council and by the medical 
ethical committee of the Leiden University Medical Center (number 
P13.034), The Netherlands.
IBD case selection
All patients diagnosed with both IBD and cutaneous melanoma be-
tween January 1991 and December 2011 in The Netherlands were 
identified by searching the PALGA-database. PALGA is the Dutch 
nationwide network and registry of histo- and cyto-pathology, 
which has complete national coverage for academic and non-aca-
demic hospitals since 199114. Multiple studies on malignancies in IBD 
were previously performed using PALGA including gastric cancer, 
neuro-endocrine tumors, colon cancer and pouch cancer15-17. In the 
current study, the following search terms were used: “Crohn’s Dis-
ease”, “Ulcerative Colitis”, “Inflammatory Bowel Disease”, “termi-
nal ileitis”, “regional ileitis”, “idiopathic colitis”, “chronic idiopathic 
bowel disease” or “enteritis regionalis” and combined them with 
“melanoma (primary and metastasis)” or “melanoma in situ”. This 
search looked for all cases that included any one or more of the first 
set of search terms and either of the second set of search terms. 
Based on the PALGA search results, anonymized patient charts in 
all hospitals were evaluated to confirm diagnoses and to collect ad-
ditional demographic and clinical data. The IBD diagnosis was based 
on a combination of clinical, endoscopic, histological and radiograph-
ic criteria18 and classified according the Montreal classification19. 
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 All patients with IBD with primary cutaneous (in situ or inva-
sive) melanoma were included in the study. Patients were excluded 
when either the IBD or melanoma diagnosis could not be confirmed, 
the incidence date of the primary melanoma was before 1991 or af-
ter 2011, IBD was diagnosed after melanoma diagnosis, or when the 
patient was known to have familial melanoma syndrome. 
Controls selection
Case-control study I: risk factor identification for melanoma 
development in patients with IBD
 For the identification of melanoma risk factors, 1,800 non- 
melanoma IBD controls were randomly selected from the IBD South 
Limburg Cohort (IBDSL Cohort)20, based on a 1:3 ratio of the first 
PALGA search results. No matching was performed as we did not 
want to exclude any potential risk factors.
 The IBDSL cohort is a population-based prospectively followed 
cohort in which all new cases of adult IBD are ernolled since 1991. 
South Limburg is an enclosed geographic area in the southeast 
of The Netherlands with 605,000 inhabitants and 3 hospitals. As 
cross-border health care is limited and migration rates are low, 
South Limburg provides a good setting for population-based re-
search. In total 2,807 patients with IBD (40.9% Crohn’s disease 
[CD], 59.0% ulcerative colitis [UC]) are included in the IBDSL Co-
hort, which represents more than 93% of the IBD population in 
South Limburg20 . 
 Analyses were performed between IBDSL controls and (1) IBD 
cases with invasive melanoma (2) IBD cases with in situ melanoma 
and (3) all IBD cases with either invasive melanoma or in situ mela-
noma, to increase the statistical power16.
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Case-control study II:  melanoma characteristics and clinical course 
in patients with IBD
To compare clinical characteristics and outcomes of melanoma 
between patients with IBD and the general population, non-IBD 
controls were selected from the (Eindhoven) Netherlands Cancer 
Registry (NCR; managed by the Netherlands Comprehensive 
Cancer Organisation [NCCO]) from January 1991 until December 
2011. Since 1989, the NCR registers the incidence of cancer in the 
Netherlands, for this study data of the region “Noord-Brabant” and 
“Noord-Limburg”, two provinces in the south of The Netherlands, 
covering an area with 2.3 million inhabitants were used. This spe-
cific region was used as in this region data on comorbidity (inclu- 
ding IBD) was registered. We used the search terms “melanoma” 
and “melanoma in situ”. Only data on cutaneous (in situ) melanoma 
were retrieved from the NCR.
Data collection
For IBD cases, the following data were anonymously collected: age, 
gender, medical history including a diagnosis of primary sclero- 
sing cholangitis, alcohol and smoking history, type of IBD based on 
histopathologic evaluation, date of IBD diagnosis, IBD phenotype 
according to the Montreal Classification19, use and duration of IBD 
related immunosuppressive therapy (corticosteroids, thiopurines, 
methotrexate, cyclosporine and anti-TNF therapy), and previous 
IBD surgery. For IBD controls, the same variables were collected, 
although alcohol and smoking history were only partially available 
and duration of immunosuppressive medication was not available. 
 The following melanoma variables were collected for both 
cases and controls: year of melanoma diagnosis, localiza-
tion, histopathologic evaluation, clinical and pathological tumor 
stage according the TNM classification (fourth edition until 
1992; revised fourth edition 1993 until 1998; fifth edition 1999 
until 2002; sixth edition 2003 until 2009), Breslow thick-
ness, Clark level, treatment (surgery, chemotherapy [inclu- 
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ding immunotherapy] and radiotherapy), and overall survival. 
 IBD cases were anonymously and encrypted linked to the NCR 
database, for reasons of quality control and completion of collected 
melanoma data.
Statistical analyses
IBD cases were compared with IBDSL and NCR controls using 
univariable analyses to identify potential risk factors and to com-
pare clinical characteristics. For the univariable analysis, we used 
a χ2-test or Fisher exact test (if expected cell counts were <5) for 
categorical data and independent Student’s t-test or Mann-Whitney 
U test for continuous data. Variables with a p value of <0.1 in the 
univariable analyses were included in the multivariable analyses. A 
p-value of < 0.05 was considered statistically significant. All our 
analyses were performed using IBM SPSS statistics version 20.0 
for Windows (SPSS In., Chicago, IL). 
 For case-control study I, a binary logistic regression analysis 
with backward elimination of non-significant confounders was 
performed to determine risk factors for patients with IBD to deve- 
lop a melanoma. The odds ratios (ORs) were presented with 95 % 
confidence interval (95 % CI). This multivariable model was always 
adjusted for the duration of follow-up (fixed variable), to correct 
for differences in follow-up between IBD cases and IBDSL controls. 
For the IBD cases, follow-up was defined as time since IBD diagno-
sis until melanoma diagnosis. For controls, follow-up was defined as 
time since IBD diagnosis until death or end of follow up. 
 As medication use in especially the distant past might not 
be reliable and may be different from current regimes, medical the- 
rapy was not included in the first multivariable analysis. Therefore, 
multivariable logistic regression analysis was performed including 
patients with an IBD diagnosis dating from 1991 in both the case 
and control group (sensitivity analysis). As UC and CD are clas-
sified different according to the Montreal classification, mul-
tivariable analyses were performed separately for UC and CD. 
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 For case-control study II survival plots were derived from Ka-
plan–Meier curves. Hazard ratios (HRs) were calculated. Con-
founder correction was performed using a Cox regression model 
with forward sampling. A covariate was considered as a confounder 
when the beta coefficient of the variable of interest changed by 
10% or more. 
 
Results
Selection of cases and controls
Five hundred eighty possible cases of patients with IBD with mela-
noma were identified (Figure 1), of which 200 were excluded after 
careful assessment (Figure 1). An additional 76 patients were ex-
cluded because IBD was diagnosed after the melanoma diagnosis. 
In total, 304 patients who developed a melanoma after IBD diagno-
sis were included (57 in situ and 247 invasive melanoma). 
 For case-control study I, we randomly selected 
a nonmelanoma control group consisting of 1800 patients with IBD 
from the IBDSL cohort (Figure 1).
 For case-control study II, the NCR search yielded 8518 non-IBD 
melanoma patients in the general population (Figure 1). We exclud-
ed 341 patients (259: unknown primary site and 82: second melano-
ma), resulting in 8177 melanoma patients selected from the general 
population.
Case control study I: risk factor identification for melanoma 
development in Patients with IBD
 IBD extent differed between IBD cases and IBDSL controls 
(Table 1): pancolitis was more common in comparison with UC 
controls (cases 44.5% versus controls 28.1%; p < 0.01). CD was 
more often located in the ileum and colon (cases 57.9% ver-
sus controls 48.9%; p = 0.02) and was more often penetrating 
(35.0% versus 23.6%; p < 0.01). Furthermore, primary sclerosing 
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Figure 1: flow chart patient selection.
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Table 1: Risk factors for melanoma development  
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cholangits was more common in cases (3.0% versus 0.7%; p = 0.01) 
compared with IBDSL controls. We found no difference in IBD-re-
lated surgery and use of thiopurines, anti-TNF therapy, methotrex-
ate and cyclosporine between cases and controls. However, use 
of corticosteroids was significantly higher in cases compared with 
controls: 75.1% versus 62.2% (p<0.01).
 In the multivariable analysis (Table 2), IBD extent was 
identified as a risk factor for melanoma development in pa-
tients with IBD, both in UC (pancolitis OR 3.09; 95% CI 1.670 
– 5.727) and CD (ileocolonic disease: OR 1.98; 95% CI 1.009 
– 3.882). The sensitivity analysis provided similar results. 
 In the sensitivity analysis for UC, we found corticosteroid use 
as risk factor (OR 1.41 – 3.72) and anti-TNF use as a protective 
factor for melanoma development in UC (OR 0.15 – 0.88) and CD 
(0.27 – 0.92). This difference was mainly attributed to the in situ 
melanoma, as this effect was not found for invasive melanoma. 
Case control study II: melanoma characteristics and outcome in 
Patients with IBD
No differences were found in age at diagnosis, sex, tumor location, 
tumor histopathology, Breslow thickness and melanoma treatment 
strategy between the IBD cases and controls with melanoma from 
the general population (Table 3). Patients with IBD presented with 
a less advanced N-stage (N+ 8.3% versus 18.2%; p < 0.01), but they 
had comparable T and M stages. 
 We found no differences in the univariable (Kaplan Meier) sur-
vival analyses for all cases (p = 0.42), in situ (p = 0.63) and malig-
nant melanoma (p = 0.68). Additional (multivariable) analyses for 
males, females, Breslow thickness > 2 or 4 mm and IBD diagnosis 
showed no difference. 
 We compared IBD cases on immunosuppressive medication 
after melanoma diagnosis with NCR controls. In the univariable 
analysis, we found no difference in survival in patients with IBD 
with melanoma using corticosteroids (n = 97; p = 0.93) and a better 
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Table 2: Final model of binary logistic regression analysis
Final multivariable regression model after adjustment for duration of follow up since IBD diagnosis and back-
ward elimination of non-significant variables for the identification of independent risk factors to develop mela-
noma. Similar inclusion periods of IBD diagnosis (since 1991) for cases and controls were used in the sensitivity 
analysis. Rx: including medication in analysis. IBD, inflammatory bowel disease. 
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Table 2: Final model of binary logistic regression analysis 
 
Model    Variable  Odds Ratio (95 %- CI) 
 
 
All melanoma   
Ulcerative colitis   Montreal E3 disease 3.09 (1.67 – 5.73) *   
(all cases = 178) 
 
Crohn’s Disease   Montreal L2 disease 2.62 (1.21 – 5.68) *  
(all cases = 121)   Montreal L3 disease 1.98 (1.01 – 3.88) *  
 
Sensitivity analysis (Rx > 1990)  
Ulcerative colitis   Montreal E3 disease 2.26 (1.11 - 4.60) *   
(all cases = 178)   Steroid use  2.29 (1.41 – 3.72) *   
    Anti-TNF use  0.37 (0.15 – 0.88) *  
 
Crohn’s Disease   Montreal L2 disease 2.60 (1.09 – 6.20) *  
(all cases = 121)   Montreal L3 disease 2.29 (1.08 – 4.84) *  
    Anti-TNF use  0.50 (0.27 – 0.923) *  
 
Melanoma in situ 
Ulcerative colitis   Age at IBD diagnosis 1.029 (1.007 – 1.052) *  
(all cases = 32) 
 
Crohn’s Disease   No risk factors identified 
(all cases = 22)    
 
Sensitivity analysis (Rx > 1990)  
Ulcerative colitis   Age at IBD diagnosis 1.028 (1.003 – 1.055) *  
(all cases = 32)    
 
Crohn’s Disease   Penetrating disease 3.15 (1.08 – 9.16) *  
(all cases = 22)   Anti-TNF use  0.13 (0.03 – 0.66) *  
 
Malignant melanoma  
Ulcerative colitis   Montreal E3 disease 2.75 (1.44 – 5.24) *  
(all cases = 146) 
 
Crohn’s Disease   Montreal L2 disease 3.70 (1.54 – 8.90) *  
(all cases = 99)   Montreal L3 disease 2.40 (1.08 – 5.31) *  
 
Sensitivity analysis (Rx > 1990)  
Ulcerative colitis   Montreal E3 disease 3.09 (1.53 – 6.22) *   
(all cases = 146)    
 
Crohn’s Disease   Montreal L2 disease 3.40 (1.38 – 8.37) *  
(all cases = 99)    
 
 
Final multivariable regressi n model after adjustment for duration of follow up si ce IBD di gnosis and backward elimination of 
non-sig ificant variables for he identifica ion of indepe dent risk facto  to develop m lanom . Similar inclusion periods of IBD 
diagnosis (since 1991) for cases and c ntrols were used in the sensitivity analysis. Rx: including medication in analysis. IBD, 
inflammatory bowel disease. 
survival of patients with IBD using anti-TNF (n=35; p=0.026 Figure 
2A) after melanoma diagnosis. In addition, we detected a trend 
towards improved survival in patients using thiopurines (n = 83; p = 
0.058; Figure 2B). In the multivariable analysis, we found no diffe- 
rence in survival in patients with IBD using anti-TNF (Hazard Ratio 
(HR) 0.32; 95% CI 0.08-1.27) and thiopurines (HR 0.72; 95% CI 
0.37 – 1.31).
 Finally, we compared the survival of IBD cases who did and did 
not use immunosuppressive medication after melanoma diagnosis. 
Patients (141 of 269) used immunosuppression after melanoma di-
agnosis; 23 / 141 (16.3%) had recurrent disease, compared with 13 
/ 128 patients with IBD (10.2%) without immunosuppressive medi-
cation use after IBD diagnosis (p = 0.14).
 Univariable, we found no difference in survival for patients us-
ing corticosteroids (p = 0.41), a trend toward better survival in pa-
tients with IBD taking thiopurines (p = 0.06; Figure 2D) and a better 
survival of patients using anti-TNF (p = 0.038; Figure 2C). In the 
multivariable analysis, no differences in survival for patients with 
IBD using anti-TNF were observed (HR 0.16, 95% CI 0.02 – 1.21). 
The HR of patients with IBD using thiopurines was 0.55 in the mul-
tivariable analysis (95% CI 0.25 – 1.23).  
 
Discussion
This nationwide cohort study describes risk factors for and the 
clinical course of melanoma in patients with IBD. The results in-
dicate that a more extensive IBD phenotype is a risk factor for 
melanoma development in patients with IBD. Histology, location, 
and survival of melanoma in patients with IBD are similar com-
pared with the general population. The use of anti-TNF thera-
py and/or thiopurines did not impair survival after melanoma. 
 It has been described in other cohorts of immunosuppressed 
(transplant) patients have that survival after melanoma diagnosis is 
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Table 3: Comparison between IBD patients with melanoma and melanoma in the general population
 
 
 
Table 3: Comparison between IBD patients with melanoma and melanoma in the general population 
 
All melanoma   IBD patients  NCR patients                  Missing / NA (n) P-value 
Variable    N = 304  N = 8177                          IBD / NCR                      
Age at diagnosis (y),   54 (43; 66) 55 (42; 67)    0 / 0 0.53  
     median (25 %; 75%)    
Female sex; n (%)   178 (58.6)  4779 (58.4)  0 / 0  0.97 
In situ melanoma; n (%)  57 (19.3)  1533 (19.3)  7 / 200  0.99 
Malignant melanoma   
     Lentigo maligna   35 (13.6)  862 (15.2)   4 / 0  0.86  
     Nodular   40 (15.5)  823 (14.5) 
     Superficial spreading  173 (67.1)  3798 (66.9)  
     Other    10 (3.9)  193 (3.4) 
     Not otherwise specified  42  2501 
Body site 
     Head / neck; n (%)   49 (16.3)  1569 (19.2)  9 / 28  0.49 
     Trunk; n (%)   107 (35.7)  2849 (34.9) 
     Arm / shoulder; n (%)  68 (22.7)  1603 (19.7) 
     Leg / hip; n (%)   76 (25.3)  2132 (26.1) 
Breslow thickness (mm) 
     ≤ 1    131 (56.5)  3064 (53.5)  72 / 2451  0.84 
     1.01 - 2    51 (22.0)  1329 (23.2) 
     2.01 – 4   30 (12.9)  816 (14.3) 
     > 4    20 (8.6)  517 (9.0) 
TNM stage 
T-stage 
     IS    57 (19.3)  1534 (19.4)  8 / 583  0.94 
     T1 – T3    218 (73.6)  5789 (73.0)   
     T4    21 (7.1)  604 (7.6) 
N-stage  
     N0     176 (91.7)  1714 (81.8)  112 / 6055 < 0.01 * 
     N1+    16 (8.3)   381 (18.2)  
M- stage 
     M0 / X    303 (97.7)  8135 (99.5)  0 / 0   1.00  
     M1+    1 (0.3)  42 (0.5)   
Initial treatment 
     Surgery (yes)   303 (99.7)  8113 (99.2)  0 / 0  0.37   
     Chemotherapy (yes)  1 (00.3)  27 (0.3)   2 / 0  1.00  
     Radiotherapy   4 (1.3)  94 (1.2)   2 / 4  0.78 
 
* p < 0.05; IBD = inflammatory bowel diseases; NCR = Netherlands Cancer Registry. 
  
* p < 0.05; IBD = inflammatory bowel diseases; NCR = Netherlands Cancer Registry.
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impaired compared with the general population, especially for pa-
tients with higher Breslow thickness (> 1.5 mm)10-12, 21. These data 
previously suggested the need for treatment adaptation in patients 
with IBD after a diagnosis of melanoma, by decreasing immune 
suppression. However, this is not supported by this study, as we 
found no differences in survival between IBD cases and the general 
population, also when specifically assessed for immunosuppression. 
Similar survival results were previously described in a smaller study 
of patients with IBD (n = 97)22, although this previous study had a 
longer inclusion period and shorter median follow up22. However, 
our results suggesting similar survival between IBD and non-IBD 
melanoma patients must be interpreted with caution for several 
reasons. First, the differences with studies in transplant patients 
may be explained by the limited number of patients with IBD de-
veloping a melanoma and by the lower doses, shorter treatment 
duration and different combinations of immunosuppressive therapy 
in patients with IBD versus transplant patients. Most patients with 
IBD discontinue or switch immunosuppressive therapy, mainly be-
cause of side effects or loss of response23, while transplant patients 
are in general lifelong on immunosuppressive therapy. Moreover, a 
significant percentage of patients with IBD is treated without im-
munosuppressive therapy24. Second, Penn25 showed that the risk of 
recurrence is highest in the first 2 years after malignancy diagnosis 
in (renal) transplant patients. As the moment of starting immuno-
suppressive therapy after melanoma diagnosis varied widely in our 
study, this may have also influenced our data, also because it was 
not possible in this study to specify exactly when patients star-
ted or stopped certain immunosuppressive medication, because of 
the retrospective study design.  Third, our finding that thiopurine 
or anti-TNF therapy did not affect survival may be explained by a 
selection bias: the fear of a (faster) recurrence implies that these 
treatments might have been started in patients with a favorable risk 
profile only. 
 IBD extent, including pancolitis and ileocolonic involvement was 
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Figure 2: survival analysis
Figure 2A: Kaplan Meier survival curve: IBD patients using anti-TNF after melanoma versus non-IBD controls
Figure 2B: Kaplan Meier survival curve: IBD patients using thiopurine therapy after melanoma versus  
non-IBD controls 
Figure 2C: Kaplan Meier survival curve: IBD patients with and without anti-TNF use after melanoma diagnosis 
Figure 2D: Kaplan Meier survival curve: IBD patients with and without thiopurine therapy after melanoma 
diagnosis 
IBD = Inflammatory Bowel Diseases
found to be a risk factor for melanoma development. IBD extent 
could be a risk factor because more extensive immune activation 
may be present, which might contribute to melanoma development. 
Although IBD extent and medication use are not the same, IBD ex-
tent could be a surrogate marker for more immunosuppression use, 
which was difficult to verify during chart reviews and therefore 
maybe underreported. Because IBDSL data are recorded prospec-
tively, underreporting wil occur less likely. This might also explain 
why anti-TNF therapy is even found as a protective factor in the 
sensitivity analysis.
  This study has several limitations. To test our hypothesis, we 
used three different databases that were constructed in different 
ways. Our data search is for example retrospective, while the IBD-
SL, PALGA and the NCR collect data prospectively. The IBDSL co-
hort only included patients diagnosed since 1991. Our PALGA study 
group included patients with diagnosis before that date and also 
the total follow-up since diagnosis of IBD is longer. This may have 
resulted in different treatment regimes due to differences in time 
frame. Underreporting of immunosuppressiva in our retrospective 
PALGA cohort can be an explanation for the results. Because IBDSL 
data are prospectively, underreporting will occur less likely. Unfor-
tunately, there is no single database available that could answer our 
research questions sufficiently.
 We performed a sensitivity analyses in which only medication 
of patients diagnosed with IBD after 1990 was included. Follow-up 
was included as fixed factor in the analyses to correct for differen- 
ces in follow-up duration, which were caused by differences in 
inclusion period. Furthermore, we did not have information about 
skin type, number of sun burns and melanoma mitotic index 
because it was not included in the registries and was often not 
recorded in the medical charts. Finally, for a number of variables 
in the analyses, there are considerable numbers of missing values. 
For these variables, results should be interpreted cautiously.
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The major strength of this study is the large cohort of IBD and 
melanoma patients, showing reassuring data on survival. This can 
influence clinical decision making for patients with IBD with mela-
noma in daily practice, especially with the current rising incidence 
and prevalence of both IBD and melanoma. For patients with IBD 
who develop or had melanoma in the past, treatment decisions still 
require close collaboration between gastroenterologists, derma-
tologists, and oncologists, and they must be based on a thorough 
knowledge of the individual case, including the IBD activity, con-
comitant therapy and melanoma stage2, 26.
  In conclusion, this first study on the clinical course of mela-
noma in IBD shows no differences in the clinical characteristics of 
melanoma in patients with IBD and the general population, besides 
a lower N stage in patients with IBD. Overall survival and survival in 
patients with IBD treated with thiopurine or anti-TNF therapy were 
not impaired. Although these survival data from our nation-wide 
cohort are reassuring for daily practice, treatment choices remain 
dependent on individual risk assessment by treating physicians and 
patients.
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Risk factors and clinical 
outcomes of head and neck 
cancer in inflammatory 
bowel disease: a nationwide 
cohort study.
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Abstract
Background
Immunosuppressed inflammatory bowel disease (IBD) patients are 
at increased risk to develop extra-intestinal malignancies. Immu-
nosuppressed transplant-patients showed increased incidence of 
head and neck cancer with impaired survival.
 This study aims to identify risk factors for oral cavity (OCC) 
and pharyngeal carcinoma (PC) development in IBD, to compare 
clinical characteristics in IBD to the general population and to as-
sess the influence of immunosuppressive medication on survival. 
Methods
We retrospectively searched the Dutch Pathology Database to 
identify all IBD patients with OCC and PC between 1993 and 2011. 
Two case-control studies were performed: we compared cases to 
the general IBD population to identify risk factors  and we com-
pared cases to non-IBD cancer patients for outcome analyses. 
Results
We included 66 IBD patients and 2141 controls with OCC; 31 IBD 
patients and 1552 controls with PC, and 1800 IBD controls. Age at 
IBD diagnosis was a risk factor for OCC development, for Crohn’s 
disease (CD) (Odd’s Ratio (OR) 1.04; 95%-confidence interval (CI) 
1.02–1.07) and ulcerative colitis (UC) (OR 1.03; 95%-CI 1.01–1.06). 
For PC this applied for UC (OR 1.05; 95%-CI 1.01–1.06).
  IBD OCC cases showed an impaired survival (p=0.018), in PC 
survival was similar. There was no effect of immunosuppression on 
survival. Human papillomavirus(HPV) testing of IBD cases revealed 
52.2% (12/23) HPV positive oropharyngeal carcinomas(OPC). 
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Conclusion
This study shows that IBD is associated with impaired OCC 
survival. Higher age at IBD diagnosis is a risk factor for 
OCC development. We found no influence of immunosup-
pression on survival. 52.2% of OPC in IBD contained HPV. 
Key words
Inflammatory Bowel Diseases, head and neck cancer, pharyngeal carcinoma, oral 
cavity carcinoma, immunosuppressive therapy.
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Introduction
 
Inflammatory bowel disease (IBD) is mainly diagnosed in young 
people and characterized by chronic relapsing intestinal inflamma-
tion. The majority of the IBD patients need long term treatment 
with immunosuppressive medication to control the disease and 
prevent complications1, 2. Furthermore, they have an increased risk 
to develop both intestinal and extra-intestinal malignancies (EIM)3. 
Immunosuppressive therapy can cause DNA damage and decrease 
immune surveillance, subsequently increasing EIM risk4-6. Reduced 
immune surveillance of the human papillomavirus (HPV) for exam-
ple is one of the contributing factors for the increased incidence of 
cervical cancer in patients with immunosuppression7-10. 
 HPV is associated with head and neck cancers (HNC) as well, 
suggesting that immunosuppression use in IBD patients may also 
impact HNC risk in these patients. HPV associated HNC primarily 
occur in the (oro)pharynx of young patients11 without a history of 
excessive exposure to alcohol and tobacco12 and account for more 
than one-half of cancers of the oropharynx in the USA13. However, 
the reported prevalence seems to vary between countries. In recent 
studies on the prevalence in the Netherlands show lower preva-
lence14-16. In immunosuppressed transplant patients, the incidence 
of HNC is doubled compared to the general population17, 18. The 
outcome is worse in this group of immunosuppressed patients17, 19, 
which may be associated with high-dose immunosuppression.
  Conflicting data on HNC risk in IBD are reported. Danish his-
torical cohorts show no increased risk for lip, oral cavity and pha-
ryngeal cancer20, 21, while more recent US data show a standar- 
dized incidence ratio (SIR) for oral cancer of 9.77 (95% confi-
dence interval (CI), 5.14–16.98)22 in IBD patients. Various reports 
advocate regular oral screening23, 24. Currently, studies on risk fac-
tor for HNC development and HNC outcome in IBD patients are 
lacking. We hypothesized a worse outcome for oral cavity cancer 
(OCC) and pharyngeal cancer (PC) in IBD patients treated with 
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immunosuppression in comparison with the general population. 
 In this study we aimed to: (I) identify risk factors in IBD patients 
that contribute to the development of OCC and PC and (II) com-
pare clinical characteristics, outcome and survival of OCC and PC 
in IBD patients with the general population.
 
 
Methods
Study design
This study consisted of two retrospective case-control studies. 
Cases included IBD patients who developed OCC or PC and were 
selected through PALGA, the Dutch nationwide network and regis-
try of histo- and cytopathology25. 
Case-control study I: 
in order to identify risk factors for the development of OCC and PC 
in IBD patients we compared IBD cases with HNC versus IBD con-
trols. Controls were randomly extracted from a population based 
IBD cohort in The Netherlands (IBD South Limburg, IBDSL)26.
Case-control study II: 
in order to compare clinical characteristics and outcomes of OCC 
and PC between patients with and without IBD, we compared IBD 
cases with HNC to patients with HNC from the general popula-
tion (controls). Controls were extracted from the Eindhoven Can-
cer Registry (ECR), a part of the Netherlands cancer registration 
(NCR; managed by The Netherlands Comprehensive Cancer Or-
ganisation (NCCO))The study was approved by the Privacy Com-
mission and Scientific Council of PALGA, by the Medical Ethics Re-
view Committee of the Radboudumc, Nijmegen, The Netherlands 
(Registration number 2013/211) and by the Medical Ethics Review 
Committee of the IBD-SL.
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Case selection
To identify all Dutch IBD patients with HNC from January 1 1993 
until December 31 2012, a search was performed in the national pa-
thology database PALGA. PALGA has nationwide coverage since 
199125 and covers all academic and non-academic Dutch pathology 
laboratories. Search terms for IBD included: “ulcerative colitis”, or 
“Crohn’s disease”, or “indeterminate colitis”, or “chronic idiopathic 
inflammatory bowel disease”. These terms were combined with 
search terms for HNC including: “head - neck”, or “pharynx”, or 
“mouth”, or “oral cavity “, or “lip”, or “tongue”, or “tooth”, or “tonsil”, 
or “adenoid”. 
 An initial selection of cases was made based on pathology re-
ports. Subsequently, medical charts were investigated for defini-
tive in- or exclusion. All IBD patients with primary OCC and PC were 
included in the study. Exclusion criteria were: OCC and PC in situ, 
lymphoma, diagnosis of IBD > 3 months after OCC or PC diagnosis, 
OCC or PC diagnosis before 1993 or after 2012 and no confirmed 
diagnosis of IBD.
Case control study I: controls from the IBDSL cohort
For the identification of risk factors, we randomly included IBD con-
trols diagnosed between 1991 and 2011 from the population based 
IBDSL cohort.
  The IBD South-Limburg (IBDSL) cohort comprises adult 
IBD patients that were diagnosed between 1991 and 2011 in the 
South-Limburg area of the Netherlands. The South-Limburg area 
is a well-defined geographic region in the southeast of the Neth-
erlands, bordered by Belgium, Germany and narrowly to the rest 
of the Netherlands in the north. Its geographic isolation results in 
a low net migration rate of 2.1 per 1,000 inhabitants per year, fa-
voring population research. A recent completeness check showed 
that 93% of all eligible IBD patients in the South-Limburg area is 
currently registered in the IBDSL cohort. For detailed information 
on the IBDSL cohort, we refer to the cohort profile26.
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We randomly included 1800 patients with an IBD diagnosis between 
1991 and 2011, similar to our previous studies27-29. An unmatched 
study design was chosen as we had a relatively large number of 
cases allowing adjustment for possible confounders and to avoid 
missing potential risk factors.
Case control study II: controls from the ECR
In order to compare clinical characteristics and outcome of HNC in 
IBD patients to the general population, we identified controls with 
OCC and PC from the ECR. The ECR is managed by the Nether-
lands Comprehensive Cancer Organisation (NCCO) and prospec-
tively registers all newly diagnosed cancers in The Southeast of The 
Netherlands since 1989. It covers an area with 2.3 million inhabitants 
(about 15% of the Dutch population), encompassing over 95% of 
all cancers in this region (http://www.eindhovencancerregistry.nl). 
The search terms used in this registry were C00, C02, C03, C04, 
C05, C06, C09, C10, C11, C12, C13 and C14 according to the ICD-0 
third edition30. We included all OPC and PC controls in the period 
from January 1 1993 until December 31 2012. In situ cancers and 
lymphoma’s were excluded.
Data extraction
Three authors (L.N., L.D. and A.J.) reviewed anonymized medical 
charts of IBD cases and extracted both IBD and HNC data. 
 The collected data for the IBD cases included the following pa-
tient characteristics: date of birth, gender, medical history, alcohol, 
smoking history, height and weight. For IBD, the following variables 
were collected: type of IBD based on histopathologic evaluation 
of the histologic specimen, date of IBD diagnosis, IBD phenotype 
according to the Montreal Classification31, diagnosis of primary 
sclerosing cholangitis, use of IBD medication (5-aminosalicylates, 
corticosteroids, thiopurines, methotrexate, calcineurin inhibitors 
and anti-TNF therapy), duration of therapy and number and type of 
surgery. IBD diagnosis was based on a combination of clinical, en-
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doscopic, histological and radiographic criteria32. For IBD controls 
from the IBDSL same variables were collected, although alcohol 
and smoking history were only partially available and duration of 
immunosuppressive medication was not available.
  HNC characteristics included for cases and controls: date of 
diagnoses, location, tumor stage according to the TNM classifica-
tion (7th edition), previous HNC or radiation, differentiation grade, 
primary treatment, (local) recurrence and overall survival.
 IBD cases were anonymously and encrypted linked to the Dutch 
Cancer Registry database, for reasons of quality control and com-
pletion of collected HNC data. 
HPV detection and genotyping
Sample preparation
DNA was isolated from formalin-fixed paraffin-embedded (FFPE) 
tissue sections (4 μM) with the EZ1 robot (Qiagen, Germany, with 
the DNA tissue kit of Qiagen) according to standard procedures 
(19)  and used for PCR analysis. A negative water control was in-
cluded with each batch of 10 samples.
Immunohistochemistry
For immunostaining an anti-p16 monoclonal antibody was used 
(clone G 175–405; BD Pharmi ngen, San Diego, CA) at a dilution of 
1:10. As positive control, a cervical carcinoma tissue specimen with 
high p16 expression was used. The p16 immunohistochemistry was 
scored positive if a strong nuclear and cytoplasmic staining was 
present in >70% of the malignant cells. All other staining patterns 
were scored as negative.
HPV-DNA detection and typing 
Broad-spectrum HPV-DNA amplification was performed using a 
short-PCR-fragment assay (HPV SPF
10
-LiPA
25
, version 1; Labo 
Bio-medical Products B.V, Rijswijk, Netherlands). This assay 
amplifies a 65-bp fragment of the L1 open reading frame of HPV 
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genotypes33.  HPV genotyping was performed using a cocktail of 
9 conservative probes in a micro titer hybridization assay, the DNA 
enzyme immunoassay (DEIA). The samples positive for HPV by DEIA 
were subsequently analyzed with the line probe assay (LiPA25) by 
reverse hybridization with type-specific probes for HPV 6, 11, 16, 
18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 
66, 68/73, 70, and 74. The LiPA strips were visually inspected and 
interpreted following the standardized reference guide. Phocine 
Herpesvirus (PhHV) was used as an internal control for 
amplification. 
Statistics
For both case control studies we assessed potential risk factors, 
HNC characteristics and / or outcomes between cases and controls 
with univariable analyses. X2 test or Fisher exact test (if suitable) 
were used for categorical data and independent Student t test or 
Mann-Whitney U test were used for continuous data. Variables 
with a P-value of <0.1 in univariable analyses were included in a 
multivariable model.
  For case control study I, we performed a multivariable logistic 
regression model with backward sampling. This model was adjusted 
for the duration of follow up (fixed variable). Follow up was de-
fined as the time since IBD onset until the date of HNC diagnosis 
(cases) or the end of follow up or dead (controls). The model was 
made separately for UC and CD patients to identify independent 
risk factors for HNC development. As medication use in especially 
the distant past might not be reliable and may be different from 
current regimes, we did not include medical therapy in the primary 
multivariable analysis. Therefore, we performed a secondary multi-
variable logistic regression analysis (called sensitivity analysis) in-
cluding patients with an IBD diagnosis since 1991 in both the case 
and control group. Medical therapy was included in this logistic re-
gression model. 
137Solid malignancies in inflammatory bowel diseases
For case control study II, we made Kaplan Meier survival curves and 
performed log rank analysis. Subsequently confounder correction 
was performed with a Cox regression model with forward sampling. 
A covariate was considered as a confounder when the beta coef-
ficient of the variable of interest changed by 10% or more. As the 
clinical behavior (and TNM classification) is different for PC sub-
sites (oro-, naso- and hypopharynx), TNM stage and survival were 
analyzed separately.
 A p-value of <0.05 was considered statistically significant. All 
statistical analyses were performed with IBM SPSS statistics ver-
sion 20.0 (SPSS Inc, Chicago, IL).
 
Results
Cases and controls
 The initial PALGA search yielded 760 IBD and cancer cases. First, 
we excluded 466 patients who did not present with either an OCC 
or a PC (Figure 1). Second, 197 patients were excluded who did not 
have confirmed IBD in their medical records, resulting in 31 patients 
with PC and 66 with OCC.
  For case control study I, 1800 IBD controls were randomly se-
lected from the IBDSL. For case control study II, we included 2141 
patients with OCC and 1552 with a PC from the ECR (Figure 2).
 
Case control study I: risk factors for OCC and PC development 
in IBD patients
OCC
The univariable comparison between IBD cases and IBDSL 
controls (Table 1) showed that cases were older at IBD diagnosis 
(median 53.5 versus 39.0 years; p<0.01) and were more frequently 
male (66.7% versus 46.5%; p<0.01). UC cases had more extensive 
disease (Montreal E3 disease: 50.0% versus 28.1%; p<0.01) and CD 
patients had more frequent Montreal L4 disease (20.0% versus 
3.6%; p=0.037).
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Figure 1: Flowchart case inclusion
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Figure 2: Flowchart ECR controls (general population) inclusion Table 1: Univariable comparison of potential risk factors between IBD patients with HNC 
(cases) and IBDSL controls
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In the multivariable logistic regression model age at IBD diagnosis 
remained an independent risk factor to develop OCC in both UC 
(OR 1.03, 95% CI 1.01 – 1.06) and CD (OR 1.04, 95% CI 1.02 – 1.07) 
(Table 2). For CD, Montreal L4 disease (OR 1.10, 95% CI 1.04 – 1.17) 
was an additional risk factor. 
PC
We included 31 IBD cases with PC: 25 with oropharyngeal carcino-
ma (OPC) and 6 with hypopharyngeal carcinoma (HPC) (figure 1). 
The univariable comparison between cases and IBDSL controls only 
showed a difference in tobacco use in CD patients (100% versus 
62.5%; p<0.01). 
 In the multivariable logistic regression model (Table 2) no risk 
factors remained for CD. For UC, age at IBD diagnoses was an in-
dependent risk factor (OR 1.05, 95% CI 1.08 – 1.06).
 The sensitivity analysis revealed a protective effect of 
5-aminosalicylates for OPC in UC patients (OR 0.02, 95% CI 0.01 
– 0.09; Table 2).
Case control study II: OCC and PC cases versus ECR controls 
OCC
IBD cases had a lower median age at OCC diagnosis (60.5 versus 
65.0 years; p=0.02) compared to controls (Table 3). OCC cases 
had less frequent well-differentiated tumors (12.2% versus 27.5%; 
p=0.03) and there was a trend towards a lower TNM stage (p=0.05). 
Overall survival was similar in the univariable analysis (p=0.30; sup-
plementary file 1). However, adjusted for confounders, IBD cases 
showed a worse survival (p=0.02; Figure 3). Immunosuppressive 
therapy did not negatively affect overall survival following OCC 
(p=0.43; supplementary file 1).
PC
Despite a lower T-stage (T1-T2: 75.0% versus 47.5%; p=0.02; Table 
4) in IBD patients with OPC, a comparable TNM stage (p=0.06) and 
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Table 2: Final multivariable logistic regression model after adjustment for confounders 
and follow up: independent risk factors for HNC developmentTable 2: Final mul ivariable logistic regression model after adjustment for confounders and follow 
up: independent risk factors for HNC development 
 
 
Model  Variable  Coefficient β Odds Ratio P-  
(95%- CI)  value 
 
 
Oral cavity 
 
Ulcerative colitis   Age at IBD diagnosis 0.03  1.03 (1.01 – 1.06) < 0.01 
all cases (n=34) 
 
Ulcerative colitis  Male sex  1.03  2.79 (1.08 – 7.18) 0.03 
Sensitivity analysis(n=26) Age at IBD diagnosis 0.05  1.05 (1.02 – 1.08) < 0.01 
 
Crohn’s disease  Age at IBD diagnosis 0.04  1.04 (1.02 – 1.07) < 0.01 
All cases (n=31)  Upper digestive (L4)  1.08  1.10 (1.04 – 1.17) 0.03 
 
Crohn’s disease  Age at IBD diagnosis 0.04  1.04 (1.02 – 1.07) < 0.01 
Sensitivity analysis (n=20) 
 
 
Oropharynx 
 
Ulcerative colitis   Age at IBD diagnosis 0.05  1.05 (1.00 – 1.09) 0.01 
all cases (n=12) 
 
Ulcerative colitis  5-aminosalicylates -4.03   0.02 (0.01 – 0.09) < 0.01 
Sensitivity analysis (n=9) 
 
Crohn’s disease  No risk factors identified      
All cases (n=12) 
 
Crohn’s disease  No risk factors identified      
Sensitivity analysis (n = 6) 
 
 
IBD = inflammatory bowel disease 
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Table 3: Univariable comparison of oral cavity characteristics between IBD cases and 
controls from the general population with oral cavity 
Table 4: Univariable comparison of pharynx carcinoma characteristics between IBD cases 
and controls from the general population with pharynx carcinoma 
 
 
 
Table 3: Univariable comparison of oral cavity characteristics between IBD cases and controls from 
the general population with oral cavity  
 
Variable   IBD patients  ECR patients                  Missing (n)                 p-value 
   N = 66  N = 2141                   IBD / ECR                       
  
 
Age at diagnosis (y),    
     median   60.50  65.00   0 / 0  0.02* 
 
Female sex; n (%)  22 (33.3)  810 (37.8 )   0 / 0  0.26 
 
Tumor location 
    Oral cavity  57 (86.4)  1506 (70.3)  0 / 0                    <0.01* 
    Lip   9 (13.6)  635 (29.7) 
 
Histology 
     SCC   62 (95.4)  2045 (96.5)  1 / 0  0.50  
Differentiation 
     Good   6 (12.2)  486 (27.5)   12 / 373  0.03* 
     Moderate  37 (75.5)  1013 (57.3) 
     Poor   6 (12.2)  269 (15.2) 
 
Staging  
     T stage oral cavity# 
T1; n (%)   33 (60.0)  619 (42.0)   2 / 31  0.07 
T2; n (%)                       12 (21.8)  401 (27.2) 
T3; n (%)   3 (5.5)  115 (7.8) 
T4; n (%)   7 (12.7)  340 (23.1)    
     N stage oral cavity# 
N0; n (%)    39 (74.2)      1270 (71.7)  2 / 80  0.87 
N1; n (%)    7 (11.3)  184 (10.4) 
N2; n (%)  9 (14.5)  300 (16.9) 
N3; n (%)    0 (0.0)  17 (1.0)    
      M stage (yes) oral cavity # 1 (1.8)  17 (1.2)   1 / 121  0.51 
 
TNM – stadium oral cavity  
Stadium I; n (%)    27 (50.9)  454 (33.8)   4 / 162 0.05 
Stadium II; n (%)    7 (13.2)  231 (17.2) 
Stadium III; n (%)    7 (13.2)  162 (12.1) 
Stadium IV; n (%)  12 (22.6)  497 (37.0)  
 
TNM – stadium lip # 
Stadium I; n (%)    7 (100.0)  248 (87.3)   2 / 351 1.00 
Stadium II; n (%)    0 (0.0)  20 (7.0) 
Stadium III; n (%)    0 (0.0)  8 (2.8) 
Stadium IV; n (%)  0 (0.0)  8 (2.8)  
 
Treatment 
 Surgery (yes); n (%)  60 (90.9)  1834 (85.7)  0 / 0 0.23 
 Chemo (yes); n (%)  1 (1.5)  69 (3.2)   0 / 0 0.44 
 Radiotherapy (yes); n (5) 23 (34.8)  750 (35.0)   0 / 0 0.98 
Previous Malignancy   14 (21.2)  460 (21.5)   0 / 0  0.96      
 
OSCC = Oral squamous cell carcinoma; IBD = Inflammatory bowel disease; ECR = Eindhoven Cancer 
Registry; SCC = squamous cell carcinoma; # according to the 7th TNM edition
 
 
 
Table 4: Univariable comparison of pharynx carcinoma characteristics between IBD cases and 
controls from the general population with pharynx carcinoma  
 
Variable   IBD patients  ECR patients                  Missing (n) P-value 
   N = 31  N = 1552                          IBD / ECR                        
Oropharynx and hypopharynx 
Age at diagnosis (y),    
     Median   59.00  61.00   0 / 0  0.65 
Female sex; n (%)  12 (38.7)  432 (27.8 )   0 / 0  0.22 
 
Tumor location 
     Nasopharynx  0 (0.0)  158 (9.4)   0 / 23  0.09 
     Oropharynx  25 (80.6)  1095 (64.9) 
     Hypopharynx  6 (19.4)  434 (25.7) 
 
Histology 
     SCC   30 (96.8)  1459 (94.0)  1 / 93   1.00  
Differentiation 
     Good   2 (9.1)  88 (6.9)   9 / 275  0.69 
     Moderate  11 (50.0)  725 (56.8) 
     Poor   9 (40.9)  464 (36.3) 
 
Oropharynx  
     T stage # 
T1 – T2; n (%) 18 (75.0)   505 (47.5)   0 / 33  0.02* 
                  T3 – T4; n (%)    7 (25.0)  557 (52.5) 
     N  stage # 
N0; n (%)    12 (50.0)      363 (34.8)   0 / 25  0.49 
N1; n (%)    3 (12.5)  160 (15.3) 
N2; n (%)  8 (33.3)  469 (45.0) 
N3; n (%)    1 (4.2)  51 (4.9)    
     M stage (yes) #  1 (4.2)  44 (4.4)   1 / 55  0.96 
    TNM – stadium # 
Stadium I -II; n (%)   9 (37.5)  222 (21.6)   1 / 65  0.06 
Stadium III - IV; n (%)  15 (62.5)  808 (78.2) 
Hypopharynx  
     T stage # 
T1; n (%)   0 (0.0)  39 (9.3)   1 / 14  0.51 
T2 – T3; n (%)              4 (80.0)  231 (55.0) 
T4; n (%)   1 (20.0)  150 (35.7)    
     N  stage # 
N0; n (%)    4 (80.0)       109 (26.7)   1 / 1  0.11 
N1; n (%)    1 (20.0)  75 (18.3) 
N2; n (%)  0 (0.0)  188 (46.0) 
N3; n (%)    0 (0.0)  37 (9.0)    
     M stage (yes) #  0 (0.0)  24 (6.0)   1 / 34  1.00 
     TNM – stadium# 
Stadium I; n (%)   0 (0.0)  11 (2.6)   1 / 18  0.03* 
Stadium II - III; n (%)   4 (80.0)  109 (26.2) 
Stadium IV; n (%)   1 (20.0)  296 (71.2) 
 
Oropharynx and hypopharynx 
Treatment 
 Surgery (yes); n (%) 14 (46.7)  348 (22.4)   1 / 0  <0.01 
 Chemo (yes); n (%) 2 (6.7)  276 (17.8)   1 / 0  0.15 
 Radiotherapy (yes) 22 (73.3)  1235 (79.6)  1 / 0  0.40 
Previous Malignancy  12 (41.4)  342 (22.0)   2 / 0   0.01 *    
IBD = Inflammatory bowel disease; ECR = Eindhoven Cancer Registry; SCC = squamous cell carcinoma
# according to the 7th TNM edition
Table 3: Univariable comparison of oral cavity characteristics between IBD cases and controls from 
the general population with oral cavity  
 
Variable    IBD patients  ECR patients                    Missing (n)                 p-value 
    N = 66  N = 2141                    IBD / ECR                       
  
 
Age at diagnosis (y),    
     median    60.50  65.00   0 / 0  0.02* 
 
Female sex; n (%)   22 (33.3)  810 (37.8 )  0 / 0  0.26 
 
Tumor location 
    Oral cavity   57 (86.4)  1506 (70.3)  0 / 0                    <0.01* 
    Lip    9 (13.6)  635 (29.7) 
 
Histology 
     SCC   62 (95.4)  2045 (96.5)  1 / 0  0.50 
Differentiation 
     Good    6 (12.2)  486 (27.5)   12 / 373  0.03* 
     Moderate   37 (75.5)  1013 (57.3) 
     Poor    6 (12.2)  269 (15.2) 
 
Staging  
     T sta e oral cavity# 
T1; n (%)    33 (60.0)  619 (42.0)   2 / 31  0.07 
T2; n (%)                                          12 (21.8)  401 (27.2) 
T3; n (%)   3 (5.5)  115 (7.8) 
T4; n (%)    7 (12.7)  340 (23.1)    
     N stage oral cavity# 
N0; n (%)     39 (74.2)      1270 (71.7)  2 / 80  0.87 
N1; n (%)    7 (11.3)  184 (10.4) 
N2; n (%)  9 (14.5)  300 (16.9) 
N3; n (%)     0 (0.0)  17 (1.0)    
      M stage (yes) oral cavity #  1 (1.8)  17 (1.2)   1 / 121  0.51 
 
TNM – stadium oral cavity  
Stadium I; n (%)   27 (50.9)  454 (33.8)   4 / 162  0.05 
Stadium II; n (%)   7 (13.2)  231 (17.2) 
Stadium III; n (%)    7 (13.2)  162 (12.1) 
Stadium IV; n (%)  12 22 6  497 (37.0)  
 
TNM – stadium lip # 
Stadium I; n (%)    7 (100.0)  248 (87.3)   2 / 351  1.00 
Stadium II; n (%)   0 (0.0)  20 (7.0) 
Stadium III; n (%)    0 (0.0)  8 (2.8) 
Stadium IV; n (%)  0 (0.0)  8 (2.8)  
 
Treatment 
 Surgery (yes); n (%)  60 (90.9)  1834 (85.7)  0 / 0  0.23 
 Chemo (yes); n (%)  1 (1.5)  69 ( .2)   0 / 0  0.44 
 Radiotherapy (yes); n (5) 23 34.8)  750 5.0)   0 / 0  0.98 
Previous Malignancy   14 (21.2)  460 (21.5)   0 / 0   0.96      
 
OSCC = Oral squamous cell carcinoma; IBD = Inflammatory bowel disease; ECR = Eindhoven Cancer 
Registry; SCC = squamous cell carcinoma; # according to the 7th TNM edition
survival (p=0.50) was found compared to controls. Immunosuppres- 
sive therapy did not negatively affect overall survival following OPC 
(p=0.10 and p=0.07; supplementary file 2A). We found no diffe- 
rence in survival between HPV positive and negative OPCs (p=0.45). 
 IBD patients with HPC (n=6) had a lower TNM stage 
(p=0.03; Table 4) and a better overall survival compared 
to the general population (p=0.01; supplementary file 2B). 
 Both OPC and HPC cases underwent more frequently surgery 
(46.7% versus 22.4%; p<0.01; Table 4).
Histopathology and HPV analysis
We obtained tissue from 48 of 66 identified OCC cases for fur-
ther analyses. All cases were squamous cell carcinomas, and five 
of 48 tumors (10.4%) were p16 positive, suggesting the possibili-
ty of HPV-related cancers. Subsequent HPV testing of these five 
cases revealed three cases with HPV 16 infection and two cases 
without HPV detection. In addition, we obtained tissue from 27 out 
of 31 PC patients for further analyses (figure 4). The p16 positive 
cases (n = 11) were all HPV positive and were all oropharyngeal of 
origin. Of the OPC 12 of 23 (52.2%) were HPV positive, most HPV 
16 (10/12; 83.3%). In 8 of 12 HPV-positive cases we were informed 
about medication use: 6 used immunosuppressive therapy before 
HNC diagnosis (4/6 at least thiopurines). 
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Figure 3: Oral cavity malignancy Kaplan Meier survival curve 
Figure 4: Pharyngeal cancers histopathology
IBD cases (N = 57) versus ECR controls (N = 1506) after adjustment for TNM stage  
IBD=Inflammatory bowel disease; ECR=Eindhoven Cancer Registry 
Discussion
In this nationwide study we found that IBD patients with OCC have 
an impaired survival compared to the general population, adjusted 
for TNM stage. Higher age at IBD diagnosis was a risk factor for 
OCC development in IBD and for PC in UC. Proximal CD localization 
was another risk factor for OCC development. Furthermore, we 
found that 52.2% of IBD associated oropharyngeal cancers were 
HPV positive compared to 30 % in general Dutch population. Immu-
nosuppression did not impact survival of HNC in IBD.
 We showed that 52.2% of the OPCs in IBD were HPV positive, 
which is in line with the reported prevalence of HPV positive OPCs 
in the (international) general population34. However, the reported 
prevalence seems to vary between countries and in recent studies 
on the prevalence in the Netherlands lower figures (30 %) have 
been reported14-16. Differences in HPV prevalence between IBD 
patients with and without immunosuppression could not be deter-
mined due to the limited number of cases. In the general population 
patients with HPV-positive tumors have better outcomes, but in 
the IBD cases no difference in survival was observed. As OPC inci-
dence is increasing mainly due to the increased incidence of HPV 
positive OPCs, the potential impact of prophylactic HPV vaccines 
is of interest35, 36. This especially applies for immunosuppressed pa-
tients on thiopurine therapy, as reduced immunosurveillance may 
cause persisting HPV infections.  
 In line with colorectal cancer in IBD, OCC in IBD arise at a 
younger age (median 60.5 versus 65.0 years; p = 0.021) and has 
an impaired prognosis3. Furthermore, immunosuppressive therapy 
may promote tumor progression and impair survival6, 37. However, 
we found no difference in tumor stage and overall survival in our 
cohort regardless of immunosuppression use. These results must 
be interpreted with caution due to the limited number of IBD pa-
tients with HNC. Furthermore, clinicians fear the negative impact 
of immunosuppression on cancer outcomes thus immunosuppres-
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sion may only be used in patients with a favorable risk profile. Final-
ly, Penn38 showed that the risk of recurrence for (renal) transplant 
patients is highest in the first two years after malignancy diagnosis. 
Our data may have been influenced by wide variations in the com-
mencement of immunosuppressive therapy after cancer diagnosis. 
 We indentified two risk factors for HNC development in IBD.
 First, proximally localized disease in CD patients (Montreal L4; in-
cluding oral cavity inflammation) (OR 1.103; 95% CI 1.040 – 1.170; p 
= 0.028). This may be related to upper gastrointestinal IBD-related 
inflammation. Furthermore, we identified older age at IBD diagnosis 
as a risk factor for both OCC and PC development. This is an inte- 
resting observation that is in line with other cancer types in IBD27, 
39 although our study does not provide an explanation for this 
observation.
 To date, this is the largest, systematically collected series of 
OCC and PC in IBD patients.  However, our study also comes with 
several limitations, such as the retrospective nature of the study. 
Especially in cases that were enrolled in early years, it was challeng-
ing to collect accurate and complete information. Therefore, we 
also performed a sensitivity analysis, enrolling only cases diagnosed 
with IBD after 1990. This did not show immunosuppressive thera-
py as a risk factor for OCC or PC development. Second, we used 
three different databases that were constructed in different ways 
to address our hypothesis. Our data search is retrospective, while 
the IBDSL and the cancer registry (including ECR) collect prospec-
tively. Unfortunately there is no single database available that could 
answer our research questions sufficiently. Third, important data 
on tobacco and alcohol use, the main risk factors for HNC develop-
ment, were incomplete for the ECR and IBDSL. As HPV presence is 
correlated inversely with tobacco (and alcohol) consumption, this 
would provide important additional information. 
 Some authors22, 24 have suggested oral screening for all 
IBD patients, especially those who are starting immunosup-
pression. As the incidence of HNC in IBD in general is low and 
149Solid malignancies in inflammatory bowel diseases
no well defined premalignant lesions analogous to cervical in-
traepithelial neoplasia in cervical cancer have been established 
yet, we would recommend increased awareness for HNC in IBD 
rather than active screening, especially in elderly onset IBD. 
 In conclusion we found that IBD patients with OCC may have 
a reduced survival compared to the general population. Proximal 
disease localization in CD is a risk factor for OCC development. 
The majority (52.2%) of IBD associated oropharyngeal cancers was 
HPV positive. Immunosuppression did not impact incidence and 
survival of HNC in IBD. 
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Abstract
Colorectal neoplasia can still develop after colectomy for inflam-
matory bowel disease. However, data on this risk are scare, and 
there have been few conclusive findings, so no evidence-based 
recommendations have been made for postoperative surveillance. 
We conducted a systematic review and meta-analysis to determine 
the prevalence and incidence of and risk factors for neoplasia in 
patients with inflammatory bowel disease who have undergone 
colectomy, including the permanent-end ileostomy and 
rectal stump, ileorectal anastomosis (IRA), and ileal pouch-anal 
anastomosis (IPAA) procedures.
 We searched PubMed, Embase, Web of Science, and Cochrane 
Library through May 2014 to identify studies that reported preva-
lence or incidence of colorectal neoplasia after colectomy or spe-
cifically assessed risk factors for neoplasia development. Studies 
were selected, quality was assessed, and data were extracted by 2 
independent researchers.
 We calculated colorectal cancer (CRC) prevalence values from 
13 studies of patients who underwent rectal stump surgery, 35 
studies of IRA, and 33 studies of IPAA. Significantly higher pro-
portions of patients in the rectal stump group (2.1%; 95% confi-
dence interval [CI], 1.3%–3.0%) and in the IRA group (2.4%; 95% 
CI, 1.7%–3.0%) developed CRC than in the IPAA group (0.5%; 95% 
CI, 0.3%–0.6%); the odds ratio (OR) for CRC in the rectal stump 
or IRA groups compared with the IPAA group was 6.4 (95% CI, 
4.3–9.5). A history of CRC was the most important risk factor for 
development of CRC after colectomy (OR for patients receiving 
IRA, 12.8; 95% CI, 3.31–49.2 and OR for patients receiving IPAA, 15.0; 
95% CI, 6.6–34.5).
 In a meta-analysis of published studies, we found the prevalence 
and incidence of CRC after colectomy to be less than 3%; in patients 
receiving IPAA it was less than 1%. Factors that increased risk of can-
cer development after colectomy included the presence of a residual 
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rectum and a history of CRC. These findings could aid in development 
of individualized strategies for post-surgery surveillance.
 
Introduction
 
Although the magnitude of the colorectal cancer (CRC) risk in in-
flammatory bowel disease (IBD) patients is still under debate, it is 
well-established that both ulcerative colitis (UC) and Crohn’s di-
sease (CD) patients with colonic involvement have an increased 
risk to develop CRC. It is one of the most detrimental complications 
of IBD, with significant morbidity and an associated mortality rate 
of approximately 15%.1 To reduce CRC risk, endoscopic surveillance 
guidelines have been developed that allow detection and poten-
tial removal of precancerous lesions. This strategy might reduce 
the increased CRC incidence in IBD patients and improve mortality 
rates.2 However, IBD surveillance guidelines have been written on 
the basis of research in patients with an intact colon.3, 4
 Although therapeutic options have expanded during the last de-
cade, bowel surgery still plays an important role in the management 
of IBD. Indeed, the cumulative risk of intestinal surgery for UC pa-
tients is 25%–30% and even higher for CD patients (70%–80%).5, 
6 For UC or extensive colorectal CD, staged restorative proctoco- 
lectomy is the surgical treatment of choice. The series of surgical 
procedures start with subtotal colectomy and ileostomy with a re-
sidual rectum left in situ. This initial approach will keep options for 
reconstructive surgery open.1 Ileal pouch-anal anastomosis (IPAA) 
is the preferred reconstructive procedure after colectomy in UC 
patients.1, 5 In patients with extensive colonic CD, ileorectal anasto-
mosis (IRA) is the first restorative option to consider.6 For several 
reasons including comorbidities and concerns about fertility, trea-
ting physicians and patients may reconsider restorative surgery, 
and these patients usually continue with a permanent ileostomy and 
rectal stump. 
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 Colectomy, with or without reconstructive surgery, substantially 
reduces the risk to develop colorectal neoplasia. However, neopla-
sia of the residual rectum or ileoanal pouch may still arise and is 
associated with a poor prognosis. The latter underlines the impor-
tance of preventative strategies such as endoscopic surveillance. In 
recent years, data have expanded regarding prevalence, incidence, 
and risk factors for colorectal neoplasia after colectomy. Lack of a 
comprehensive approach and interpretation of these data has led 
to the absence of endoscopic surveillance recommendations for 
these patients. Thus, integrated data on CRC risk in postsurgical 
IBD patients are needed to further aid development of surveillance 
guidelines. We therefore conducted a systematic review and me-
ta-analysis that aimed to determine prevalence, incidence, and risk 
factors regarding colorectal dysplasia and cancer after colectomy 
in 3 groups of IBD patients including (1) patients with a permanent 
ileostomy and rectal stump, (2) patients with IRA, and (3) patients 
with IPAA.
 
Methods
Search strategy
Medline, Embase, the Cochrane Library, and Web of Science were 
independently searched with the help of a clinical librarian until May 
2014 by 2 authors (L.D., L.N.) to identify studies that evaluated the 
colorectal neoplasia risk after colonic resection in IBD patients. We 
used the medical subject headings (MeSH) “Inflammatory bowel 
disease” OR “Ulcerative colitis” OR “Crohn’s disease”, combined 
with “Surgical anastomosis” OR “Colectomy” OR “Restorative 
proctocolectomy” and combined with “Colorectal neoplasms” OR 
“Rectal neoplasms” OR “Colon neoplasms” OR “Anus neoplasms”. 
Simultaneously, a title/abstract search was performed with similar 
search terms and synonyms. The full search strategy is described 
in Supplementary Table 1. No restrictions regarding language, year 
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of publication, or publication type were imposed. A manual search 
for references in the initially selected articles (Figure 1) was per-
formed to identify additional relevant articles. The reporting check-
list proposed by the Meta-analysis of Observational Studies in Ep-
idemiology was used as a guideline in this systematic review and 
meta-analysis. 
Inclusion and exclusion criteria
Studies were eligible for inclusion if the authors reported a series 
of IBD patients who underwent colonic resection and if occurrence 
of postoperative neoplasia in the residual rectum or pouch was de-
scribed. In addition, we included studies that specifically assessed 
risk factors for neoplasia development after colectomy. Studies in-
cluding patients with a Hartmann procedure or segmental resection 
and studies not defining the total IBD patient group were excluded. 
Furthermore, we excluded case reports, case series, studies inclu- 
ding < 20 patients, and conference abstracts because these might 
not be representative for the target population. In case of duplicate 
publication or similar data from same institutions, the most recent 
and complete data sets were considered. Multiple studies from one 
institution were both considered if less than 25% of the inclusion 
years overlapped.
Quality assessment of retrieved articles
On the basis of the guidelines for critically appraising studies of 
prevalence or incidence, we composed a list of parameters for qual-
ity judgment.7 These comprise whether the study was single center 
or population based, the number of patients (more or less than 100; 
a calculated sample size of 114 patients would be needed to show 
a prevalence of 5% with an error rate of 4%; a smaller sample size 
would give a higher risk of bias), duration of follow-up (cutoff mean 
or median 1 year), proctectomy or pouch excision rate, whether a 
clear pathologic classification system was used for grading neopla-
sia, whether the study was retrospective or prospective, 
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and whether the study was consecutive. Two authors (L.D., L.S.) 
independently determined a quality score for each study, with a 
maximum of 7 points. Disagreement was resolved by discussion and 
consensus with a third reviewer (F.H.).
Data extraction
Different parameters were independently extracted by 2 authors 
(L.D., L.S., in consensus with F.H.) from the original articles inclu- 
ding demographics, IBD characteristics, neoplasia prevalence 
and incidence, and risk factors such as a history of preoperative 
colorectal neoplasia, primary sclerosing cholangitis (PSC), pouchitis, 
and type of pouch anastomosis. IBD characteristics included the 
type and duration of IBD. For each group of IBD patients (rectal 
stump, IRA, and IPAA), the prevalence of colorectal neoplasia was 
calculated by dividing the cases by the total patient group at risk. 
Patients with either adenocarcinoma, including carcinoma in situ, 
or dysplasia were included as cases. The first group with a rectal 
stump was defined as the group of patients who underwent a co-
lonic resection including the hepatic and splenic flexure and who 
received a permanent ileostomy. A rectal or rectosigmoidal stump 
was still in situ and at risk for neoplasia development. Patients who 
were lost to follow-up, postoperatively deceased, or undergoing 
secondary reconstruction of IRA or IPAA were not included in this 
group. The IRA and IPAA groups included all patients who under-
went IRA or IPAA in 1 or more stages, respectively. Patients with an 
ileosigmoidal or cecorectal anastomosis were also included in the 
IRA group. In accordance with the rectal stump group, patients who 
were lost to follow-up or postoperatively deceased were excluded 
from the IRA and IPAA groups.
Statistics
We performed a meta-analysis to estimate pooled prevalences and 
cumulative incidences of colorectal neoplasia after colectomy. Ran-
dom-effect models were used because of heterogeneity of studies. 
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Figure 1. Flowchart showing inclusion of articles for analysis.
a Twelve articles are included in both the rectal stump group and the IRA group.  
b One article is included in both the IRA group and the IPAA group.
We assessed publication bias with the visual inspection of a funnel 
plot and used the Egger test to analyze funnel plot asymmetry.8 
Subsequently, we compared prevalences between subgroups (for 
example UC versus CD) with a logistic regression model calculating 
odds ratios (ORs).
  To analyze potential risk factors for developing CRC after 
colectomy, ORs were separately calculated for each study and 
subsequently pooled with a random-effect model. Risk factors that 
comprised continuous data were analyzed in a pooled model by 
calculating a weighted mean difference.
 To compare equality of follow-up duration between the 3 
groups, we used one-way analysis of variance. Correlations between 
duration of follow-up and prevalence were analyzed with Spearman 
correlation coefficient. A P value less than 0.05 was considered 
statistically significant. All statistical analyses were performed by 
using StatsDirect Statistical Software version 2.8.0 (StatsDirect, 
Sale, Cheshire, UK), Statistical Analysis Software version 9.2 (SAS 
Institute, Cary, NC), or IBM SPSS statistics version 20.0 (SPSS 
Inc, Chicago, IL).
 
Results
Study selection
The systematic study selection flowchart is depicted in Figure 
1. Sixteen, 68, and 56 articles were included in the rectal stump 
group, the IRA group, and the IPAA group, respectively. Because 
of duplicate data, 2 studies in the rectal stump group, 32 studies in 
the IRA group, and 18 studies in the IPAA group were not used for 
prevalence calculations (references for excluded studies are listed 
in Supplementary Material). For both the rectal stump group and 
the IRA group we included 1 article and for the IPAA group 5 articles 
that specifically assessed risk factors.
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Study characteristics and quality assessment
Summarized quality scores for all included studies are depicted in 
Supplementary Tables 2–4 for the rectal stump group, IRA group, 
and IPAA group. Full quality assessment is displayed in Supplemen-
tary Tables 5–7.
  The mean quality score of selected studies in the rectal 
stump group was 2.3 out of 7. All studies included retrospective, 
single-center cohort studies. Sample sizes were insufficient, 
and none of the studies mentioned the pathologic classification 
system that was used to evaluate rectal neoplasia. Proctecto-
my rates differed between 46% and 95%, resulting in a reduced 
number of patients at risk to develop rectal neoplasia. However, 
there was no correlation between proctectomy rates and cancer 
prevalence (P = 0.510).
 Studies included in the IRA group had better overall quality, with 
average quality score of 4.0. This was mainly caused by better docu-
mentation and longer duration of follow-up, lower proctectomy rate, 
and larger number of included patients per study. Higher proctectomy 
rates were not correlated with lower cancer prevalence (P = 0.311). 
 Included articles on the IPAA group had a mean quality score 
of 3.0. The difference in quality score with the IRA group might be 
attributed to absence of the pouch excision rate, which was not 
reported in most articles. No correlation between follow-up 
duration and prevalence was observed (P = 0.515).
Ileostomy and rectal stump
Prevalence and incidence. 
A pooled analysis including 1011 IBD patients demonstrated a 
carcinoma prevalence of the rectal stump of 2.1% (95% confidence 
interval [CI], 1.3–3.0; Supplementary Table 2, Supplementary 
Figures 1 and 4). This value represents the prevalence in a variable 
duration of reported follow-up between 0.25 and 40 years. None of 
the included studies evaluated dysplasia development. One study 
specifically assessed the cumulative rectal cancer incidence in 
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UC patients with a rectal stump or secondary IRA (constructed in 
2 stages), resulting in an incidence of 12.6% after 24 years after 
surgery.9
Risk factors. 
Only 1 study assessed risk factors for the development of rectal 
stump cancer.10 This retrospective case-control study included 12 
rectal stump carcinomas and 18 control patients without rectal 
stump neoplasia and identified PSC and IBD duration until subtotal 
colectomy as risk factors. The study design of this case-control 
study was not sufficient to identify a history of colorectal neopla-
sia as risk factor because these patients were excluded from the 
control group.
  We detected no difference in carcinoma prevalence of the 
rectal stump between UC and CD (2.2%, 95% CI, 1.3%–3.4% 
versus 2.1%, 95% CI, 0.6%–4.4%; OR 1.4, 95% CI, 0.4–5.0, 
p = 0.574).
Ileorectal anastomosis
Prevalence and incidence. 
A pooled rectal carcinoma prevalence of 2.4% (95% CI, 1.7%–3.3%) 
was calculated in the IRA group, including 2762 patients with a vari-
able duration of reported follow-up between 1 and 35 years (Supple-
mentary Table 3, Supplementary Figures 2 and 5). Development of 
rectal dysplasia after IRA was described in 16 studies including 1425 
patients, resulting in a pooled dysplasia prevalence of 2.5% (95% CI, 
1.2%–4.2%). Because the year of publication and the duration of fol-
low-up may influence the prevalence, we performed subgroup analy-
sis on the basis of these variables. There was a statistically significant 
lower carcinoma prevalence (OR, 2.3; 95% CI, 1.3–4.1; p = 0.003) in 
studies published after 1990 (1.6%; 95% CI, 0.8%–2.6%) compared 
with earlier studies (3.2%; 95% CI, 2.1%–4.4%). No differences 
were found between studies with a duration of follow-up of at least 8 
years (start surveillance colonoscopies), compared with studies with 
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a shorter duration of follow-up (2.0%, 95% CI, 0.9%–3.4% versus 
2.4%, 95% CI, 1.3%–3.7%; OR, 1.1, 95% CI, 0.5–2.2; p = 0.899).
Three studies reported a cumulative incidence of rectal carcinoma 
in the IRA group after onset of IBD.11–13 A pooled analysis showed 
cumulative incidences of 0%, 5% (95% CI, 3.0%–7.5%), and 10% 
(95% CI, 7.0%–12.0%) after 10, 20, and 25 years after IBD onset, 
respectively. One study estimated cumulative incidences after IRA 
construction. After 5, 10, 15, and 20 years, respectively, cumulative 
incidences were 0%, 2%, 5%, and 14% for rectal carcinoma and 
7%, 9%, 20%, and 25% for rectal dysplasia.14
Risk factors. 
UC, a history of CRC, and IBD duration emerged as risk factors 
for developing rectal carcinoma after IRA construction. None of 
the included studies specifically evaluated PSC as a risk factor. UC 
patients, including patients with indeterminate colitis, were more 
likely to develop rectal carcinoma after IRA construction compared 
with CD patients. A higher pooled carcinoma prevalence of the rec-
tum was estimated in UC patients versus CD patients (3.2%, 95% 
CI, 2.3%–4.3% versus 0.7%, 95% CI, 0.2%–1.6%) with OR of 10.3 
(95% CI, 2.5–41.9; p = 0.001).
 A forest plot evaluating prior CRC as a risk factor to develop 
rectal carcinoma after IRA construction is displayed in Figure 
2A. Three studies were available for meta-analysis because they 
reported prior CRC both in the patients who developed rectal 
carcinoma and in the patients who did not.11, 12, 15 A pooled OR of 12.8 
(95% CI, 3.3–49.2) favors prior CRC as risk factor to develop rectal 
carcinoma in patients with IRA. This is further supported by another 
study that described rectal neoplasia after subtotal colectomy in 
17 CD patients with a history of CRC.16 Six of 17 patients (28.6%) 
developed rectal carcinoma after subtotal colectomy, which is 
significantly higher than a pooled prevalence of 2.4% (P < 0.001). A 
history of colorectal dysplasia could not be assessed as risk factor 
because of insufficient data.
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 A longer duration of IBD also predisposes development of 
rectal carcinoma after colectomy and IRA. Others have reported 
an increasing risk over time in which none of the 22 rectal 
carcinomas after IRA developed within IBD duration of 10 years 
(3534 patient-years of follow-up). Beyond 10 years, the risk was 
1 in 185 patient-years between 10 and 20 years of IBD duration and 
1 in 117 patient-years in patients with IBD history of more than 20 
years.12 Furthermore, 1 study showed that patients who developed 
rectal cancer had a statistically significant longer duration of IBD 
compared with patients who did not develop rectal cancer (P = 
0.030).14 Nine studies reported IBD duration until rectal carcinoma 
development, and none of the 49 patients developed cancer within 
10 years of IBD duration.9, 12, 14, 17–22
Ileal pouch-anal anastomosis
Prevalence and incidence.
 The pooled prevalence of carcinoma in the ileoanal pouch was 0.5% 
(95% CI, 0.3%–0.6%; Supplementary Table 4, Supplementary Fig-
ures 3 and 6). This analysis included 8403 patients with a variable 
duration of follow-up. Thirty-one articles including 7647 patients 
reported pouch dysplasia development, resulting in a pooled pouch 
dysplasia prevalence of 0.8% (0.5%–1.3%). Even studies that only 
included high-risk patients, such as patients with chronic pouchitis, 
prior CRC, long pouch duration (> 8 years), or PSC, showed rela-
tively low pouch neoplasia prevalence (0.9%–4.6%).23–26
 Three studies reported cumulative incidences of pouch carci-
noma after IPAA construction, resulting in a pooled cumulative inci-
dence of 0.4% (95% CI, 0.1%–0.9%), 0.9% (95% CI, 0.2%–1.9%), 
1.4% (95% CI, 0.04%–3.0%), 2.7% (95% CI, 2.1%–3.4%), and 3.4% 
(95% CI, 2.8%–4.0%) after 5, 10, 15, 20, and 25 years, respective-
ly.11, 27, 28 Cumulative incidences of pouch dysplasia were reported in 
2 of these studies. A pooled analysis showed cumulative incidences 
of pouch dysplasia after IPAA of 0.6% (95% CI, 0.2%–1.2%), 0.9% 
(95% CI, 0.8%–1.8%), 1.5% (95% CI, 1.2%–1.9%), and 3.0% (95% 
CI, 2.0%–5.0%) after 5, 10, 15, and 20 years, respectively.27, 28
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Risk factors. 
Risk factors for pouch neoplasia development are a history of col-
orectal neoplasia and IBD duration. There was insufficient evidence 
available to evaluate a stapled anastomosis, PSC, and pouchitis as 
risk factors.
 Prior colorectal neoplasia is the most important risk factor for 
developing pouch neoplasia. A pooled analysis including 5216 pa-
tients showed that patients with prior CRC had a statistically sig-
nificant increased risk to develop pouch carcinoma (OR, 15.0; 95% 
CI, 6.6–34.5; Figure 2B) compared with patients without a history 
of CRC.11, 23, 27–30 Moreover, an analysis excluding patients with prior 
CRC showed that prior colorectal dysplasia was also a risk factor 
for developing pouch carcinoma (OR, 4.4; 95% CI, 1.9–10.1; Sup-
plementary Figure 7).11, 23, 27–29 A systematic review of all described 
pouch carcinoma cases in IBD patients reported that 57.1% of these 
cases (28 of 49) had prior colorectal neoplasia. 
 IBD duration might also be considered as a risk factor because 
patients who developed pouch neoplasia had a significantly longer 
IBD duration before pouch construction compared with patients 
who did not develop pouch neoplasia in the univariate analysis of 
the 2 largest cohort studies. A pooled analysis of these 2 studies 
including 4403 patients showed that patients with pouch neoplasia 
had 5.1 years (95% CI, 2.5–7.6) longer IBD history before pouch 
construction (P < 0.001).27, 28 Mean pouch duration before cancer 
was 10.8 7.3 years in all cases described in the literature.31
 Patients with a hand-sewn anastomosis with mucosecto-
my carry a higher risk to develop pouch carcinoma compared 
with patients with a stapled anastomosis as shown in a pooled 
meta-analysis (OR, 2.9; 95% CI, 1.3–6.6; Supplementary Figure 
8). However, no statistical difference was reached when com-
paring stapled and hand-sewn anastomosis for pouch neoplasia 
development (OR, 1.7; 95% CI, 1.0–3.1; Supplementary Figure 9). 
 Less conclusive evidence is available regarding the role of 
PSC and pouchitis in pouch neoplasia development. One small 
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study including 22 patients with IPAA found that patients with 
PSC had a higher risk to develop atrophic pouch mucosa.32 Pou-
chitis was associated with atrophic pouch mucosa development 
in 2 other studies.33, 34 These patients with PSC or pouchitis might 
indirectly carry an increased risk to develop pouch neoplasia be-
cause atrophic pouch mucosa is associated with pouch neopla-
sia development.35 By contrast, both PSC and pouchitis were 
not identified as risk factors for pouch neoplasia development in 
the 2 largest IBD cohorts with IPAA (n = 120028 and n = 320327). 
 
Comparison of rectal and pouch neoplasia in the rectal stump, 
ileorectal anastomosis, and ileal pouch-anal anastomosis 
A summary of the prevalence, incidence, and risk factors for each 
group is shown in Figure 3. Pooled prevalences of both rectal car-
cinoma and rectal dysplasia in patients with a residual rectum (rec-
tal stump or IRA) were significantly higher compared with pouch 
carcinoma and pouch dysplasia (IRA and rectal stump carcinoma 
versus pouch carcinoma, OR, 6.4, 95% CI, 4.3–9.5, p < 0.001; IRA 
carcinoma versus pouch carcinoma, OR, 7.1, 95% CI, 4.8–10.7, p 
< 0.001; IRA dysplasia versus pouch dysplasia, OR, 3.3, 95% CI, 
2.1–5.2, p < 0.001; rectal stump carcinoma versus pouch carci-
noma, OR, 4.5, 95% CI, 2.5–7.9, p = 0.049). Prevalence of rectal 
carcinoma in the rectal stump group versus the IRA group did not 
show significant differences (OR, 0.6, 95% CI, 0.4–1.0, p = 0.074). 
Because the duration of follow-up after colectomy might influence 
the prevalence, we compared this between the 3 groups. 
No differences in follow-up duration were observed between the 
rectal stump, IRA, and IPAA groups (p = 0.544). In addition, no 
increasing trend of pooled prevalences over time was observed 
when analyzed per 5-year mean or median duration of follow-up 
(Figure 4).
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Figure 2. (A) Forest plot displaying effect of CRC before colectomy on development of 
rectal carcinoma after IRA.
I2 (inconsistency) = 0%. (B) Forest plot displaying effect of CRC before colectomy on development of IPAA 
carcinoma. I2 (inconsistency) = 7.1%.
A
B
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Discussion
One of the key findings that can be derived from our systematic 
review is a low overall carcinoma prevalence and incidence in IBD 
patients after (reconstructive) colonic surgery. The cancer pre- 
valence appeared to be dependent on the type of surgery and was 
highest in IRA patients (2.4%), followed by patients with a rectal 
stump (2.1%), and lowest in IPAA patients (0.5%). Prior CRC was 
the most important risk factor for developing rectal or pouch carci-
noma (IRA group: OR, 12.8; IPAA group: OR, 15.0). Furthermore, we 
identified IBD duration and a diagnosis of UC as risk factors.
 The calculated prevalences and cumulative incidences of rectal 
and pouch carcinoma need to be placed in perspective. The lifetime 
incidence for developing CRC in the general population approaches 
5%.36 Although the cumulative incidence of rectal carcinoma after 
IRA is based on only 1 study, 5% equals the cumulative rectal car-
cinoma risk 15 years after IRA construction. The pooled cumula-
tive incidence of pouch carcinoma 25 years after IPAA construction 
(3.4%) is below the general lifetime CRC risk. None of the reported 
rectal carcinomas in the IRA group developed within 10 years after 
IBD onset. Pouch carcinomas developed after mean 10.8 years af-
ter IPAA. Furthermore, for proper interpretation of prevalences and 
incidences we should take a declining CRC risk over time into ac-
count because of improved IBD treatment strategies and advanced 
endoscopic procedures. This may have resulted in lower CRC pre- 
valences and incidences for rectal stump, IRA, and IPAA patients 
in recent years. Moreover, prevalences and incidences may even 
be lower because mainly single-center studies rather than popula-
tion-based cohorts were available for analysis.
 A history of colorectal neoplasia before IRA or IPAA surgery 
is the most important risk factor for subsequent development of 
rectal and pouch carcinoma (IRA: OR, 12.8; IPAA: OR, 15.0). This is 
underlined by a shorter pouch duration before cancer diagnosis in 
IPAA patients with prior dysplasia or cancer compared with those 
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Figure 3. Summary chart of prevalence, incidence, and risk factors for colorectal neopla-
sia in the rectal stump, IRA, and IPAA. NA, not available
Figure 4. Pooled prevalences of carcinoma in the rectal stump, IRA, and IPAA groups 
when analyzed per 5-year mean or median duration of follow-up after colectomy. 
without prior pouch neoplasia.31 Furthermore, the majority of the 
carcinomas in the IPAA group arose from therectal mucosa rath-
er than from the ileal pouch mucosa.31 Therefore, it could be spe- 
culated that residual colonic mucosa is the main contributor to an 
increased risk to develop colorectal neoplasia, especially in patients 
with prior colorectal neoplasia.
 As a corollary, one may hypothesize that the total amount of 
colorectal mucosa in situ may correlate with the subsequent risk 
to develop rectal or pouch carcinoma. The significantly lower can-
cer prevalence in the IPAA group compared with the groups with a 
rectum in situ fuels this hypothesis. In line with this, patients with 
a complete colon in situ may bear an even higher risk for colorectal 
neoplasia. This is supported by other authors who showed a lower 
risk of CRC per patient-year in patients after IRA compared with 
patients with an intact colon.12 On the other hand, patients with a 
stapled anastomosis, leaving a few centimeters rectal mucosa in 
situ, were not carrying a higher risk compared with patients with a 
hand-sewn anastomosis with mucosectomy. The presence of resid-
ual colonic mucosal islands that remain even after “complete” mu-
cosectomy might form an explanation for this latter observation.37
 UC patients had approximately 10-fold increase in risk to deve-
lop rectal carcinoma after IRA construction in comparison with CD 
patients. This might suggest an association with the inflammatory 
process, because the rectum is more frequently involved in UC pa-
tients. On the other hand, pouchitis, inflammation of the pouch, 
was not identified as a risk factor. However, pouchitis is variable 
and often poorly defined, making it difficult to assess this potential 
risk factor. 
 Our findings may impact clinical practice because they could 
provide guidance in developing a postsurgical endoscopic surveil-
lance strategy. Similar to the guidelines for CRC screening, direct 
evidence regarding the benefit of colorectal surveillance is not 
available.3, 4 To this end, the identified risk factors may assist in 
recommendations on surveillance. The current British surveillance 
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guidelines distinguish low-risk (no high-risk factors) and high-risk 
groups (PSC, prior colorectal neoplasia, atrophic mucosa) after 
colectomy and recommend surveillance intervals of 5 years and 
1 year, respectively.4 On the basis of our findings, we believe 
that the presence of a residual rectum after surgery is the major 
determinant for cancer development. Furthermore, the cancer risk 
is determined by a history of preoperative colorectal neoplasia, the 
duration of IBD, and a UC rather than a CD diagnosis. All these 
factors should be assessed by the clinician and taken into account 
in a postoperative surveillance strategy. IPAA patients, especially 
those without prior colorectal neoplasia, have a low cancer risk, and 
a very limited surveillance program might be sufficient for these 
patients.
 One of the limitations of this review is that the included studies 
have a high risk of bias, especially those in the rectal stump group. 
Most studies were retrospective single-center studies introducing 
selection and recall bias. Furthermore, neoplasia development was 
often one of the secondary outcomes, and study heterogeneity 
was significant across studies. For example, some studies offered 
routine surveillance after colectomy, whereas other studies only 
performed an endoscopic procedure on indication. In addition, the 
included studies had a highly variable duration of follow-up, and the 
year of publication of the included studies varied between 1956 and 
2014, which may also introduce bias. In older studies, diagnosis of 
IBD, detection of dysplasia and carcinoma, and IBD treatment dif-
fered from current practice. More recent treatment strategies such 
as thiopurines and biologicals may have decreased the burden of 
chronic colonic inflammation and have led to a reduction of can-
cer risk. In addition, advancing endoscopic visualization techniques 
may have further reduced cancer rates over time. Indeed, we ob-
served statistically lower carcinoma prevalence in studies published 
after 1990.
 In conclusion, we found significantly lower carcinoma preva-
lence in the IPAA group (0.5%) compared with the rectal stump 
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group (2.1%) and IRA group (2.4%). A history of CRC was the most 
important risk factor, with 15.0-fold (IPAA) and 12.8-fold (IRA) 
increase in risk. Furthermore, IBD duration and UC rather than a 
diagnosis of CD emerged as risk factors for rectal or pouch neopla-
sia. These findings may aid in developing individualized postsurgical 
endoscopic surveillance strategies to optimize prevention of CRC 
development in IBD patients.
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Supplementary Figure 1. Forest plot displaying pooled carcinoma prevalence in the 
rectal stump of IBD patients.
Supplementary Figure 2. Forest plot displaying pooled carcinoma prevalence for IBD 
patients with IRA.
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Supplementary Figure 3. Forest plot displaying pooled carcinoma prevalence for IBD 
patients with IPAA.
Supplementary Figure 4. Funnel plot analyzing publication bias of prevalence studies regarding 
rectal cancer in IBD patients with a rectal stump. Visual inspection of the funnel plot may indi-
cate that some low prevalence studies are missing. Indeed, asymmetry of the plot is confirmed 
with the Egger test. However, because prevalence cannot extend below “0”, some asymmetry 
of the funnel plot may be expected. In addition, there are no outliers. 
Supplementary Figure 5. Funnel plot analyzing publication bias of prevalence studies regard-
ing rectal cancer in IBD patients with IRA. Visual inspection of the funnel plot does not indicate 
publication bias, although the Egger test showed some asymmetry of the funnel plot. Many low 
prevalence studies are included contradicting publication bias. 
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Supplementary Figure 6. Funnel plot analyzing publication bias of prevalence studies regard-
ing pouch cancer in IBD patients with IPAA. Both visual inspection of the funnel plot and the 
Egger test showed no indication for publication bias. 
Supplementary Figure 7. Forest plot displaying effect of colorectal dysplasia before colecto-
my on development of IPAA neoplasia. I2 (inconsistency) = 0%. 
 
 
 
Supplementary Figure 6. Funnel plot analyzing publication bias of prevalence studies regarding pouch cancer in IBD patients 
with IPAA. Both visual inspection of the funnel plot and the Egger test showed no indication for publication bias.  
 
 
Egger test: bias = –0.14 (95% CI, –0.45 to 0.16); p = 0.346. 
 
 
Supplementary Figure 7. Forest plot displaying effect of colorectal dysplasia before colectomy on development of IPAA 
neoplasia. I2 (inconsistency) = 0%.  
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Supplementary Figure 8. Forest plot displaying effect of type of anastomosis on development 
of IPAA carcinoma. I2 (inconsistency) = 0.1%.
Supplementary Figure 9. Forest plot displaying effect of type of anastomosis on development 
of IPAA neoplasia. I2 (inconsistency) = 0%.
190 3.4 191Solid malignancies in inflammatory bowel diseases
Supplementary Table 1. Full search strategy that was used to identify studies for inclusion. Supplementary Table 2. Overview of included articles that assessed prevalence of carcinoma in 
rectal stump after colectomy in IBD patients.
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MeSH terms (inflammatory bowel diseases OR colitis, ulcerative 
OR Crohn disease) AND (anastomosis, surgical OR 
colectomy OR proctocolectomy, restorative OR co-
lonic Pouches OR ileostomy) AND (colorectal neo-
plasms OR rectal neoplasms OR colonic neoplasms 
OR  anus neoplasms)
Emtree terms (inflammatory bowel disease (exploded) OR ul-
cerative colitis OR Crohn disease OR colon Crohn 
disease) AND (colon resection (exploded) OR proc-
tocolectomy (exploded) OR ileum pouch OR ileosto-
my OR continent ileostomy) AND (colorectal tumor 
(exploded) OR anus tumor (exploded))
Title/abstract 
words
(inflammatory bowel OR IBD OR ulcerative colitis 
OR colitis ulcerosa OR indeterminate colitis OR 
Crohn* OR idiopathic proctocolitis OR regional 
Enteritis OR granulomatous enteritis OR granulo-
matous colitis OR ileocolitis OR terminal ileitis OR 
regional ileiti*) AND (colectom* OR ileostom* OR 
restorative proctocolectom* OR pouch* OR IPAA 
OR ileoana* OR ileo-ana* OR ileal stoma* OR ileo-
rect* OR ileo-rect* OR ileosigmoid OR ileo-sigmoid 
OR IRA OR rectoileal ) AND (neoplas* OR dyspla-
sia* OR tumor* OR tumour* OR carcinoma* OR 
cancer* OR malignanc* OR adenocarcinoma)
 
PubMed, Web of Science, and Cochrane search strategies were based on MeSH terms and title/abstract words. 
Emtree terms combined with title/ abstracts words were used for the Embase search. 
MeSH, Medical Subject Headings.
192 3.4 193Solid malignancies in inflammatory bowel diseases
Supplementary Table 3. Overview of included articles that assessed prevalence of carcinoma 
in the rectum after subtotal colectomy with IRA in IBD patients.
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Supplementary Table 4. Overview of included articles that assessed prevalence of pouch 
carcinoma after restorative proctocolectomy with IPAA in IBD patients.
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Supplementary Table 5. Quality assessment table for included studies in group with ileosto-
my and rectal stump.
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Supplementary Table 7. Quality assessment table for included studies in IPAA group.
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204 Chapter 3
General discussion 
Both life expectancy and inflammatory bowel disease (IBD) preva-
lence show an increasing trend in recent decades. Consequently, a 
growing number of IBD patients will develop and may be cured of 
cancer, resulting in new clinical challenges and questions concer- 
ning IBD management. Balancing the effects and risks of IBD treat-
ment versus optimal cancer treatment is very important in order 
to achieve the best IBD and cancer outcomes for every individual 
patient. Therefore it is of crucial importance to establish the impact 
of IBD and immunosuppression on the development, clinical course 
and recurrence of malignancies. At this time, data on this topic are 
very limited and treatment decisions are made on expert opinion 
rather than evidence-based, resulting in a case-by-case approach.
This thesis consists of two parts. Chapter 2 focuses on lymphopro-
liferations and aims to correlate histopathological assessment and 
clonality analyses with clinical outcomes. Chapter 3 includes solid 
malignancies. The objective was to identify IBD-specific risk fac-
tors for specific malignancies in IBD, and to compare the clinical 
course of these malignancies in IBD with the general population. 
This general discussion addresses these two parts combined with 
a focus on interpretation of results, future perspectives, as well as 
identification of knowledge gaps that are possible topics for further 
research. 
In Table 1 an overview of the aims, main findings and conclusions of 
this thesis are presented.
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Table 1: Aims, main findings and conclusions (part 1)
2
: 
L
ym
p
h
o
p
ro
lif
er
at
io
n
s
3
: 
S
o
lid
 M
al
ig
n
an
ci
es
Aim(s) 
 
 
• Assess utility of histological aberrations in  
 predicting EBV presence 
• Correlate histological assessment and EBV load  
 with clinical outcomes 
 
 
 
 
 
 
• Correlate IG clonality to clinical outcomes for 
 risk stratification in PTLD and IBD-related  
 lymphoproliferations 
 
 
 
 
 
 
• Explore risk factors for GC development in IBD 
• Compare histological features and clinical  
 course of GC in IBD to general population 
 
 
 
 
 
• Identify IBD-specific risk factors for melanoma  
 development 
• Compare clinical course of melanoma in IBD to  
 general population
 
 
 
 
 
 
Main findings and conclusions 
 
 
• Atypical infiltrate more frequent in EBV+  
 patients: warrants EBV testing 
• High EBV load more frequent in EBV+  
 patients undergoing colectomy 
• IMS reduction effective in decreasing  
 and loss of mucosal EBV 
• Prognosis lymphoproliferation in IBD   
 seems better than in PTLD 
 
 
• IG-clonality might be useful in risk  
 stratification in PTLD 
• In IBD low disease stage is more  
 predictive of survival, regardless of  
 clonality 
• IMS reduction effective treatment of IBD  
 lymphoproliferations 
 
 
• Elderly onset IBD is risk factor for GC  
 development in IBD 
• GC survival is reduced in IBD patients 
• IMS did not impact GC survival 
• Hp prevalence 25 % in IBD GC, EBV+ in  
 4.2 % of IBD GC 
 
 
• IBD extent is risk factor for melanoma  
 development in IBD 
• No impaired survival after melanoma in  
 IBD, independent of IMS use
 
 
 
 
 
 
Comments 
 
 
• Selection bias: EBV  
 testing on clinical or  
 histological grounds 
• Single tertiary centre 
• What is the influence of IBD  
 activity? 
• WHO PTLD classification   
 applicable for IBD 
 
 
• Retrospective 
• Limited sample size 
 
 
 
 
 
 
 
• IMS duration and timing 
 related to GC important to  
 asses IMS influence 
• Three different databases 
• Propensity bias? 
 
 
 
• No information about skin   
 type, sun burns and mitotic  
 index 
• Propensity bias? 
• IMS duration and timing    
 related to melanoma  
 important to asses IMS  
 influence 
• Retrospective: under- 
 reporting of IMS use? 
 
Chapter 
 
 
2.1 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 
 
 
 
 
 
3.1 
 
 
 
 
 
 
 
3.2 
Part 
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Table 1: Aims, main findings and conclusions (part 2)
3
: 
S
o
lid
 M
al
ig
n
an
ci
es
Aim(s) 
 
 
• Identify risk factors for development of OCC  
 and PC in IBD 
• Compare clinical course of OCC and PC in IBD  
 to general population 
• Assess influence of IMS on clinical course of  
 OCC and PC in IBD
 
 
 
 
 
• Determine prevalence, incidence and risk  
 factors regarding CRC following colectomy in  
 3 groups of IBD patients (permanent ileostomy  
 and rectal stump;  IRA and IPAA)
Main findings and conclusions 
 
 
• Higher age at IBD diagnosis risk factor for  
 OCC and PC development (PC in UC) 
• Proximal CD localization risk factor for  
 OCC development 
• Impaired OCC survival in IBD compared to  
 general population 
• Majority of IBD associated oropharyngeal  
 cancers are HPV positive 
• IMS did not impact OCC and PC survival
 
 
• Prevalence and incidence of CRC after  
 colectomy <  3% 
• Prevalence and incidence of CRC after  
 IPAA < 1% 
• History of CRC most important risk factor  
 for CRC development after colectomy 
• IBD duration and a diagnosis of UC other  
 risk factors
Comments 
 
 
• HPV prevalence PC in line   
 with general population 
• HPV related to timing and   
 duration of IMS? 
• Data influenced by wide   
 variations in commencement  
 of IMS after cancer  
 diagnosis? 
• Awareness instead of regular  
 oral screening
 
• Pouchitis and PSC emerged  
 not as risk factors 
• Post-colectomy screening   
 only in high risk patients? 
• Included studies had highly  
 variable follow-up duration   
 and publication year, many   
 single centre studies
Chapter 
 
 
3.3 
3.4
Part 
 
EBV: Epstein-Barr virus; IBD: inflammatory bowel diseases; IMS: immunosuppression (including steroids, 
thiopurines, metothrexate and anti-TNF alpha); WHO: World Health Organization; Ig: immunoglobulin; PTLD: 
post-transplantation lymphoproliferative disorder; GC: gastric cancer; OCC: oral cavity cancer; PC: pharyngeal 
carcinoma; UC: ulcerative colitis; CD: Crohn’s disease; HPV: human papilloma virus; CRC: colorectal carcinoma; 
IRA: ileorectal anastomosis; IPAA: Ileal pouch-anal anastomosis; PSC: primary sclerosing cholangitis. 
Lymphoproliferations
 
Results
We studied a cohort of 58 IBD patients who were evaluated for colonic 
Epstein-Barr virus (EBV) presence, through histopathological 
testing. The World Health Organization post-transplant lympho- 
proliferative disorders (PTLD) classification1 was used to classify 
IBD-related lymphoproliferations. An atypical inflammatory infiltrate 
and presence of atypical B-lymphocytes were significantly more 
common in EBV positive colonic mucosa. Monomorphic lesions 
contained a higher EBV load and these patients needed surgery 
more often. Reduction of immunosuppression was an effective 
strategy to achieve morphological normalization and loss of EBV 
(chapter 2.1). 
 This cohort was also part of a multicentre cohort study in 
which we studied Immunoglobulin (Ig) clonality assessment in IBD 
patients with EBV positive lymphoproliferations (chapter 2.2). 
In IBD patients, Ig clonality analyses were not useful for clinical 
course risk stratification, and low disease stage of the lymphopro-
liferation was more predictive of survival. There was no mortality 
in this cohort with IBD-related lymphoproliferations. 
Implications
Based on our study, histopathological assessment can guide EBV 
diagnostics as well as classification of IBD-related lymphopro- 
liferations. An atypical inflammatory infiltrate and/or presence of 
atypical B-lymphocytes warrants EBV testing. At this moment, the 
body of evidence to guide treatment decisions is limited at best 
and patients are treated on a case-by-case base. Our classification 
provides objective criteria for lymphoproliferations in IBD, enabling 
more standardized research and treatment evaluation. Especially 
for patients with monomorphic lesions (atypical inflammatory 
infiltrate and presence of atypical B-lymphocytes) at the very least 
immunosuppressive therapy should be reduced in order to prevent 
lymphoma development.
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Mortality in IBD-related lymphoproliferations is low in contrast 
to PTLD, and this is reassuring for daily practice. Reduction of 
immunosuppression for lower stages of lymphoproliferations is 
an appropriate treatment and should be considered by treating 
physicians. 
Strengths and limitations
This is the first study that described the lymphoproliferative 
spectrum in IBD providing a solid basis for further research. Several 
limitations should be taken into account. Firstly, we mainly 
studied a small, single tertiary centre population, and confirma-
tion in a general IBD population is needed. The study is limited by a 
selection bias, as EBV testing was performed on clinical and 
histological grounds and retrospectively studied. Nevertheless, 
our conclusions withstood repeated statistical testing after expan-
sion of our selection without clinical or histological grounds in the 
same population. Finally, all biopsies were reviewed by an expert 
gastrointestinal pathologist who also has extensive experience in 
lymphoproliferations. We did not study interobserver agreement 
and do not know to what extent the results are reproducible with 
reviews by a less dedicated pathologist.
Future perspectives
EBV-positive cells can be found in the inflamed colonic mucosa 
of the majority of IBD patients. At this time we are unable to 
distinguish inflammation-driven EBV presence that will resolve 
upon anti-inflammatory treatment and the EBV presence that will 
cause lymphoproliferations. Nor do we know if and where there is a 
turning point in ‘physiologic’ EBV presence in inflamed mucosa and 
the origin of lymphoproliferations. Further research is needed to 
answer these questions. 
 In PTLD preventive treatment strategies exist to prevent 
lymphoma development. In IBD there are none. There are even 
suggestions that pre-emptive treatment with Rituximab has a 
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negative influence on the IBD course. We need further research 
to identify markers of IBD-related lymphoproliferations and 
criteria that help in clinical risk stratification and decision making.
 Finally, prospective research in a larger cohort with an interob-
server agreement study is needed to confirm our results. 
 
Solid malignancies
 
Studies guiding the management of IBD after a specific cancer are 
very scarce. Due to this paucity of data, a case-by-case approach 
is advocated2, 3. We performed studies focusing on cancer-specific 
clinical course, consisting of case-control studies on gastric can-
cer (chapter 3.1), melanoma (chapter 3.2), oral cavity cancer and 
pharyngeal cancer (chapter 3.3) and of a systematic review on 
neoplasia in IBD patients following subtotal colectomy (chapter 3.4) . 
 
Case control studies
Results
Gastric cancer (chapter 3.1)
We studied 63 IBD patients who developed gastric cancer (GC) and 
found impaired survival for IBD patients. No differences in survival 
related to immunosuppression use were observed. Elderly onset 
IBD emerged as a risk factor for GC development. Finally, histo-
pathological assessment showed no increased incidence of EBV 
and Helicobacter pylori (Hp) positive GC in IBD. 
Melanoma (chapter 3.2)
We included 304 IBD patients who developed melanoma and found 
that melanoma survival in IBD patients is similar compared to the 
general population. The use of immunosuppressive therapy did not 
impair survival following melanoma. A more extensive IBD (pancoli-
tis in UC; ileal and colonic involvement in CD) is a risk factor for 
melanoma  development in IBD patients. 
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Oral cavity and pharyngeal cancer (chapter 3.3)
We evaluated 66 patients with oral cavity cancer (OCC) and 31 
with pharyngeal cancer (PC). Survival analyses showed that the 
overall survival in OCC is impaired and in PC similar compared to 
the general population. Use of immunosuppressive medication did 
not affect survival after cancer diagnosis. For both OCC and PC 
development in IBD elderly onset IBD was a risk factor. For OCC, 
proximal disease activity was also a risk factor. Histopathological 
assessment showed human papillomavirus (HPV) presence in 52 % 
of the oropharyngeal cancers in IBD patients, comparable with the 
general population.
Implications
Our nationwide studies contribute to the knowledge about the 
clinical course of malignancies in IBD. As a corollary they may aid in 
guiding IBD management after a specific cancer diagnosis.
  In line with multiple recent publications4, 5 we found no evidence 
for a negative influence of immunosuppressive therapy on the can-
cer course. Therefore our data may suggest that immunosuppres-
sive therapy can still be used after GC, melanoma, OCC and PC 
diagnosis. Furthermore, survival of melanoma and PC in IBD is not 
impaired. Although these data may be reassuring in daily practice, 
they have to be interpreted with great caution for a number of rea-
sons. The first is the possible presence of selection bias. Solid data 
in transplant medicine have shown that immunosuppressive therapy 
can negatively influence the clinical course and recurrence of malig-
nancies. IBD clinicians may be aware of these risks and do not pre-
scribe immunosuppressive drugs to IBD patients with a malignancy 
with high risk of recurrence, positively influencing the outcomes of 
the retrospective studies. Secondly, the moment of starting immu-
nosuppressive therapy after cancer diagnosis varied widely. As the 
influence of immunosuppression is greatest in the two years after 
cancer diagnosis6, this may have influenced our data. Thirdly, not 
all IBD patients use immunosuppressive therapy and the number of 
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patients who actually used it after cancer diagnosis in our studies 
was limited. Fourthly, the number of studied patients with a diag-
nosis of cancer and using immunosuppressive therapy is too small 
to draw robust conclusions regarding the risk of cancer recurrence. 
Therefore, we still advocate the case-by-case approach for IBD 
patients with a malignancy: balancing the effects and risks of IBD 
treatment with optimal cancer treatment to achieve the best IBD 
and cancer outcomes.
 Elderly onset IBD emerged in our GC, OCC and PC studies as 
a risk factor for malignancy development. Although the explanation 
is not elucidated yet, it may be related to the aging of the immune 
system: aging-related reduced immunosurveillance might increase 
the risk for malignancy development7. With the growing aging 
population it is important that clinicians are especially aware of 
cancer development in elderly onset IBD patients. 
Strengths and limitations
These cancer specific studies are the largest series on the clinical 
course of specific malignancies in IBD. The comparable retrospec-
tive design of our case-control studies explains the corresponding 
limitations. Due to the retrospective character of the studies, it was 
not possible to assess the exact dose, duration and time between 
cancer diagnoses and (re)start of (immunosuppressive) thera-
py. Therefore it was impossible to draw firm conclusions on this 
subject. We considered linking our patients with the Dutch 
pharmacology database, but this database was only available for a 
small part of the Netherlands. 
 In our studies we used three different databases: the Dutch 
pathology database PALGA8, the Eindhoven Cancer Registry and 
the IBD South Limburg cohort9. This may have caused biases as the 
design and definitions between the three databases varied. Unfor-
tunately, we could not answer our research questions using a single 
database.
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At the start of this PhD trajectory we also planned to calculate the 
relative risk (RR) for IBD patients to develop a specific tumor. De-
spite our efforts, it remained difficult to determine the extent of the 
Dutch IBD population: at present and in the past.
Future perspectives
To determine the risk of developing a specific cancer in IBD pa-
tients and to establish the effects of immunosuppressive therapy 
on the risk and the clinical course of that specific cancer, large pro-
spective databases are needed. As malignancies in IBD are relative-
ly rare, there are large databases needed which include sufficient 
cases with a specific malignancy to draw conclusions that can guide 
clinical decision-making. In these databases the timing, dose, dura-
tion and time between cancer diagnoses and start of (immunosup-
pressive) therapy should be accurately registered. Furthermore, 
the effect of the cancer treatment on the IBD activity should be 
observed to assess the influence of cancer therapy on IBD. With 
these data we can achieve optimal IBD and cancer management.
 
Systematic review (chapter 3.4)
Results
The colorectal cancer (CRC)  prevalence for patients with a 
rectal stump was 2.1% (95% confidence interval (CI) 1.3%-3.0%), 
2.4 % for patients with an ileorectal anastomosis (95% CI 1.7%-
3.0%) and 0.5% for patients with an ileal pouch – anal anastomosis 
(IPAA; 95% CI 0.3%-0.6%). In all three groups, the most important 
risk factor for developing CRC post colectomy was a prior CRC. 
Other risk factors were IBD duration and ulcerative colitis rather 
than Crohn’s disease. Pouchitis and primary sclerosing cholangitis 
did not emerge as risk factors. 
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Implications
Surveillance guidelines for IBD patients after subtotal colectomy 
are lacking. This may result in ineffective screening in these 
patients with intervals that are either too long or too short. Our 
data suggest that high-risk patients, with a history of CRC, should 
be screened more frequently after subtotal colectomy. In contrast, 
in the absence of risk factors, surveillance interval may be reduced 
to 5 years. Furthermore, as UC is another risk factor, surveillance 
intervals may be different for UC and CD. Finally, IPAA patients 
without a CRC history may no longer need endoscopic surveillance.
Strengths and limitations
As malignancies in IBD are relatively rare, large cohorts are needed 
to yield enough power to detect differences and risk factors. To 
increase statistical power, this review and meta-analysis was 
performed with pooled data from several cohorts. Nevertheless, this 
also introduced bias because the included studies had highly variable 
follow-up duration and year of publication. As the publication 
 year varied by more than 50 years, treatment options, treatment 
guidelines, surveillance strategies and endoscopic techniques were 
very different between studies. Furthermore, many of the included 
studies were single centre studies.
Future perspectives
To assess the benefit of surveillance following subtotal colectomy, 
we need large prospective studies with long-term follow-up, to 
standardize our policies, and to follow widely accepted guidelines. 
To further optimize this surveillance, we need more knowledge 
about the pathophysiology of progression of low grade dysplasia to 
high grade dysplasia and factors influencing this process. This can 
aid in optimizing surveillance strategies. 
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Conclusions
 
Cancer development is one of the most serious complications in 
IBD. A growing number of IBD patients will develop and may be 
cured of cancer, providing new clinical challenges and questions. In 
this thesis we correlated histopathological assessment with clinical 
outcomes in IBD. Furthermore, we assessed IBD-specific risk fac-
tors and clinical outcomes for solid malignancies and determined 
cancer risks after colectomy.
 We found that histopathological assessment can guide EBV 
diagnostics and that IMS reduction is an effective treatment for 
IBD-related lymphoproliferations. Survival is reduced in IBD for GC 
and OCC, but not for melanoma and PC. In our studies, immuno-
suppression (including anti-TNF alpha) did not influence survival in 
solid malignancies. A prior CRC is the most important risk factor for 
developing a post-colectomy CRC.
  As data on malignancies in IBD are limited, these findings may 
guide clinical decision making for patients with the studied malig-
nancies. As our studies are retrospective, prospectively collected 
data are needed to further optimize IBD and cancer management.
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Summary
 
Inflammatory bowel diseases (IBD) include Crohn’s disease (CD) 
and ulcerative colitis (UC) and are characterized by chronic re-
current intestinal inflammation. The medical treatment of IBD 
aims to induce and maintain prolonged remission and to prevent 
complications. One of the most serious complications of IBD is 
cancer development. Continuous chronic intestinal inflammation 
increases the risk of intestinal malignancies, such as colorectal can-
cer (CRC). Moreover, the risk of extra-intestinal malignancies is 
increased by the use of immunosuppressive medication.  
Both life expectancy and IBD prevalence are increasing.  Conse-
quently, a growing number of IBD patients will develop cancer, 
resulting in new clinical challenges and questions concerning IBD 
management. Balancing the effects and risks of IBD treatment 
versus optimal cancer treatment is very important in order to 
achieve the best IBD and cancer outcomes. Therefore, it is very 
important to establish the impact of IBD and immunsuppression 
on the development, clinical course and recurrence of malignan-
cies. Currently, data on this topic are limited and treatment deci-
sions are expert based rather than evidence-based, resulting in a 
case-by-case approach. 
This thesis covers mainly two subjects. Chapter 2 focuses on 
lymphoproliferations and aims to assess the utility of intestinal 
histologic features in predicting EBV presence and to correlate 
histopathological assessment with clinical outcomes in IBD pa-
tients. Chapter 3 includes studies on solid malignancies and aims 
to identify IBD-specific risk factors for particular malignancies 
and to compare the clinical characteristics of these malignancies 
in IBD patients to unselected non-IBD patients. This includes also 
the influence of immunosuppressive therapy on clinical charac-
teristics. 
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Lymphoproliferations 
Post-transplant lymphoproliferative disorders (PTLD) are proli-
ferations of B-cells that develop as a consequence of immunosup-
pression use in transplant patients and are frequently associated 
with the Epstein-Barr virus (EBV). PTLDs are classified according 
the histological World Health Organization (WHO) PTLD classi-
fication. Lymphoproliferative disorders in IBD are histologically 
comparable to PTLD and are also predominantly EBV associated. 
Immunosuppressive IBD medication causes decreased immuno-
surveillance of EBV and facilitates reactivation of this oncogenic 
virus with subsequently (intestinal) lymphoproliferation 
development. 
Chapter 2.1 aimed to assess whether histological aberrations 
aid in predicting intestinal EBV. We retrospectively included 58 
IBD patients from our tertiary hospital with prior EBV testing on 
their intestinal biopsies. An atypical inflammatory infiltrate was 
more frequent in EBV-positive than in EBV-negative patients (57.1 
versus 3.3%; p < 0.001). This implicates that the presence of an 
atypical infiltrate in the intestinal mucosa of IBD patients war-
rants EBV testing. Reduction of immunosuppression is an effec-
tive strategy to achieve morphological normalization and loss of 
EBV. Furthermore, the histological EBV load was correlated with 
clinical outcomes. EBV-positive patients undergoing colectomy 
had more frequent a high EBV load compared to EBV-positive pa-
tients without colectomy. We also studied the use of the WHO 
PTLD classification in IBD related lymphoproliferations. This 
classification is suitable for IBD associated lymphoproliferations, 
enabling more standardized research and treatment evaluation. 
 Immunoglobulins (Ig) are antibodies produced by B-cells and 
are used by the immune system to neutralize pathogens such as 
pathogenic viruses. The aim of chapter 2.2 was to correlate Ig 
clonality with clinical outcomes of lymphoproliferations in both 
PTLD and IBD. This may lead to pre-treatment risk stratification 
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to guide therapeutic decisions. We found no clear difference in 
clonality pattern in monomorphic subtype PTLDs versus the re-
active/polymorphic PTLDs. A statistical analysis was performed 
to identify pre-treatment risk factors for poor outcome (mortali-
ty). In PTLD, Ig-clonality might be useful for risk stratification. In 
IBD lower disease stage is more predictive of survival. 
 Both chapter 2.1 and 2.2 indicate that IBD related lympho- 
proliferations appear to have less aggressive clinical behaviour 
than PTLDs, what is reassuring for daily IBD practice. Reduction 
of immunosuppression is an appropriate treatment, especially for 
lower stages of lymphoproliferations, and should be considered 
by treating physicians.
 Chapter 2.3 presents a case-report with a CD patient who 
developed a hepatosplenic T-cell lymphoma (HSTCL). HSTCL is 
a rare, not EBV related non-Hodgkin lymphoma with a high mortality 
rate. Higher incidence is reported in IBD patients, specifically 
in male patients younger than 35 years, treated with thiopurine 
and anti-TNF alpha combination therapy for over 2 years. This 
case is unusual as the presented patient is 47 years old and 
developed HSTCL after 14 years thiopurine monotherapy. This 
emphasizes that HSTCL risk is not limited to young men receiving 
combination therapy.
 
Solid malignancies
Studies guiding IBD management after a specific cancer are 
scarce and a case-by-case approach is advocated. In the second 
part of this thesis, specific malignancies in IBD are studied, aiming: 
  I: to assess IBD specific risk factors for cancer development 
(chapter 3.1 - 3.4). 
  II: to compare clinical characteristics and survival be-
tween IBD cases with a specific malignancy versus non-IBD 
controls with the same malignancy (chapter 3.1, 3.2 and 3.3).
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IBD patients with a specific malignancy (IBD cases) were iden-
tified using PALGA, the Dutch pathology database. This registry 
contains pathology reports generated in the Netherlands since 
1971 and has complete national coverage since 1991 encompassing 
all pathology laboratories from all hospitals in the Netherlands.
 For the first (I) aim we compared IBD cases with a specific 
malignancy to random IBD controls, derived from the population 
based IBD South Limburg (IBDSL) cohort. South Limburg is an 
enclosed geographic area in the southeast of The Netherlands 
with 605,000 inhabitants and three hospitals. The total number 
of IBD patients in this registry is 2807 IBD patients representing 
93% of the regional IBD population.
 For the second (II) aim, controls were derived from the 
Eindhoven Cancer Registry (ECR; maintained by the Nether-
lands Comprehensive Cancer Organization). Since 1989, the ECR 
prospectively registers all newly diagnosed cancers in the regions 
“Noord-Brabant” and “Noord-Limburg”, encompassing over 95% 
of all cancers in this region.
Two factors are important in the development of malignancies in 
IBD: local inflammation and immunosuppression use (causing re-
duced immunosurveillance). In the malignancies we studied, we 
hypothesized that at least one of these factors might be involved. 
Local inflammation may be important for gastric cancer (GC) and 
oral cavity cancer (OCC) development (beside colorectal can-
cer). Both EBV and H. pylori are pathogens that increase the GC 
risk and their activity may be influenced by immunosuppression. 
In addition to EBV, human papillomavirus (HPV) is also import-
ant in (oro)pharyngeal cancer development. Finally melanoma 
was studied, as anti-TNF therapy increases the risk for melanoma 
development. 
 In chapter 3.1 63 IBD patients with GC were included. Elderly 
onset IBD emerged as a risk factor for GC development and sur-
vival in IBD patients was impaired. Histopathological assessment 
showed no increased incidence of EBV and Helicobacter pylori 
(Hp) positive GC in IBD.
 In chapter 3.2 we included 304 IBD patients with cutaneous 
melanoma. A more extensive IBD (pancolitis in UC; ileal and co-
lonic involvement in CD) is a risk factor for melanoma develop-
ment in IBD patients. Melanoma survival in IBD patients is simi-
lar compared to the general population.
 In chapter 3.3 we studied two head and neck cancer locali- 
zations: OCC and pharyngeal cancer (PC). 66 IBD patients with 
OCC were included, showing that the overall survival of OCC 
in IBD is impaired. 31 IBD patients with PC were included, with 
similar survival compared to the general population. 
 For both OCC and PC development in IBD elderly onset IBD 
was a risk factor. For OCC, proximal disease activity was also a 
risk factor. 
 Histopathological assessment of (O)PC showed HPV 
presence in 52 % of the oropharyngeal cancers in IBD patients, 
comparable with the general population. 
 In chapter 3.1, 3.2 and 3.3 we also studied the influence of 
immunosuppressive therapy on survival. We observed no diffe- 
rences in survival related to immunosuppression use after cancer 
diagnosis. Although these data may be reassuring in daily prac-
tice, they have to be interpreted with great caution for a number 
of reasons. First, selection bias may have occurred since clinicians 
may have prescribed immunosuppressive medication to patients 
with a favourable risk profile. Second, the moment of starting im-
munosuppressive therapy after cancer diagnosis varied widely. As 
the influence of immunosuppression is greatest in the two years 
after cancer diagnosis, this may impact our findings. Third, the 
number of IBD patients using immunosuppressive therapy after 
cancer diagnosis was limited. 
 Chapter 3.4 includes a systematic review and meta-analy-
sis to determine risk factors and assess CRC risk in IBD patients 
following subtotal colectomy. We studied three groups: patients 
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with a rectal stump, patients with an ileorectal anastomosis 
(IRA) and patients with an ileal pouch–anal anastomosis (IPAA). 
We calculated CRC prevalences based on 13 studies about CRC 
development in the rectal stump, 35 IRA studies and 33 IPAA 
studies. 
 The CRC prevalence was 2.1% in patients with rectal stump, 
2.4 % in IRA patients and lowest in IPAA patients (0.5 %). Pri-
or CRC was the most important risk factor for developing CRC 
following subtotal colectomy (IRA group: odds ratio 12.8; IPAA 
group: odds ratio 15.0). Furthermore, IBD duration and a diagno-
sis of UC rather than CD were identified as risk factors. Pouchitis 
and primary sclerosing cholangitis did not emerge as risk factors. 
These data may help in developing endoscopic surveillance 
recommendations for IBD patients after subtotal colectomy. 
In conclusion, in this thesis we correlated histopathological 
assessment with clinical outcomes in IBD. We found that his-
topathological assessment can guide EBV diagnostics and that 
immunosupression reduction is an effective treatment for IBD- 
related lymphoproliferations. Furthermore, we assessed IBD- 
specific risk factors and clinical outcomes for solid malignancies 
and determined cancer risks after colectomy. Survival is 
reduced in IBD for GC and OCC, but not for melanoma and PC. 
In our studies, immunosuppression did not influence survival in 
solid malignancies. As data on malignancies in IBD are limited, 
these findings may guide clinical decision making for patients 
with the studied malignancies. As our studies are retrospective, 
prospectively collected data are needed to further optimize IBD 
and cancer management.
Maligniteiten bij inflammatoire darmziekten
 
 
Inflammatoire darmziekten (IBD) bestaan grotendeels uit de 
ziekte van Crohn (ZvC) en colitis ulcerosa (CU) en zijn chroni-
sche, recidiverende onstekingsziekten van het maag-darmstelsel. 
De medische behandeling van IBD heeft als doel om de ziekte 
in remissie te brengen en te houden en complicaties te voorko-
men. Een van de ernstigste IBD complicaties is de ontwikkeling 
van maligniteiten. Aanhoudende chronische inflammatie van 
de darm verhoogt het risico op intestinale maligniteiten, zoals 
colorectaal carcinoom (CRC). Om de chronische ontsteking te 
onderdrukken, worden IBD patiënten regelmatig behandeld met 
immunosuppressieve medicatie. Deze medicatie verhoogt het 
risico op extra-intestinale maligniteiten.
 Omdat de levensverwachting van mensen toeneemt en het 
aantal IBD patiënten stijgt, zullen steeds meer IBD patiënten een 
maligniteit ontwikkelen. Dit resulteert in nieuwe klinische vragen 
en uitdagingen in de behandeling van IBD. Het afwegen van de 
effecten en risico’s van de IBD behandeling ten opzichte van het 
geven van de optimale kanker behandeling is zeer belangrijk om 
de beste IBD- en maligniteit gerelateerde uitkomsten te behalen. 
Om goede afwegingen te kunnen maken, is het belangrijk om de 
invloed vast te stellen van IBD en van de IBD behandeling op de 
ontwikkeling en het klinisch beloop van maligniteiten. 
 Op dit moment zijn er slechts zeer beperkte data beschikbaar 
over dit onderwerp en behandel beslissingen worden genomen op 
basis van ‘expert opinion’ in plaats van ‘evidence based medicine’.
 Dit proefschrift bestaat uit twee delen. Hoofdstuk 2 bevat 
studies over lymfoproliferaties in IBD met als doel de waarde van 
histologische kenmerken te bepalen voor het voorspellen van 
de aanwezigheid van EBV en om de histologische boordeling te 
correleren met klinische uitkomsten bij IBD patiënten. Hoofd-
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stuk 3 bevat studies over solide maligniteiten. Het doel is om 
IBD specifieke risicofactoren te identificeren voor bepaalde 
maligniteiten, om het klinische beloop van maligniteiten bij IBD te 
vergelijken met het beloop bij niet-IBD patiënten. Hierin bestu-
deren we ook de invloed van immunosuppressieve therapie op de 
klinische karakteristieken. 
Lymfoproliferaties
Post-transplantatie lymfoproliveratieve aandoeningen (PTLD) 
zijn proliferaties van B-cellen, die zich ontwikkelen als het 
gevolg van het gebruik van immuunsuppressieve medicatie bij 
transplantatie patiënten. Ze  zijn vaak Epstein-Barr virus (EBV) 
geassocieerd. PTLDs worden geclassificeerd volgens de histo- 
logische World Health Organization (WHO) PTLD classificatie. 
IBD gerelateerde lymfoproliferaties zijn histologisch vergeli-
jkbaar met PTLD en ook voornamelijk geassocieerd met EBV. 
Immunosuppressieve medicatie vermindert de immunosurveil-
lance van EBV waardoor er reactivatie van dit oncogene virus 
kan ontstaan. Dit kan vervolgens leiden tot de ontwikkeling van 
(intestinale) lymfoproliferaties. 
 Hoofdstuk 2.1 heeft als doel het beoordelen of histologische 
afwijkingen kunnen helpen bij het voorspellen van intestinale 
EBV aanwezigheid. Hiervoor includeerden we retrospectief 58 
IBD patiënten uit ons tertiaire ziekenhuis, waarbij reeds eer-
der EBV diagnostiek verricht was op intestinale biopten. Een 
atypisch ontstekingsinfiltraat kwam frequenter voor bij EBV-posi-
tieve patiënten dan bij EBV-negatieve patiënten (57.1 versus 3.3%; 
p < 0.001). Dit impliceert dat de aanwezigheid van een atypisch 
ontstekingsinfiltraat in de intestinale mucosa van IBD patiënten 
EBV diagnostiek rechtvaardigt. Het reduceren van immuunsup-
pressieve medicatie is effectief om morfologisch herstel en verlies 
van EBV aanwezigheid te bereiken 
Tevens werd de histologische EBV concentratie gecorreleerd met 
klinische uitkomsten. EBV-positieve patiënten die een colectomie 
ondergingen, hadden vaker een hoge EBV concentratie in vergelij-
king met patiënten die geen colectomie ondergingen. 
Ook bestudeerden we of het gebruik van de door de wereld- 
gezondheidsorganisatie (WHO) vastgestelde PTLD classificatie 
ook geschikt was voor gebruik bij IBD gerelateerde lymfoprolifera-
ties. Het gebruik van de WHO PTLD classificatie is geschikt om te 
gebruiken bij IBD gerelateerde lymfoproliferaties. Hierdoor kan 
er meer gestandaardiseerd onderzoek en behandeling verricht 
worden. 
 Immuunglobulines (Ig) zijn antilichamen die door de B-cel 
geproduceerd worden en gebruikt worden in het immuunsys-
teem om pathogenen (zoals EBV) te neutraliseren. Het doel van 
hoofdstuk 2.2 was het correleren van immuunglobuline (Ig) 
clonaliteit met klinische uitkomsten, ten behoeve van risico 
stratificatie, zowel bij IBD als PTLD gerelateerde lymfopro- 
liferaties. Dit kan mogelijk helpen bij pre-treatment risicostrati-
ficatie en bij het nemen van behandel beslissingen. We vonden 
geen verschil in clonaliteitspatroon tussen monomorfe en reac-
tieve of polymorfe PTLDs. Een statistische analyse werd verricht 
om risicofactoren voor slechter uitkomst (mortaliteit) te bepalen. 
Bij PTLD patiënten kan het bepalen van Ig-clonaliteit nuttig zijn 
ter risico stratificatie, maar niet voor IBD. Bij IBD was voorname-
lijk een lager ziekte stadium voorspellend voor overleving. 
 Zowel hoofdstuk 2.1 en 2.2 laten zien dat IBD gerelateerde 
lymfoproliferaties een minder agressief klinisch beloop lijken te 
hebben dan PTLD. Dit is geruststellend voor de dagelijkse IBD 
praktijk. Het reduceren van immuunsuppressie is een geschikte 
behandeling voor IBD geassocieerde lymfoproliferaties, met 
name in de lagere stadia.
 Hoofstuk 2.3 presenteert een case-report van een ZvC patient 
die een hepatosplenisch T-cel lymfoom (HSTCL) ontwikkelt. 
Een HSTCL is een zeer zeldzame, niet EBV gerelateerd non-Hodgkin 
lymfoom met zeer hoge mortaliteit. Dit lymfoom komt vaker 
voor bij IBD patiënten, met name bij mannen onder de 35 jaar, die 
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langer dan twee jaar behandeld zijn met combinatie therapie van 
thiopurines en anti-TNF alpha. Deze casus is ongewoon, omdat 
de gepresenteerde patient 47 jaar oud is en HSTCL ontwikkelde 
na 14 jaar thiopurine monotherapie. Dit laat zien dat HSTCL 
ontwikkeling niet beperkt is tot jonge mannen die combinatie 
therapie krijgen. 
Solide maligniteiten
Studies die de IBD behandeling na specifiek tumoren bestuderen 
zijn zeer schaars. Derhalve wordt gepleit voor een ‘case-by-case’ 
benadering. In het tweede deel van dit proefschrift, worden spe-
cifieke maligniteiten bij IBD patiënten bestudeerd met als doel: 
I: het bestuderen van IBD specifieke risicofactoren voor het ont-
wikkelen van een specifieke maligniteit (hoofdstuk 3.1 – 3.4). 
II: het vergelijken van klinische karakteristieken en overle-
ving van IBD cases met een specifieke maligniteit met niet-
IBD patiënten met die maligniteit (hoofdstuk 3.1, 3.2 en 3.3). 
IBD patiënten met een specifieke maligniteit (IBD cases) zijn ge-
identificeerd met behulp van PALGA, de Nederlandse pathologie 
database. Deze database bevat pathologie verslagen zijn sinds 
1971 en heeft nationale dekking van alle ziekenhuizen in Neder-
land sinds 1991
.  Voor het eerste doel (I) vergeleken we IBD cases met een 
specifieke maligniteit met random IBD controles, die we verkre-
gen uit het population-based IBD Zuid-Limburg (IBDSL) cohort. 
Zuid-Limburg is een ingesloten gebied in het Zuid-Oosten van 
Nederland met 605.000 inwoners en 3 ziekenhuizen. Het totaal 
aantal IBD patiënten in de database is 2807, wat 93 % van regiona-
le IBD populatie vertegenwoordigt. 
 Voor het tweede doel (II) verkregen we controles uit de Eind-
hoven Cancer Registry (ECR; onderdeel van Integraal Kanker- 
centrum Nederland). Sinds 1989, registreert de ECR alle nieuw 
gediagnosticeerde maligniteiten in “Noord-Brabant” en 
“Noord-Limburg” en bevat meer dan 95 % van alle maligniteiten 
in dit gebied.
 De twee factoren die het belangrijkst zijn in de ontwikkeling 
van maligniteiten bij IBD zijn locale ontsteking en het gebruik van 
immuunsuppressie (wat de immuunsurveillance vermindert). 
Van de maligniteiten die in dit proefschrift worden beschreven, 
was de hypothese dat tenminste 1 van deze 2 factoren betrokken 
kon zijn. Locale inflammatie zou, behalve bij een colorectaalcarci-
noom, een belangrijke factor kunnen zijn bij de ontwikkeling van 
een maagcarcinoom of een mondholte carcinoom. Zowel EBV als 
H. pylori zijn pathogenen die het risico op de ontwikkeling van een 
maagcarcinoom vergroten. Hun activiteit kan beïnvloed worden 
door het gebruik van immuunsuppressie. In aanvulling op EBV 
is het humaan papillomavirus (HPV) een belangrijke factor in de 
ontwikkeling van (oro)pharynx carcinoom. Als laatste hebben 
we het melanoom bestudeerd, omdat het bekend is dat het risico 
hierop verhoogd wordt door het gebruik van anti-TNF therapie. 
 In hoofdstuk 3.1 includeerden we 63 IBD patiënten met maag-
carcinoom. Het ontwikkelen van IBD op oudere leeftijd bleek een 
risicofactor voor het ontwikkelen van maagcarcinoom bij IBD. De 
overleving van IBD patiënten met maagcarcinoom was slechter 
dan van controles. Histologische beoordeling liet geen toename 
van incidentie van Helicobacter pylori of EBV positieve tumoren 
zien bij IBD patiënten.
  In hoofdstuk 3.2 werden 304 IBD patiënten met een cutaan 
melanoom geïncludeerd. Uitgebreidere IBD (pancolitis bij CU en 
zowel colon als ileum betrokkenheid bij ZvC) is een risicofactor 
voor melanoom ontwikkeling bij IBD patiënten. De overleving 
van melanomen is vergelijkbaar tussen IBD patiënten en niet IBD 
patiënten. 
 Hoofdstuk 3.3 beschrijft 2 tumoren in het hoofd-hals ge-
bied: mondholte carcinomen (OCC) en pharynx carcinomen 
(PC). Er werden 66 patiënten met OCC en IBD geïncludeerd, 
waarbij de overleving van IBD patiënten verminderd is. Ook 
werden 31 patiënten met PC en IBD geïncludeerd, waarbij geen 
verschil gevonden werd in overleving tussen IBD patiënten 
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en niet-IBD controles. Voor zowel OCC als PC bleek het 
ontwikkelen van IBD op hogere leeftijd een risicofactor. Bij OCC 
bleek ook proximale ziekte activiteit een risicofactor te zijn.   
 Histologische beoordeling liet zien dat 52 % van de oropharyn-
geale carcinomen HPV positief waren, wat vergelijkbaar is met het 
percentage HPV positieve tumoren in de algemene bevolking.
  In hoofdstuk 3.1, 3.2 en 3.3 werd ook de invloed van immuun-
suppressieve medicatie op overleving bestudeerd. Er werden geen 
verschillen gevonden als gevolg van het gebruik van immuunsup-
pressieve medicatie na maligniteit diagnose. Hoewel deze be-
vindingen enerzijds heel geruststellend zijn voor de dagelijkse 
praktijk, is het belangrijk dat deze data zeer voorzichtig geïnter-
preteerd worden. Dit heeft meerdere redenen: ten eerste kan er 
een selectiebias zijn. Artsen zijn zich bewust van de mogelijke ri-
sico’s van immuunsuppressieve medicatie, waardoor ze dit alleen 
voorschrijven bij patiënten met maligniteiten met een laag risico 
profiel. Ten tweede is het moment van starten van immuunsup-
pressieve medicatie van belang, omdat de (negatieve) invloed van 
immuunsuppressie het grootst is in de twee jaar na de maligniteit 
diagnose. In onze studie was er ruime variatie in tijd tussen malig-
niteit en starten van immuunsuppressieve medicatie. Ten derde, 
het totaal aantal patiënten wat immuunsuppressie gebruikte na 
maligniteit diagnose was beperkt.
  Het laatste artikel in hoofdstuk 3.4 bevat een systematische 
review en meta-analyse met als doet het bepalen van risicofac-
toren en het absolute risico op het ontwikkelen van een CRC na 
subtotale colectomie. Er werden 3 groepen bestudeerd: patiënten 
met een rectum stomp, patiënten met een ileorectale anastomo-
se en patiënten met een ileoanale pouch (IPAA). Berekende CRC 
prevalenties waren gebaseerd op 13 studie over rectum stomp, 35 
IRA studies en 33 IPAA studies. De CRC prevalentie was 2.1 % bij 
patiënten met een rectum stomp, 2.4 % bij IRA patiënten en 0.5 
% bij IPAA patiënten. Het eerder gehad hebben van een CRC was 
de belangrijkste risicofactor om een CRC te ontwikkelen na sub-
totale colectomie (IRA patiënten: odds ratio 12.8; IPAA patiënten: 
odds ratio 15.0). Verder bleken IBD duur en CU meer dan ZvC 
risicofactoren voor de ontwikkeling van CRC en niet pouchitis en 
primair scleroserende cholangitis. Deze data helpen bij het op-
stellen voor surveillance aanbevelingen bij IBD patiënten met een 
subtotale colectomie. 
In conclusie hebben we in dit proefschrift de histopathologische 
beoordeling gecorreleerd met klinische uitkomsten bij IBD. His-
tologische beoordeling kan leiden tot inzet van EBV diagnostiek. 
Het reduceren van immuunsuppressieve medicatie is een effec-
tieve behandeling voor IBD geassocieerde lymfoproliferaties. 
 Verder bestudeerden we IBD specifieke risicofactoren en de 
klinische uitkomsten bij solide tumoren. Ook bepaalden we het 
CRC risico na subtotale colectomie. De overleving bij IBD pa-
tienten is verminder bij maagcarcinomen en OCC, maar niet bij 
melanomen en PC. In onze studies was er geen negatieve bein-
vloeding van survival door het gebruik van immuunsuppressie. 
 Omdat data over maligniteiten bij IBD beperkt zijn, kunnen 
deze resultaten besluitvorming in de dagelijkse klinische praktijk 
beïnvloeden bij IBD patiënten met de bestudeerde maligniteiten. 
Omdat onze studies retrospectief zijn, zijn prospectieve data hard 
nodig om de behandeling van IBD patiënten met maligniteiten te 
optimaliseren. 
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Dankwoord
 
Dit proefschrift was niet tot stand gekomen zonder de steun, inzet 
en interesse van velen. Zonder jullie was dit niet gelukt! 
Dr. F. Hoentjen, beste Frank, onze samenwerking in dit promotie-
traject wordt gekenmerkt door enkele noodgedwongen onderbre-
kingen als gevolg van jouw ziekte. Ik vind het ontzettend knap hoe 
je iedere keer de draad weer oppakte en je gedrevenheid en focus 
behield. Ik wil je bedanken voor je kritische en opbouwende input 
op mijn manuscripten, dat heeft dit proefschrift naar een hoger plan 
getild. Veel heb ik geleerd van jouw rustige en weloverwogen manier 
van werken. Bedankt daarvoor! Hopelijk kunnen we onze samen- 
werking voortzetten met het onderzoek naar IBD en mindfulness.
Prof. Dr. J.P.H. Drenth, beste Joost, jij gaf mij de mogelijkheid 
om nog laat in mijn opleiding tot MDL-arts te starten met een 
promotietraject, ondanks twijfels die je had naar aanleiding van 
soortgelijke trajecten. Dit heeft mij de kans gegevens mezelf 
verder te ontwikkelen, in het doen van onderzoek maar ook  qua 
persoonlijke ontwikkeling. Hoewel de ‘dagelijkse begeleiding’ meer 
bij Frank lag, was je er op belangrijke momenten om met jouw uit-
gebreide onderzoekservaring het onderzoek een duwtje in de rug 
te geven en mee te denken over de te varen koers. Dank daarvoor. 
Prof. Dr. I.D. Nagtegaal, beste Iris, jouw PALGA zoekvraag omtrent 
IBD en maagcarcinomen was de start van mijn promotietraject en 
dit was zeker niet de enige PALGA zoekvraag die bijgedragen heeft 
aan mijn proefschrift. Ook is er mede dankzij jou verdieping in de 
PALGA stukken gebracht, door het verrichten van aanvullende his-
tologische beoordelingen. Op het moment dat Frank uitviel heb 
je zonder moeite de wekelijkse begeleiding overgenomen, zodat 
de voortgang van mijn onderzoek niet in het gedrang kwam. Ook 
was je persoonlijk geïnteresseerd en gaf je tips en adviezen over de 
ontwikkeling van persoonlijke skills, wat ik zeer gewaardeerd heb. 
Dankjewel daarvoor. 
Beste paranimf, beste Lauranne, de afgelopen jaren zijn wij elkaar 
steeds weer opnieuw tegen gekomen. Het begon op de afdeling 
MDL van het Groot Ziekengasthuis in ’s-Hertogenbosch en vervol-
gens in het Radboud, eerst in de kliniek, later als collega IBD-on-
derzoekers. Ik vind het knap hoe je rustig, weloverwogen en doel-
gericht te werk gaat en je eigen koers volgt. Ik wil je bedanken voor 
onze samenwerking, alle (kritische en rode J) input die je hebt 
geleverd op mijn stukken en ook voor het mee coördineren van de 
ziekenhuisbezoeken en het meenemen van ‘mijn’ gegevens terwijl 
ik klinische werkzaamheden verrichtte. Dit heeft zeker bijgedragen 
aan de voortgang van mijn onderzoek. Hopelijk gaan onze gesprek-
ken nu weer meer over andere zaken dan alleen onderzoek, nu we 
allebei ons proefschrift hebben afgerond. 
Prof. Dr. N.M.A. Blijlevens, beste Nicole, op het meest cruciale moment 
van mijn promotietraject stond jij als mentor klaar met een luiste-
rend oor en met heldere, nuchtere en praktische adviezen. Dit heeft 
mijn belangrijke inzichten opgeleverd, voor nu en in de toekomst. 
Leden van de manuscript commissie, Prof. dr. dr. P.C.M. van 
de Kerkhof, Prof. dr. W.R. Gerritsen en Prof. dr. G. Dijkstra en 
leden van de corona, Prof. Dr. G.E.H.M Rutten, Dr. J. Tol en Dr. B. Ol-
denburg, bedankt dat jullie deze taak op jullie hebben willen nemen. 
Dit proefschrift was niet mogelijk geweest zonder het gebruik van 
diverse databases, te weten PALGA (Pathologisch Anatomisch Lan-
delijk Geautomatiseerd Archief), IBDSL (IBD Zuid-Limburg co-
hort) en de ECR (Eindhoven Cancer Registry).  Speciaal wil ik be-
danken Lucy (PALGA), Tim (IBDSL promovendus) en Rob (ECR) 
voor het aanleveren van data, het uitleg geven bij deze data en zo 
nodig nog aanvullende informatie verzorgen. Dit heeft vrijwel aan 
alle manuscripten in dit proefschrift bijgedragen!
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Wietske, bedankt voor jouw input bij de analyses in de diverse ma-
nuscripten. Als ik door de bomen het bos niet meer zag, dan wist jij 
zodanig uitleg te geven dat ik weer wist hoe ik verder kon.
Bedankt Andrea van der Meulen, Marieke Pierik, Dirk de Jong, 
Walter van der Velden, Maartje van de Meeberg, Elke de Jong, 
Elsemieke Plasmeijer, Carla van Herpen, Willem Melchers, Robert 
Takes en  alle andere co-auteurs voor het meedenken over vraag-
stellingen, methodologie, het leveren en interpreteren van data en 
het reviseren van diverse manuscripten.
Dank aan alle MDL-artsen, pathologen en andere specialisten 
die in hun drukke dagelijkse praktijk statusonderzoek hebben 
mogelijk gemaakt om klinische gegevens te verkrijgen. Bedankt ook 
Eemke, Alexander, Anouk, Anne en Inge voor het verzamelen van 
de data. Dit is de basis van diverse manuscripten!
Onderzoekers en analisten van de afdeling pathologie, Nikki, 
Michiel, Niek, Monika, Annemarie, Steven, Femke, Jeroen, Elisa en 
Shannon bedankt voor jullie hulp, uitleg en input bij de diverse onder- 
zoeken in dit proefschrift. Jeroen, Elisa en Shannon, ontzettend 
bedankt voor jullie hulp bij het uitvoeren van de diverse extra kleu-
ringen. Chella, Elise en Prof. Dr. J.H.J.M. van Krieken, bedankt dat 
jullie bij het uitvoeren van (her)beoordelingen de tijd hebben geno-
men om mij uitleg te geven en manuscripten te reviseren, dit was 
zeer inzicht gevend! Patricia, je hebt samen met Han mij betrokken 
bij verder onderzoek naar lymfoproliferaties, wat geresulteerd heeft 
in een 2e artikel over lymfoproliferaties in dit proefschrift. Bedankt 
daarvoor. 
 
Arts-onderzoekers MDL, waaronder Yasmijn, Titus, Hedwig, Floor, 
Myrte, Marten, Mark, Jos, Karina, Angelique, Isabelle en Tom, in 
mijn gefragmenteerde onderzoeksperiode heb ik met velen van 
jullie korter of langer samengewerkt, koffie gedronken, gelunched, 
gevoetbald en geborreld. Dank voor de ondersteuning waar nodig, 
de prettige sfeer en gezellige werkomgeving. Hedwig, steeds 
opnieuw kwamen we elkaar tegen, hebben veel meegemaakt samen 
en tijdens mijn begin periode in het JBZ heb ik zelfs van jouw ap-
partement gebruik mogen maken. Ik bewonder je optimistische, 
energieke en bewuste manier van doen en hoop dat we elkaar re-
gelmatig blijven zien!
Collega’s in het JBZ, inmiddels maak ik bijna 3 jaar deel uit van de 
vakgroep MDL in het JBZ. Ik ben blij met jullie als collega’s, met de 
sfeer in ‘onze’ groep, de borrels op vrijdagmiddag, de bereidheid 
om voor elkaar in te springen en elkaar te helpen. Ik vind het leuk 
dat ik mijn promotie ook met jullie kan vieren! Tessa, IBD colle-
ga en collega promovendus, in hetzelfde schuitje wat betreft jong 
gezin en promoveren. Dankjewel voor onze gesprekken, je ent- 
housiasme en positiviteit, ik hoop dat jij nu ook heel snel je proef-
schrift zal afronden.
Lieve Es en Rens, vriendinnen sinds de eerste werkgroep van 
geneeskunde. We hebben veel meegemaakt samen. Dank jullie wel 
voor jullie luisterend oor ten aanzien van mijn onderzoek beleve-
nissen. Maar vooral bedankt voor de gezellige etentjes, borrels, 
weekendjes weg etcetera. Fijn om zulke vriendinnen te hebben en 
altijd het gevoel te hebben bij elkaar terecht te kunnen. 
Ruud en Roel, eerst hele goede vrienden en nu samen onderdeel 
van onze ‘extended-family’. Wat wij met elkaar hebben is heel bij-
zonder en mij zeer dierbaar. Dank jullie voor jullie luisterend oor, 
nuchtere adviezen, positieve energie en voor de gezellige borrels 
en heerlijke etentjes. Dr. RAW, gewaardeerd collega, dank voor alle 
scopieen, maar vooral voor de fantastisch mooie lay-out van dit 
proefschrift.  
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Lieve schoonfamilie, bedankt voor het oppassen als ik weer eens 
achter de computer zat,  jullie steun,  de gezelligheid en het 
luisterend oor!
Lieve Luuk en Maaike, jullie weten hoe het is om een proefschrift 
af te ronden en nog beter: hoe is het om het afgerond te hebben. 
Dank voor het delen van ervaringen, het relativeren en de gezellige 
momenten samen. 
Lieve Pap en Mam, dank jullie wel voor jullie steun en jullie ver-
trouwen in mij. Jullie hebben mij geleerd om hard te werken en 
door te zetten als je ergens voor wil gaan. Dat heeft zeker bijgedra-
gen aan het voltooien van de proefschrift! Nu is het tijd om te gaan 
genieten van hetgeen bereikt is. 
Lieve Ties en lieve Fem, jullie zijn geboren tijdens mijn promotie-
traject. Ik ben ontzettend blij met jullie komst. Jullie aanwezigheid 
is een verrijking, relativering van werk en bovenal een bron van 
geluk. Jullie enthousiasme, energie, vragen, gekke fratsen etcetera 
leveren steeds weer nieuwe en onverwachte gebeurtenissen op. 
Last but not least, lieve Melinda, dankjewel voor steun, begrip en 
relativerende woorden, ondanks de vele (‘vrije’) tijd die ik achter 
de laptop heb doorgebracht. Jij zorgde ervoor dat ik ook focus 
hield op andere zaken die belangrijk zijn, je houdt me een spiegel 
voor en je prikkelt me om mijzelf in de breedte te ontwikkelen. 
Jij hebt dit proefschrift zeker mede mogelijk gemaakt!! Na het 
afgelopen jaar waarin we ontzettend veel hebben meegemaakt 
samen en jij gelukkig weer grotendeels hersteld bent na je operatie, 
hoop ik dat we nu in rustiger vaarwater komen en kunnen genieten 
van wat we samen hebben opgebouwd.
Loes Nissen
Rosmalen, maart 2018
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